Superior economic performance in a small state: the pharmaceutical industry in Malta by Joseph Vella-Bonnici (7196978)
  
Superior Economic Performance in a Small 
State: The Pharmaceutical Industry in Malta 
  
 By 
 
Joseph Vella Bonnici 
 
Doctoral Thesis 
 
Submitted in fulfilment of the requirements 
for the award of 
a Doctor of Philosophy 
 
Loughborough University 
 
 
 
 
 
 
 
 
2015 
©2015 – Joseph Vella Bonnici
 2 
 
Abstract  
 
Various academic disciplines have attempted to explain the factors underpinning superior 
economic performance. Generally they neglect the realities of small states.  
  
The literature fails to clearly define a ‘small state’. Mainstream theories associate smallness 
with ‘sub-optimality’. Small states studies tend to be conditioned by a ‘vulnerability’ 
complex. Yet, a good number of small states have an economic track record which is the 
envy of much larger states.  
 
This thesis adopts an interdisciplinary approach to investigate the theoretical explanations of 
superior economic performance, at both the state and firm level. Resource-advantage theory, 
which claims to be a general theory of competition, offers valuable insights in understanding 
the superior economic performance of small states.  
 
The field research follows Porter (1998) in studying the performance of particular industries 
to understand the competitiveness of nations. A qualitative, case study approach, involving  
both primary and secondary investigation, explores the performance of the pharmaceutical 
industry in Malta following the country’s decision to join the EU.  
 
This work perceives a small state as an organisation with well-defined, but permeable, 
boundaries. This ‘open system’ is characterised by both a lack of market power and a small 
population. Through the secondary field research a small number of ‘higher-order’ resources, 
competencies and dynamic capabilities (RCDCs) are identified. The field research’s findings 
affirm the relevance of these arch-RCDCs in creating  competitive advantage for the 
pharmaceutical industry in Malta. It also elucidates the key role played by an external 
catalyst, foreign direct investment, to circumvent domestic limitations.  
 
The study finds that it is still relevant to study small states and that achieving a strategic fit 
between the resource base and international market opportunities is essential if small states 
are to enhance their market power and achieve a superior economic performance.
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1. Introduction 
 
The purpose of this chapter is to set the scene for the subject of the thesis. While some small 
states have done well economically, many others are still struggling to ensure a good 
standard of living for their citizens. How will this change in a post-industrial era? An outline 
as to the reasons motivating this research and its structure is given. 
 
Every generation believes that it is living an era of significant change. Yet, change has been a 
constant phenomenon in human history. What varies is the speed at which change occurs. 
Change destabilises the status quo that creates new winners and losers. As Darwin (1859) 
said, it is not the strongest, nor the most intelligent, of species that survives, but the most 
adaptable. The pace and reach of present change is, perhaps, unprecedented. Technological 
developments in communications, information processing and transport are re-defining our 
sense of space and time (Herbolzheimer & Amann, 2007). Globalisation has become the 
hallmark of our time, but the world remains far from being a ‘global village’, as Levitt (1983) 
predicted. Humanity continues to be divided by culture, wealth, knowledge and race.  
 
Decolonisation in the 1950s and 1960s led to the emergence of several new nation-states, and 
many of these states consider themselves as small; they soon realised that they were ‘born’ in 
a world which is not designed to cater to their specific needs. They have craved for economic 
development to strengthen their newly acquired sovereignty and improve their standard of 
living. They have been campaigning under the banner ‘trade not aid’ in the hope that 
international business will help them find their place in the global community. Many of these 
states initially relied on import substitution to drive economic growth. The ‘infant industry’ 
argument became popular among policymakers, who advocated the protection of new 
enterprises, allowing them time to mature and withstand international competition. Import 
substitution has generally proven to be wasteful and unsuccessful. 
 
Other small states sought to push for industrialisation by making themselves attractive for 
foreign direct investment. They attempted to compensate for their perceived disadvantages 
(e.g. higher transport costs and the lack of technology and significant domestic market) by 
offering generous tax incentives. Some managed to exploit the advantages of their location, 
often attracting ‘near shore’ activities rather than ‘offshore’ ones. In the 1990s, policymakers 
 14 
 
in the Third World came to believe that their only chance at economic development was neo-
liberalism, including privatisation and trade liberalisation. Today, many of these states, ‘are a 
mish-mash, combining the productive with the unproductive’ (Rodrik, 2011a) and 
globalisation has been entrenching rather than helping them overcome dualism.  
 
Our understanding of society is defined by context and time. Kor et al. (2007, p. 1189) argue 
that ‘time and knowledge belong together’. The foundations of modern economics, as well as 
business studies, were largely moulded in the industrial age, in times of relative stability. 
Nowadays, ‘firms exist in highly turbulent and chaotic environments that produce disorder, 
disequilibrium and substantive uncertainty’ (Hitt et al., 1998, p. 23). Although competition 
and market structures have long been a primary concern of economic theory, understanding 
the dynamics of value creation, requires different assumptions for value creation (Allen, 
2004). Neo-classical prescriptions ‘are flawed not because they are theoretically unsound, but 
because we do not live in a neoclassical world’ (Wint, 1998, p. 282). 
 
Economists consider size to be a paradox (Mehmet & Tahiroglu, 2003; Prasad, 2004). Small 
economies are generally regarded as ‘sub-optimal’ (Downes, 2006). Salvatore’s theorem 
about ‘the importance of being unimportant’ is an exception (Armstrong & Read, 2003). 
Salvatore believes that small states are able to exploit their relative insignificance through 
international free riding and rent seeking. In an era dominated by industrialisation with its 
emphasis on mass production, mass markets, intensive resource utilisation and economies of 
scale, small economies were seen as being handicapped. Given existing technologies, a small 
home market was seen as hindering critical mass and preventing enterprises from operating at 
the minimum scale, necessary for efficient output. Often lacking reliable suppliers of 
materials and components, enterprises had to maintain larger stocks. Also, the cost of living 
is relatively higher due to additional transport costs.  
 
The post-industrial era, and in particular, the increased importance of tertiary activities, opens 
new opportunities for small states. As the global scenario continues to evolve, small states 
will have to manage their change process to adapt, if not pre-empt, emerging realities. 
Globalisation is undercutting the validity of traditional, state-centred forms of social science: 
‘the exclusive attention to this level of aggregation is becoming less useful in light of the 
changes occurring in the organisation of economic activities which increasingly tend to slice 
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through, while still being unevenly contained within, state boundaries’ (Henderson et al., 
2002, p. 437). ‘It is fair to argue that the (nation) state is less capable of providing a suitable 
reference or explanation to contemporary dynamics’ (Baldacchino, 2010, p. 40). Ohmae 
(1995) proclaims the end of the nation state, insists that it is no longer a meaningful unit and 
questions its usefulness in understanding and interpreting flows of economic activity. Killick 
(1999) agrees that the sovereign state is becoming an outmoded entity. Weiss (1998) stresses 
that globalists tend to over-state and over-generalise state powerlessness.  
 
Globalisation and states are not necessarily antagonistic. Strong states are able ‘to adapt, 
internationalise their capabilities and assist their firms to adjust to the external environment’ 
(Weiss, 1998, p. 206). Globalisation, the latest stage of capitalist development, seems to be 
losing much of its appeal as has largely failed to deliver many of its promises (Piasecki & 
Wolnicki, 2004, p. 312). Although globalisation is creating new wealth, some of which is 
trickling down to people in many corners of the world, for the working classes in more 
mature economies, globalisation has become a threat to their jobs. Jagdeo (2007) discusses 
the deep impact, consequences and manifestations of globalisation and warns that 
globalisation is giving rise to increased income inequality. 
 
‘Globalization seems to capture both the menace and the promise of change’ (Fonseca, 2002, 
p. 5). Stiglitz (2003, p. 20) argues that with globalisation, ‘even many of those who are better 
off feel more vulnerable’. The swift emergence of globalisation as a core interpretative 
category throughout the social sciences is challenging ‘not only humanity’s understanding of 
the world but also the tools it uses to develop that understanding’ (Kirby, 2006, p. 651). 
Baldacchino (1998, p. 276) suggests that ‘the world is now constituted by both a space of 
places and a space of flows’. Places are being transformed by flows of capital, labour, 
knowledge and power, and at the same time, are transforming these flows through their 
institutional and social structures.  
 
Some small states have sought to overcome the limitations of ‘smallness’ through economic 
integration with other states. However, this alone does not necessarily lead to increased 
efficiency (Mehmet & Tahiroglu, 2003). The 2008 global economic crisis proved to be a 
reality check for the fundamentalist belief in the supremacy of the ‘invisible hand’. The real, 
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productive economy has been giving way to speculation, which has become a primary 
determinant of currency values, international prices of commodities and portfolio investment.  
 
Will globalisation lead to a world with fewer borders or an increasing number of small states? 
(Alesina & Spolaore, 2003). The tasks of national economic management are ever changing 
(Weiss, 1998, p. 2), and small states are finding it increasingly hard to determine their role in 
the emerging global constellation. Then, what are the strategic options available? Should 
small states seek to ‘stand-alone’ or should they move closer to each other (as is the case of 
Caribbean countries)? Should they join an economic bloc, as Cyprus and Malta did when 
they joined the EU? The future of small states largely depends on the emerging global 
economic scenario. Their openness obliges them to adapt to forces arising from the external 
environment. Nevertheless, small states continue to look up at bigger states in understanding 
the threats and opportunities emanating from globalisation (United Nations, 2006).   
 
The key research problem relates to the strategies that small states need to follow so as to 
enhance their competitiveness and achieve what can be considered as a ‘superior economic 
performance’. To date mainstream theories scarcely give any attention to the specific realities 
of small states. Small state studies generally fail to give coherent and comprehensive 
explanations of what needs to be done for them to achieve such a performance. This research 
proposes to delve into the dynamics underlying small states’ competitiveness. 
 
This thesis is motivated by the belief that current academic explanations relating to the 
competitiveness of small states do not provide adequate guidance to policymakers in these 
states, which prevents them from managing strategically their economies (especially in their 
interface with international  markets). As a result achieving an ‘adequate’ economic 
performance has proven to be a formidable challenge for most small states.  
 
This research brings together three levels of analysis and seeks to argue that ‘proximity’ (both 
space and people) as well as ‘time’ considerations in small states render these levels more 
interdependent. These three levels are as follows: 
 
• The EU (the supra-national level, which in the context of this research, triggers the 
change process)  
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• Malta (the national level, through which most changes arising from the supra-national 
level are channelled to enterprises within a specific sector)  
• The pharmaceutical industry (the sector level, at which change impacts the immediate 
environment in which enterprises operate).  
 
The externally generated change process which this research examines was triggered by 
Malta’s membership in the EU. For illustrative purposes, the field research will entail a case 
study of  how EU membership impacted on the evolution of the pharmaceutical industry in 
the country. The pharmaceutical industry is considered as a knowledge-intensive, high value-
added economic activity offering good remuneration to employees and is the type of 
economic activity which all small states wish to develop.  The development of the 
pharmaceutical industry involves many of the challenges that small states have to overcome, 
at both the sector and enterprise level, to achieve a superior economic performance. At a time 
when the relative contribution of manufacturing  to the Maltese economy was declining, the 
pharmaceutical sector was growing at a significant pace. 
 
Competition has been the subject of study of various disciplines. Neo classical economists 
believe that perfect competition, where both suppliers and buyers have no control over price, 
maximises economic welfare. Under such conditions, all players have the same market 
power, and none of them reap higher returns (profits). If, for any reason, a player achieves 
greater market power than the other players, enabling him to manipulate prices and reap 
abnormal profits, this is deemed to be a ‘temporary’ phenomenon, as market forces will 
eventually bring all players back to having the same market power. 
 
By contrast, the very purpose of business studies is to help enterprises perform better than 
their competitors so as to achieve some desired objective (such as increased market share or 
higher profits).  Achieving such a performance gives an enterprise an advantage over its 
competitors which, if properly exploited, can help it sustain its market power. Porter (1980) 
deemed that industries characterised by ‘perfect competition’ were unattractive. High 
competitive intensity impacted negatively on the industry’s overall profitability and hence its 
attractiveness. The five forces model proposed by Porter (1980), is based on the structure-
conduct-performance paradigm of industrial organizational economics, and eventually 
provided the thinking for him to study competitiveness at the national level. His approach 
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was to study successful industries (for example, electronics in Japan, fashion wear in Italy 
and engineering industries in Germany) to identify forces underlying the competitive 
advantage of national economies. Porter(1998) came to the conclusion that the achievement 
of  competitive advantage is a localised process. His decision to focus on attractive, 
‘successful’ industries implicitly implied that, not only where they not characterised by 
perfect condition, but also that enterprises enjoying high market power had managed to 
extend it to global markets.  
 
The approach taken by this research follows that adopted by Porter (1998) in his seminal 
work on the competitiveness of nations. The nation is seen as a set of contextual variables 
which influence the competitive performance of industries and firms. To arrive at the 
competitiveness of nations, Porter (1998) studies the origins of an industry in that nation, how 
it grew, when and why the industry’s companies developed international competitive 
advantage. This research goes beyond Porter’s work by including changes triggered at the 
supra-national level and examines their impact at the national and sector level. A limitation of 
this research is that it does not delve deeply into the enterprise level even if, ultimately, this is 
the level at which competitive advantage is created (Porter, 1998).  
 
In a tradition set by International Relations, most academic disciplines continue to associate 
small states to ‘lack of power’ and hence vulnerability.  In the light of the work carried out by 
Porter (see 1998) a key question for the subject matter of this thesis becomes: what does it 
take for small states to achieve ‘market power’ and build a capacity to influence (if not 
determine) the prices they fetch for their exports? Porter (1998) states that wealth is created 
not inherited, implying that a superior economic performance is the result of competitive 
advantage rather than comparative advantage. This does not imply that the wealth of oil-rich 
Saudi Arabia is not real, but that it is of a lower order than that of for example Japan which 
competes on innovation. 
 
Adam Smith (1776) argues that free trade is superior to mercantilism as it benefits all 
participants. According to the law of ‘absolute advantage’, for this to happen, countries need 
to specialise and produce those goods in which they have an advantage. The key 
consideration for small states is: what form should their specialisation take if they are to 
benefit from international trade? As this research will elaborate later on the search for 
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specialisation by small states is even more problematic given limited economies of scale and 
their emphasis on risk minimisation (not being over-dependent on a few economic activities). 
 
The foregoing indicates that there does not exist in mainstream economics and business 
studies an adequate explanation of the dynamics of small states’ competitiveness and this 
research is intended to help fill this void. The key research questions which this thesis 
proposes to answer are: 
 
a. How do small states’ economies differ from those of larger states?  
b. Why are these differences important for competitiveness and superior economic 
performance?  
c. How can insights from existing theories contribute towards developing an alternative 
approach? 
d. How does EU membership impact on the development of the pharmaceutical industry 
in Malta? 
e. Does the experience of the pharmaceutical industry in Malta confirm or otherwise the 
relevance of the major components of the proposed theoretical framework? 
This research throws new light on the limited relevance of existing academic explanations 
and theories on competitiveness and superior economic performance to small states. This 
should make policymakers and the business community within small states aware about the 
limited applicability and usefulness of these theories to the strategic management of their 
economies. The thesis does not stop at explaining why this is so but goes further and 
proposes an alternative theoretical framework intended to give a better understanding of the 
dynamics of small state’ competitiveness. In particular, this research’s focus on the need to 
develop key competencies has important implications for policymakers and the business 
community in small states. 
 
This research also opens a new chapter in both International Business and Small State 
Studies. The former has largely ignored small states as a distinct area of study (even though 
more recently additional attention has been given to the specific role of small and medium 
enterprises). The latter have never before applied, or sought to build upon, theory emerging 
from business studies. In this respect this research opens new horizons which can lead to 
further research. 
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Following this introductory chapter, the rest of the thesis is structured as follows: 
 
Chapter two elaborates on academic explanations arising from small state studies and why 
these are not deemed to offer coherent and comprehensive explanations of what underpins the 
competitiveness of small states.  
 
Chapter three explores mainstream theoretical explanations of superior economic 
performance at three levels: state, enterprise as well as state and enterprise. Those relating to 
the state give no particular attention to the specific conditions of small states. Those relating 
to the enterprise were considered so as to explore whether explanations offered could be 
extrapolated to small states and their enterprises.  
 
Drawing on the literature review chapter four proposes an alternative theoretical framework  
offering an explanation as to the dynamics of building and sustaining competitive advantage 
in small states.  
 
Chapter five elaborates on the methodology followed by this research and the role played by 
case studies in qualitative research. 
 
Chapter six presents the results of the case study and these are divided into two parts: 
 
• Those relating to the context of the case study.  A schema which draws on  Resource-
Advantage theory is utilised to help understand the setting of the development of the 
pharmaceutical industry in Malta after its joining the EU . 
 
• Those emerging from the field research relating to the applicability of the alternative 
theoretical framework proposed by this research. The proposed framework guided the 
data gathering process, its analysis as well as evaluation. 
 
Chapter seven presents a discussion, draws some conclusions on the research findings and re-
assesses the contribution of this research in the light of the research problem and questions it 
sought to address. 
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This introduction outlines the research layout. The research problem and key research 
questions were defined in the light of the existing literature gap. The possible contribution of 
the thesis to academic knowledge as well as to policymakers and the business community is 
also explored and an outline of the research’s structure given. 
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2. Small States and Superior Economic Performance 
 
This chapter focuses on issues relating to small states and theoretical explanations 
addressing their superior economic performance. The chapter finds that the literature is 
dominated by a ‘vulnerability’ complexity, equating smallness to weakness. It further argues 
that economic success achieved by some small states is creating an awareness that this need 
not be so. 
 
The decolonisation process and the disintegration of the Soviet Empire (1990s) led to a 
significant increase in the number of sovereign small states across the world (Read, 2002). 
Until then, the majority of small independent states were to be found in Europe. Most ‘small 
states’ are now non-Western nations with economies which are still developing. Within large 
sovereign states, there has been a tendency towards granting increased economic and political 
autonomy to regions with distinct identities (Armstrong & Read, 1998). This is ‘further 
blurring the differences between sovereign states, territories and regions’, especially as 
globalisation and the build-up of supra-national regional trade blocs accelerate (Read, 2002, 
p. 171). The world economic order as conceived at Bretton-Woods did not last long. 
Persistent confrontation between the United State and the Soviet Union escalated tension, and 
many newly independent countries sought refuge in the UN. This organisation is founded on 
the principle that every sovereign state, large or small, has a right to self-determination. The 
fact that every state, irrespective of its size or power, is entitled to one vote at the General 
Assembly gives small states a sense of importance. Using ‘the United Nations as a forum and 
a force and claiming “non-alignment” as an important diplomatic innovation, small states 
have risen to prominence if not power’ (Neumann & Gstohl, 2006, p. 55).  
 
Katzenstein (1985, p. 42) finds that ‘[m]ultilateral commercial diplomacy still focuses 
primarily on the big states, and small states often find their special needs and interests 
disregarded’. In 1973 at the UN, the small states, together with other developing countries, 
voted in favour of the creation of a New International World Order. In reality, no concrete 
results were obtained and the declaration remains just a statement of good intent. Since the 
collapse of the Soviet system, a broader distribution of global economic and political power 
has been emerging, as evidenced by the increased importance of the G8 and G20. Small 
states are not represented at this level, but this has not discouraged them from being more 
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active in international forums, emphasising their particular needs arising out of 
‘characteristics that pose special development challenges’ (Commonwealth Secretariat and 
World Bank, 2000, p. ii 
 
The literature of small states has significantly evolved in the past two decades, drawing 
primarily on international relations, natural sciences (including geography), economics and 
public policy. To date, studies on small states by business, strategic and management analysts 
have been surprisingly limited. This may be due to the inherent belief within these disciplines 
that a ‘best practice’ has no territorial boundaries.  
 
The modern state system goes back to the Treaty of Westphalia in 1648 and ‘owes much to 
the enforcement by European states of their concept of an international society of judicially 
sovereign states’ (Sanders, 2005, p. 57). International relations see the nation state as a 19th-
century European phenomenon. The state is a political institutional structure having authority 
over a specific territory, which is acknowledged by other countries and has its own 
government. The concept of the state too is a messy one (Mann, 1994). Warrington (1994b, p. 
4) observes that the term state ‘is itself not unambiguous’ and that, at times, it is used to refer 
to territories with distinct political/ constitutional status arising from historical or 
geographical anomalies. 
 
Sovereignty can refer to both internal and external considerations. ‘Internal sovereignty’ 
acknowledges that the state is the supreme law-making authority within its defined territory 
and has the coercive power to enforce laws. ‘External sovereignty’ arises from the fact that a 
state is independent of all other entities and, internationally, speaks and acts for itself. 
Political sovereignty is not a simple binary variable but a discrete scale ranging from full 
independence to relative autonomy (Schaffer, 1975). ‘De jure’ economic sovereignty does 
not necessarily imply ‘de facto’ economic policy autonomy (Read, 2002).  
 
A nation is a collectivity of people who live as a community, share a common heritage and 
destiny and have mutual identification. Nationhood, with its powerful symbols, has become a 
potent force that complements statehood. The concept of a small (nation) state is contested in 
both the theory and practice of international affairs and the simplest way of defining a small 
state is its not being a great power (Neumann & Gstohl, 2006). Thorhallsson and Wivel 
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(2006) disagree with such an approach, arguing that such a definition is tautological and 
evades the real question of what is small. As a state-centric, power-focused discipline, 
international relations, generally, perceives smallness as being synonymous with weakness. 
‘Smallness is powerlessness’ (Sanders, 2005, p. 38). From a ‘legal’ point of view, all 
sovereign states are meant to be equal, but in reality, their power differs. The ‘realist’ school 
sees small states as pawns in the games of larger states. Pace (2006, p. 35) remarks that UN 
resolutions indicate that ‘small states may be particularly vulnerable to external threats and 
acts of interference in their internal affairs’. Smallness is also viewed as a handicap to state 
action and limiting the capability, influence and survival of states (Browning, 2006). It is a 
mistake to view micro-states as scaled-down versions of ‘ordinary’ or normal states 
(Warrington, 1994a). Baldacchino (2008) agrees that it is not right to think about large 
jurisdictions and territories as being ‘normal’. According to the 2006 CIA World Fact book, 
out of 237 jurisdictions, only 23 have populations of over 50 million and 158 jurisdictions 
have populations of less than 10 million, of which 41 have a population of less than 100,000.  
 
Most economic studies of small states adopt the ‘rational actor’ model, which assumes that 
the state is a unitary and value-maximising calculator. Small states are often perceived as 
being more ‘unitary’ than larger ones. Weiss (1998, p. 15) disputes such a perspective, 
arguing that far from being unitary or monolithic structures, states are ‘organisational 
complexes whose various ‘parts’ represent different ages, functions and (at times) 
orientations’. The Lewis model perceives industrialisation as the key to structural transition 
‘from low productivity labour-surplus agriculture to more technologically intensive, large 
scale manufacturing founded upon low-cost, labour-intensive production techniques’ 
(Armstrong & Read, 2003b, p. 102). Smallness is inevitably seen as a negative factor 
generating diseconomies of scale (Mehmet & Tahiroglu, 2003). Oberst and McElroy (2007) 
find that small island literature has traced three major threads, sequentially emphasizing 
various aspects of 
 
(1) economic structure  
(2) economic performance and  
(3) the role of domestic policy.  
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Campling and Rosalie (2006) identify three historical shifts in the evolution of the literature 
on small island states: 
 
1970s: emphasis on structuralism, exploitative forms of neo-colonialism and realisation that 
an alternative, people-centred development is needed 
1980s: shift towards neo-liberal ideology, focusing on the role of export-oriented production 
and a growing pre-occupation with geopolitical security  
1990s: focus on environmental and economic vulnerabilities.  
 
During the 2000s, the primary concern is environmental and economic vulnerabilities 
coupled with new streams of study trying to explain the ‘superior performance’ of some small 
states (resilience and strategic flexibility schools). Rising global concerns on climate change 
has re-enforced the pre-occupation surrounding the fragile eco-systems of small island states, 
while geopolitical issues re-surfaced from time to time in the light of the experience of ‘failed 
states’ (Scheyvens & Momsen, 2008). Prasad (2004) states that ‘country size’ has been a 
paradox in economic theory. He refers to Salvatore’s (2007) hypothesis of ‘the importance of 
being unimportant’. Small states, because they are small, have often succeeded ‘in dispensing 
with standard regimens, and in slipping subtly through the nets of conformity’ (Baldacchino 
& Milne, 2000b, p. 238). Offshore financial centres are considered by bigger countries to be 
illegitimate or as questionable activities with ‘capital-distorting effects’ (Baldacchino & 
Milne, 2000, p. 238), while Prasad (2004) claims that export processing zones violate the 
principles of free trade since they create artificial incentives for investors. 
 
In the effort of small states to circumvent the ‘constraints associated with a sub-optimal 
domestic market size’, trade is essential as ‘increased specialization improves domestic 
efficiency and competitiveness’ (Read, 2002, p. 175). The degree of openness of an economy 
influences its flexibility since trade is a ‘potent medium both for the transfer of information 
and for the transmission of incentives to adapt’ (Killick, 1995, p. 22). Alesina (2003, p. 230) 
states that the relationship between country and market size depends on the trade regime and 
that the ‘viable’ size of a country decreases with economic integration. ‘The bottom line is 
that small countries can prosper as long as they are open to international trade...Given that 
small countries need international trade to prosper, they need peace to be able to trade’.  
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Easterly and Kraay (2000) also find a positive correlation between economic openness and 
income. Goods embody technological know-how and small states can acquire foreign 
knowledge through trade (Grossman & Helpman, 1991; Aubert & Chen, 2008). Productivity 
growth in small states tends to be higher as they are more sensitive to changes in trade-related 
technology diffusion (World Bank, 2008a). The trade multiplier in small states has a 
significant impact on economic growth. International trade, however, cannot completely 
offset the absolute size effects of a small state (Armstrong & Read, 1998). Baldacchino 
(2006, p. 46) points out that ‘[i]n the case of small, densely populated territories starved of 
land – such as the city states of Singapore, Hong Kong, Bermuda and Malta – 
industrialisation or tertiarisation have been the inevitable growth poles, obliging a quick shift 
of mind-frame towards export promotion and the penetration of export markets’. International 
economic theory considers small size to reflect a country’s inability to influence its own 
terms of trade, rendering it a price-taker on world markets (Armstrong & Read, 1998a). 
Elsewhere, Armstrong and Read (2002, p. 436) state that smallness is equated with the 
inability of a country to affect its own terms of trade, that is, the world prices of its imports 
and exports, and conclude that ‘this definition can be seen to be the minimum criterion for a 
large country, rather than a means to classify small states as a distinct group’. Armstrong and 
Read (2003b) point out that ‘structural openness’ (a high share of trade in GDP) also has 
important macroeconomic policy implications in terms of the balance of payments, 
international monetisation, exchange rate and domestic monetary autonomy. The authors add 
that any gains from specialisation through trade must be offset against the greater risk of 
exogenous shocks. Integration with the global trading system creates a critical risk 
asymmetry for small states (Read, 2002). The World Bank (2008a) notes that small size 
limits the capacity to diversify risk. Given the experience of Fiji, Malta and Mauritius, 
Baldacchino (1998, p. 271) cautions that although ‘[s]ome success has been admittedly 
achieved in terms of that seductive option: export oriented industrialisation by invitation ... 
But the price to be paid is heavy and the benefits gained may be largely illusory. The main 
beneficiary is also likely to be footloose capital which does not generate the sustained, export 
growth orientation so many microstate governments desire’. 
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UNCTAD’s typology of small states is based on their principal economic activities and 
includes the following: 
 
• External rental income from worker remittances and the sale of licences from fishing and 
other resources (MIRAB economies) 
• Exports of natural resources and primary products 
• Service-oriented, notably tourism, with or without other important economic activities 
• Diversified economies possessing large manufacturing sectors 
 
2.1 Vulnerability School 
 
Vulnerability is a multi-dimensional concept (Pace, 2006) with small countries being more 
vulnerable than large ones, ‘economically, politically and militarily’ (Katzenstein, 1985, p. 
80). The defining feature of smallness is not the lack of economic development opportunities, 
‘but rather a much higher than average dependency on, and vulnerability to changes in, the 
wider global political and economic environment’ (Heron, 2008, p. 245). Small state 
vulnerability revolves around their economic viability, environmental degradation, cultural 
survival, security and demographic instability (Warrington 1994a; 1997a). The social 
vulnerability of small states arises from illicit drugs, violence, organised corruption, 
HIV/AIDS and the greater than average risk posed by internal and external factors in 
undermining social cohesion, introducing systematic pathologies and eroding social capital 
(Thomas, 2003).  
 
Environmental vulnerability refers to the susceptibility of small states (in particular islands) 
to natural catastrophes and their ecological and environmental fragility as well as the long-
term consequences of global climate change. The impact of natural shocks on aggregate GDP 
and long-run growth in small states can be devastating (Armstrong & Read, 2003b). The 
political and strategic vulnerability of small states has long been recognised and it ‘arises 
from their susceptibility to external political pressures and strategic manoeuvring by larger 
neighbouring states and the major powers’ (Armstrong & Read, 2000, p. 286). The economic 
vulnerability of small states arises from their inherent economic sub-optimality, concentration 
in domestic economic activity and a high degree of dependence upon external trade, 
particularly imports (Armstrong & Read, 2003b). Also, the ‘adverse macroeconomic shocks 
 28 
 
in microstates have the potential for a disproportionately large impact on poverty and human 
welfare’ (Chand, 2006, p. 70). 
 
The implications of smallness have been pursued in all major multilateral circles, including 
the UN where the focus has been on small island developing states (SIDS) (UNCTAD, 2007). 
The WTO has a ‘Work Programme on Small Economies’ but to date, it still has ‘no formal or 
informal definition of small, weak and vulnerable economies’ (Faizel, 2006). Small states are 
portrayed as victims of their geographical circumstances, actions and lack of expertise 
(Turnball, 2003). Bourne (2003, p. 13) suggests that ‘[i]t is easy to become pessimistic about 
the future of small states in a world that is tending so dramatically towards agglomeration and 
concentration of wealth and power’. It was easy for the ‘convention that “smallness equals 
weak” to take root uncritically’ (Baldacchino & Milne, 2000a, p. 4).  
 
2.1.1 Vulnerability indices 
 
Available data ‘obscures marked differences in economic performance of small states’ 
(Favoro & Peretz, 2008, p. 266) with methodological problems having hindered the 
emergence of ‘robust evidence concerning the impact of vulnerability on growth’ (Armstrong 
& Read, 2003b, p. 115). GDP per capita and other income-based measures ‘do not provide a 
complete picture of the long-term structural and institutional constraints on their growth’ 
(Armstrong & Read, 2003b, p. 108). A number of indices have been devised to gauge small 
state vulnerability. The vulnerability indices produced by the University of Malta, 
Commonwealth Secretariat and United Nations Commission for Development Policy, 
generally, focus ‘on permanent or quasi-permanent features associated with economic 
vulnerability’ (Briguglio et al 2006:27). 
 
Briguglio’s economic vulnerability index (EcVI) was initially developed to explain the 
seeming contradiction that a small state can be economically vulnerable and yet, register a 
relatively high GDP per capita. There are a number of versions of the EcVI produced, first by 
Briguglio (1992; 1995; 1997) and subsequently, Crowards and Coultier (1998). The 
conclusion that emerges from these indices is that small (island, developing) states, as a 
group, tend to be more economically vulnerable than other countries (Briguglio & Galea, 
2010). However, empirical results convincingly support the growing view in the literature 
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that small size is not necessarily a disadvantage (Easterly & Kraay, 2000). Smaller countries 
are not poorer than average (Browning, 2006) with many registering a relatively strong 
performance ‘whether in terms of their growth rates or income levels’ (Armstrong & Read, 
2006, p. 79). Indeed, of the ten richest countries in the world, in terms of GDP per capita, 
only four have populations above 1 million (Alesina, 2003). The empirical evidence gathered 
by Alesina et al. (2000) shows that country size does not matter for economic growth or the 
level of GDP per capita when trade is relatively free. Given that many small states generate a 
relatively higher GDP per capita, despite their high exposure to exogenous economic shocks, 
there must be other factors which offset the disadvantages associated with vulnerability 
(Briguglio et al., 2006b). Briguglio (2003) refers to the seeming contradiction that a country 
can be highly vulnerable and yet attain high levels of GDP per capita, as the Singapore 
Paradox. 
 
2.2 Resilience 
 
Kuznets was the first economist to observe that small states have advantages which allow 
them to adapt relatively quickly to change (Easterly & Kraay, 2000). While it is important not 
to romanticise the situation of small islands (states) or their peoples, ‘it is essential that we 
recognise their strengths by identifying positive attributes or forces for change, and then to 
develop strategies which utilise these strengths’ (Scheyvens & Momsen, 2008, p. 502). The 
search for explanations to the Singapore Paradox gave rise to a branch of the vulnerability 
school which seeks to identify those factors leading to the ‘resilience’ of successful small 
states (Pace, 2006). Resilience can be defined in many ways (Briguglio, 2004) and has at 
least three interpretations relating to the ability to do the following: 
 
(a) recover quickly from shock: ‘shock-counteraction’ 
(b) withstand the effect of shock: ‘shock-absorption’ 
(c) avoid shock altogether: ‘shock avoidance’ 
 
Generally, the resilience of small states refers to the ability of an economic system to return 
to its initial steady-state position after a perturbation or exogenous shock (Downes, 2006). 
GDP per capita is ‘more sensitive to resilience variables than to vulnerability ones’ 
(Briguglio et al., 2006b, p. 282). Cordina (2008, p. 133) views resilience in terms of the 
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asymmetric effects of shocks to which an economy may be exposed, arguing that ‘[t]ypically, 
the effects of negative shocks would outweigh those of positive ones’. He adds that after 
exogenous shocks, it is essential that resources are allocated as efficiently as possible and 
quickly reallocated to their best possible uses. Briguglio (2004) distinguishes between 
inherent and nurtured resilience. ‘Inherent’ resilience is the obverse of vulnerability, in the 
sense that inherently resilient countries should register low vulnerability scores. ‘Nurtured’ 
resilience is that which is developed and managed and often the result of good policymaking 
and effective governance (figure 1). 
 
The private sector plays an important and crucial role in building economic resilience. ‘The 
private sector as opposed to the public sector is generally more exposed and therefore more 
responsive to market realities and is therefore better equipped to absorb and recover from 
shocks’ (Vella, 2008, p. 147). Policies aimed at developing the private sector need to be 
credible and sustained, ‘clear and consistent rules and regulations are critical in this regard’ 
(Vella, 2008, p. 159). 
 
Figure 1: Risks Associated with Being Adversely Affected by External Shocks 
(Reproduced from Briguglio et al., 2006b) 
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Briguglio (2004) explains the Singapore Paradox in terms of the juxtaposition of economic 
vulnerability and resilience. Briguglio et al. (2006b, p. 31) presents four possible scenarios 
that combine inherent vulnerability or resilience with policymaking (figure 2). 
 
Figure 2: Four Scenarios of Vulnerability and Resilience 
(Reproduced from Briguglio et al., 2006b) 
 
1. ‘self-made’ countries: have a high degree of inherent economic vulnerability but adopt 
the right policies to build economic resilience 
2.  ‘prodigal son’ countries: have a relatively low degree of inherent economic vulnerability 
but have policies that are harmful to economic resilience  
3.  ‘best case’ countries: although not inherently vulnerable, these countries still adopt 
resilience-building policies 
4.  ‘worst case’ countries: these compound the adverse effects of inherently high 
vulnerability by adopting policies that run counter to economic resilience 
 
Briguglio et al. (2006b) propose a ‘resilience index’ intended to measure the effect of shock 
absorption or shock counteraction policies, which is constructed using the following 
variables: 
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• macroeconomic stability 
• microeconomic market efficiency 
• good governance 
• social development 
 
The issue of resilience building in small states is important because it carries the message that 
these states should not be complacent and adopt measures that boost economic, 
environmental and social resilience. UNCTAD’s (2007) approach to structural weakness and 
vulnerability rests on the goal of building resilience. 
2.3 Economic integration 
 
The World Bank (2008a, p. 4) suggests that rather than focusing on size and geographic 
considerations, it is more fruitful to study ‘the integration of these economies with their 
neighbours or with the rest of the world’. Productivity improvement in small states has been 
closely related to integration and those small states that failed to integrate have had much 
weaker economic performances (Thomas & Pang, 2007). The issue of economic integration 
is becoming increasingly important, as more small states are considering membership in a 
regional bloc. ‘Neither size nor geography can be changed, but integration can help overcome 
size and distance disadvantages’ (Warrington, 1997a, p. 103). These advantages are not as 
clear cut given that the growth benefits of economic integration schemes tend to favour 
relatively developed countries (Armstrong & Read, 1998).  
 
Small state membership in larger blocs can entail the dissolution of the flexible regulatory 
environment, with which many of them have overcome the structural disadvantages of their 
economies. ‘At the same time, they would have to bear the increased costs of (EU) 
governance, without any clear prospect of the benefits they could reap there from’ (Dózsa, 
2008, p. 102). Government and policy advisers should stop thinking of international 
integration as an end in itself; openness should be part of a development strategy and not a 
substitute for one (Rodrik, 1999). Economic integration yields benefits only when 
complementary policies and institutions are domestically in place. Katzenstein (1985, p. 203) 
points out that ‘[h]igh integration does not necessarily mean the displacement of “national” 
economies as the locus of accumulation or weakening of national economic management’. 
Policymakers must also reinforce their external strategy of liberalisation with an internal 
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strategy that gives the state substantial responsibility in building physical and human capital 
and mediating social conflicts (Rodrik, 1999). 
 
Baldacchino and Greenwood (1998, p. 15) observe that ‘the so-called “new economy” of 
globalisation and information technologies must be engaged critically by small islands’. The 
emergence of a knowledge society points towards the continued relevance of ‘local’ 
conditions given that most knowledge creation is tacit, person-embodied and context-
dependent (Morgan, 2004). Globalisation is becoming a powerful influence on the future 
competitiveness of enterprises in the world’s smallest economies (Wignaraja et al., 2004). 
Globalisation offers small states’ enterprises access to new technologies, skills, markets, 
financial sources and hence, better outward-oriented growth prospects. But, globalisation also 
exposes these enterprises to intensive competition from imports, foreign investment and low-
cost developing country enterprises. There is a real prospect of winners and losers among 
small states and enterprises within them. The double-edged nature of globalisation is 
daunting to both policymakers and enterprises in small states.  
 
Browning (2006) suggests that in the globalisation era, the ‘big-small’ state dichotomy is 
increasingly less relevant. In the 21st century, ‘smallness’ is not defined by absolute 
variables, but by processes; globalisation is leading to the emergence of new economic 
trends, ‘increased openness of economies, internationalization of technology and the 
geographic dispersion of economic activity’ (Tonurist, 2010, p. 11). These are the real 
determinants of the ‘size’ of states, and Tonurist outlines how the forces of globalisation 
‘determine’ size using the following illustration (figure 3): 
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Figure 3: Influence of globalisation on the ‘size’ of states  
(Reproduced from Tonurist, 2010) 
 
‘Smallness’ defined in such a manner has important implications for the economic 
performance of states. The effects of the chosen processes intensify with the influence of 
geography (core-periphery relationships), developmental level and technological and 
industrial specialisation of states (Tonurist, 2010). Seen from this perspective, countries with 
much larger populations can also be considered ‘small’. Baldacchino (1998, p. 276) 
comments that ‘Today, globalisation appears to have replaced development as the onerous 
strait-jacket, obliging all and sundry to conform’. From the viewpoint of small states, 
globalisation is not homogeneous, uniform or equal, but messy and often richly asymmetrical 
(Prasad, 2004). Small states are likely to be extremely sensitive to the impact of globalisation 
because of the interaction between their high degree of integration in the international 
economy and their inherent vulnerability (Read, 2002).  
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2.4 Good Governance 
 
Governments’ role in driving economic development remains controversial. Neo-classical 
prescriptions for the appropriate form of government intervention are flawed, not because 
they are theoretically unsound, but because people do not live in a neoclassical world (Wint, 
1998). Governance is defined as the exercise of political, economic and administrative 
authority in the management of a country’s affairs (United Nations Development Programme, 
1997). Generally speaking, in small states, a relatively higher degree of government 
intervention is warranted to rectify market failures. Prasad (2008, p. 947) argues that 
‘productive transformation’ cannot happen automatically through relying exclusively on 
market forces. Public direction and resources are needed. Basic needs and capabilities are too 
important to be left solely to market forces’. Policy, more than size, plays a critical role in 
economic growth (Commonwealth Secretariat, 1997). In today’s complex world, there is a 
need for increased convergence and co-ordination in public policymaking (Inskeep, 1991). 
Warrington (1994a, p. 109) refers to a state’s ‘capacity for policy management’. He 
differentiates between ‘good practice’ and ‘best practice’ and expresses a preference for 
‘good practice’, as it indicates that ‘decision-makers have a choice of alternative strategies 
and models of administrative development’ and conveys the importance of standards in 
governance (Warrington, 1997b, p. 5).  
 
Economic growth is significantly conditioned by the quality of a state’s bureaucracy (Knack 
& Keefer, 1995; Campos & Nugent, 1999). All states need good governance, especially small 
states (Curmi, 2009). Effective public policy has led to the success of various ‘micro’ 
European states such as Liechtenstein, Luxembourg and San Marino (Milne, 1999). The 
state’s machinery in small states tends to loom larger than life (House, 1998). Favoro and 
Peretz (2008) point out that improving public sector efficiency and effectiveness is crucial for 
small states, where, on average, government consumption as a proportion of GDP is high 
(20.6%) relative to that of middle-income (14.7%) and low-income countries (11.9 %) Given 
the relatively greater importance of the public sector in small states, the consequences of 
policy failure are even more serious (Krueger. 1990). ‘Local institutions (or clusters of 
institutions) and policies (especially in supporting “the technological progress and 
innovativeness” of enterprises) are of critical importance’ (Kozul-Wright & Stanbury, 1998, 
p. 1) The private sector in many small states is frequently plagued by fragmentation, with too 
 36 
 
many representative and business support organisations trying to achieve the same objectives. 
The private sector in these states needs to be empowered to overcome its dependence on 
government. Good intentions in public policymaking are necessary but not sufficient. The 
‘[a]bsence of political will, lack of stakeholder participation, policy ambiguity, partisan 
tensions, poor coordination and communication can all lead to policy failure’ (Dodds, 2007, 
p. 63). Successful outcomes are not necessarily due to good policy design, ‘[i]mperfect 
policies may produce successes in propitious circumstances and carefully designed initiatives 
may come unstuck for unforeseen reason’ (Thomas & Pang, 2007, p. 28).  
 
Resilience can be ‘nurtured’ through good policymaking and effective governance. ‘Good 
governance is an essential underpinning to appropriate policy formulation and hence an 
indispensable element of economic resilience’ (Briguglio et al., 2008, p. 11). It requires not 
only good practices but also high quality institutions (Prasad, 2008). Proper institutions are 
key in formulating and implementing policies (Baldacchino & Greenwood, 1998). 
Institutions have moved to the forefront of the economic development literature (Bertram, 
2006; Taymaz, 2009). States are important society-shaping institutions (Weiss, 1998). 
Institutions are a critical variable in determining how states manage openness and play a key 
role in how exogenous pressures are translated into new policies. High-quality institutions 
make a difference in the ability of small countries to manage globalisation (Bräutigam & 
Woolcock, 2002).  
 
Institutions are self-regenerating ‘systems of constraints regulating human interactions’ and 
providing a context for transactions ‘in an environment marked by uncertainty’ (North, 1990, 
p. 142). Institutions serve both formal and informal organisations by regulating exchanges 
and making it easier (relative to individuals) to manage risks. Small states demonstrate high 
levels of institutional coherence (Scheyvens & Momsen, 2008) and their experience provides 
considerable material on the diverse role of policies and institutions on development (The 
World Bank, 2008). Although practically all small states have replaced former colonial 
institutions with their own institutions, they exhibit relatively stronger institutional quality.  
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Sutton (2008) identifies four behavioural features which shape the performance of the public 
service of small states: 
 
o Exaggerated personalism, including domineering ministers and favouritism 
o Limited resources, with multiple portfolios and a limited ability to provide a broad range 
of public services 
o Inadequate service delivery, with high cost and the lack of motivation in middle-level 
management and employees  
o High dependence on foreign consultants 
 
Warrington (1999) finds that in emerging polities, the task of institutional innovation is 
achieved through 
 
• an effective framework capable of meeting growing popular demands 
• a high degree of national integration capable of maintaining social order during times of 
crisis 
• an expansion of responsible participation in political processes 
• a viable civic culture comprising autonomous and differentiated sectors of society capable 
of articulating and aggregating interests  
2.5 Social capital 
 
The coherence and unitary nature of states tends to be over-emphasised. The state is 
essentially a ‘conglomeration of varied crystallizations’ (Weiss, 1998, p. 16). Cheung (2008, 
p. 122) describes the state as ‘a conglomeration of overlapping strategic linkages’. A political 
economy suggests that polarized societies are prone to competitive rent-seeking by different 
groups, which have difficulty agreeing on public goods, such as infrastructure and education 
(Fearon, 2003). Weak states are easily captured by powerful groups, which then exploit their 
power to extract rents (Fritz, 2003). The effect of shocks on growth is larger: the greater the 
latent social conflicts in an economy, the weaker its institutions of conflict management 
(Rodrik, 1998). The literature on small states identifies social cohesion as a primary factor 
leading to economic success. Small states possess greater social homogeneity and cohesion as 
well as communal consensus in decision making which contribute to social capital formation 
and provide an appropriate environment for growth (Armstrong & Read, 2002). Small 
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European states have been often seen as harmonious manifestations of Bacon’s New Atlantis 
endowed with coherence, agility and intelligence (Katzenstein, 1985). 
 
Sutton (1987) argues that polarisation in party politics is largely absent in small states and 
this political accord is due to in-group solidarity against constant external threats. Ordinary 
citizens of small states enjoy a remarkable degree of democratic voice and tend to have direct 
access to governing elites (Farrugia, 1993). Social development is one of the components of 
the economic resilience index proposed by Briguglio et al. (2006b). Social development in 
this context refers to the extent to which relationships within a society are properly developed 
through social dialogue, enabling the undertaking of corrective measures effective in the face 
of adverse shocks. Social cohesion is generally defined as the ‘resourcefulness of a people to 
respond positively, collectively and responsibly to an identified political, economic, labour-
related or social challenge’ (Prasad, 2008a, p. 293). Social cohesion and ‘social capital’ are 
often used interchangeably. Social capital results from the ability to form ‘solidarity’, 
networks of mutual support, in the face of threats or danger (Bertram, 2006) and involves the 
ability of actors to secure benefits by virtue of membership in such social networks (Portes, 
1998). Social capital is also used to include considerations relating to leadership, discipline, 
personal responsibility, forward planning and adaptability (Connell, 2007).  
 
The level of trust in a society is the cornerstone of economic success (Bartmann, 2000). 
Strong leadership has an immediate and major impact in small countries because of their 
limited size. Polarization in party politics is seen to be largely absent in small states and 
inhabitants identify themselves closely with the state. Political harmony finds its source in the 
necessity of fostering in-group solidarity against constant external threats (Gagné et al., 
2007). Vertical, as well as horizontal, inequalities seem to be less pronounced in small states, 
and this reduces the risk of internal strife. Micro states are not immune from the conflicts that 
afflict larger polities, and small-scale societies are not invariably consensual (Warrington, 
1997a, p. 105). Small size in itself is no guarantee of lower opportunistic and rent-seeking 
behaviour (Read, 2006). Gagné et al. (2007) note that even if group conflicts in small states 
tend to be less frequent, once they break out, they may persist and lead to a breakdown of 
social unity. This is especially true if there is power disparity between the social groups. 
Warrington (1997a, p. 105) warns that generalisations are risky and that ‘the structures of 
power, political culture, patterns of leadership and discourse of a micro-state will explain 
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numerous phenomena that might otherwise be glibly attributed to size’. Various studies have 
sought to pit the assertive, emerging political elite against the traditionally pre-eminent civil 
servants of small states (Warrington, 1994a, p. 122), but ‘by setting up the bureaucracy in 
opposition to politicians, this view ignores the social roots and values of civil servants’. 
 
Farrugia (1993) notes that ‘personal proximity’ in small states has its disadvantages and may 
lead to increased nepotism. Familiarity among the population, coupled with personal, family, 
and tribal rivalries and/or traditional political and cultural systems, can partiality result in 
government decisions, making it difficult to generate the necessary consensus and cohesion 
for sustainable improvements in governance. Social capital is a necessary, although a not 
sufficient condition for dynamic capabilities (Blyler & Coff, 2003).  
 
2.6 Strategic flexibility  
 
Baldacchino and Bertram (2009, p. 141) observe a ‘disposition’ among small states to engage 
with their ‘turbulent and dynamic environments’ to seize opportunities and create and 
transfigure resources. They refer to this as ‘strategic flexibility’ (in this context, ‘strategic’ is 
being used in the sense that the action taken is part of a thought-out process and not purely an 
intuitive one). The flexibility and adaptability of small states has captivated the interest of 
many analysts. Katzenstein (1985, p. 211) suggests that small European states ‘continue to 
prosper-not because they have found a solution to the problem of change but because they 
have found a way to live with change’. This has also been found true of small firms in small 
economies, which seem to prosper by exploiting the benefits of flexibility gained from their 
need to adapt to forces outside their control (Blazic-Metzner & Hughes, 1982). Although 
researchers generally find that small states are more flexible and can adjust more quickly to 
rapid changes (Bräutigam & Woolcock, 2002), not everyone agrees. Favoro and Peretz 
(2008, p. 275), for example, emphasise that small size ‘implies that flexibility to adapt to 
external shocks is limited’. Why small states are generally more ‘strategically flexible’ than 
larger ones, and the dynamics leading to different levels of ‘strategic flexibility’ among small 
states themselves, is academically a ‘black box’, which this research proposes to explore. 
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There is no one definition of what is a ‘small state’. Over the years the study of small states 
has moved from structuralism to neo-liberalism to a concern with environmental and 
economic vulnerability most of these studies associated smallness with being ‘sub-optimal’ or 
‘weak’. The Singapore Paradox turned the study of vulnerability into one of resilience. 
Various other approaches also emphasise the importance of quality public policy, an efficient 
public service and institutional coherence in achieving a superior performance. Others focus 
on the role of social cohesion and trust in the formation of ‘social capital’.  Small states show 
a high propensity towards flexibility, but no adequate explanation of what drives this is given.  
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3. Mainstream theories of Superior Economic Performance  
 
This chapter explores various theoretical explanations of superior economic performance 
arising from mainstream academic disciplines. The literature review includes approaches 
that explain superior economic performance at the state, enterprise as well as the state and 
enterprise levels. Insights from R-A theory are used to propose a schema meant to help define 
the research setting to the development of the pharmaceutical industry in Malta following EU 
accession.  
 
3.1 State Level 
3.1.1 International Trade Theory 
 
International trade theory makes a case for countries to participate in trade and rejects 
interventionist policies, as these distort the international division of labour.  
 
Adam Smith (1776) argues that international trade is a win-win proposition for participating 
countries and presents the case for specialisation on the assumption that countries have 
different opportunity cost ratios. His main proposition became known as the theory of 
absolute advantage. David Ricardo (1817) took this thinking a step further and argued that 
even if a country is more efficient than another in producing all goods, it still benefits both of 
them to specialise in them, with each country producing a good in which it is most efficient. 
This is the essence of Ricardo’s theory of comparative advantage. Factors of production 
(land/raw materials, capital and labour) were considered to be homogeneous (perfectly 
substitutable) and mobile within, but not between, countries. According to the Heckscher and 
Ohlin (see Ohlin, 1967)  specialisation and comparative advantages arise from a country’s 
relative abundance of factor endowments. Fordism (production on a mass basis) and 
Taylorism (analysis and simplification of work processes) from the 1930s gave specialisation 
a new dimension. Specialisation started to be perceived as being structurally determined 
through cost advantages, derived from tightly controlled work processes.   
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International trade theory also seeks to provide answers regarding how gains from trade will 
be shared among the participating countries (‘unequal’ distribution can lead to superior 
performance): 
 
a. Mainstream theory emphasises the role of demand, with the terms of trade being 
dependent on the relative strength of the demand for the respective products. This is not a 
fully satisfactory explanation as it fails to clarify how the determinants of demand come 
about (Caballero et al., 2011). 
b. Structuralism perceives the world as comprising an exploitative centre and an exploited 
periphery. The Singer-Prebisch thesis (see Singer 1949) contends that while the centre 
specialises in exporting manufactured industrial products, the periphery exports primary 
commodities. The terms of trade between them is embedded in the structure of the global 
trade system, income elasticity of demand for commodities and impact of technological 
change. 
c. The unequal exchange school views international trade exchanges as being ‘unfair’ 
because production conditions (including wages) in the periphery lead to exporting goods 
and services at cheaper prices. While structuralism focuses on the trend in the terms of 
trade over time, the proponents of unequal exchange adopt a normative approach towards 
what these terms should be at a given point in time.  
d.  Dependency theorists argue that favourable production conditions at the centre are 
closely related to unfavourable conditions in the periphery. Inequalities in trade can be 
attributed to those in development and a colonial past. The whole international economy 
is seen as a system of domination organised to the advantage of the centre. Real 
development entails breaking away from the system of dependency through self-centred 
growth strategies.  
 
Structuralism became popular with policymakers in Third World countries and there emerged 
the idea that the only way towards industrialisation was through self-reliance and the 
promotion of South-South trade. Developing countries criticise traditional trade theory as 
being static and irrelevant to the development process (Salvatore, 2007). Trade theory is 
silent on the determinants of the economic characteristics of nations, including size (Alesina 
& Spolaore, 2003). For small states that have a comparative advantage in some commodity or 
primary product, specialisation has assumed negative connotations as it has generally led to 
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negative terms of trade and unstable export earnings. Free trade has not led to a win-win 
situation, as predicted by international trade theory. The experience of many small states is in 
sharp contrast to the benefits derived from international business by more advanced 
economies. 
 
3.1.2 Economic development studies 
 
The legacy of the past 50 years of development economics is not as inspiring as one would 
expect it to be (Piasecki & Wolnicki, 2004).  
 
Keynesian economics, the leading economic paradigm of the post-World War II era reserves 
an important role for the state which ‘was at the heart of the writings of the early 
development economists’ (Woo-Cumings, 1999, p. 5). Development evolved into a world 
view that accords industrialisation higher priority than other societal goals, with the state 
playing the lead role (Schneider, 1999). Western scholars viewed ‘under-development’ as a 
permanent ‘slump’ within cyclical growth economics; according to ‘big push’ theory, 
significant investments are needed to help a country overcome its backwardness.  
 
Soon after Bretton-Woods, the western economic development model was challenged by the 
Soviet model, with its emphasis on state control over the productive sectors of the economy, 
the collectivisation of agriculture and the enhancement of industrial power. The Soviets relied 
on extensive economic planning under the direction of a State Planning Commission.  
 
Johnson (1982) introduced the term ‘capitalist developmental state’ to refer to the experience 
of modern Japan, which was characterised by strong state intervention and extensive 
regulation and planning. In this model of capitalism, which is mostly associated with East 
Asian economies, the state engages in extensive macroeconomic planning and has extensive 
power and control over the economy. Johnson (1999, p. 32) conceives the term 
developmental state as ‘[going] beyond the contrast between the American and Soviet 
economies’. A fundamental goal of the developmental state ‘is the improvement of its 
economic conditions relative to other states’ (Pempel, 1999, p. 147). The search for superior 
performance is not only relative to other states, but also, over time, to itself. The 
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developmental state with its emphasis on economic nationalism and neo-mercantilism is a 
logical descendent of the German historical school (Pempel, 1999).  
 
Weiss (1998) notes that developmental states have been engaged in three types of economic 
transformation: 
 
1. Revolutionary: requires breaking the power of the dominant class 
2. Structural: involves a shift from agrarian to industrial activities  
3. Sector (industrial technological): leads to new sectors of production. 
 
The ruling political elites of ‘new’ developing countries soon realised that to legitimise their 
power, they had to underpin political independence with economic development. The 
ideological warfare over the path towards this development became entangled in the politics 
of the Cold War. The governments of many new states believed that they should play a 
leading role in economic development. They often tried to emulate the Yugoslavs, who were 
combining state ownership of enterprises with market mechanisms. In general, developing 
states were finding it hard to develop their economies, as they ‘could not generate foreign 
exchange out of their specialisation in the export of primary commodities subject to the 
declining terms of trade’ (Meseguer, 2009, p. 75).  
 
The new states lobbied hard within the UN to change the global trade rules, which they 
deemed as being detrimental to their economic development. In 1964, the UN called a 
Conference on Trade and Development to study the economic challenges faced by these new 
states. Subsequently, UNCTAD was established as a permanent organisation and became 
another trade forum. This somehow duplicated the work conducted by GATT, but was 
essentially seen by the new states as a ‘club of the rich’ countries. As the frustration of the 
new states grew, development thinking took two contrasting paths: one that followed by neo-
liberals, who deemed the interests of nations and social classes as being harmonious, and the 
other followed by neo-Marxists, structuralists and radicals, for whom development is an 
extension of class conflict and imperialism and who called for radical social engineering or 
revolutionary change (Black, 1999).  
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Both schools of thought shared the conviction that industrialisation was the only way forward 
(Piasecki & Wolnicki, 2004). Attempts to industrialise led to myopic behaviour by 
developing economies as they sought to establish the manufacturing industry at a prohibitive 
cost, especially in their flirtations with import substitution (Wint, 1998). By the mid-1970s a 
new stream of development thinking began to flourish. Tinbergen (1976) presented to the 
Club of Rome the  publication which he co-ordinated entitled  ‘RIO: Reshaping the 
International Order’ and which included the work of twenty experts from both developing 
and developed countries. The Report criticised the more advanced societies for the non-
sustainability of their growth trajectories. The term ‘sustainable development’ was coined by 
the Brundtland Commission (United Nations, 1987) to project a type of development that 
meets the needs of the present generation without compromising those of future ones1.  
 
In the meantime, a number of Latin American economists, frustrated by the corruption and 
incompetence of their politicians, and by the selfishness of the bureaucrats who usurped a 
large part of foreign aid, began to question the role of the state in promoting economic 
development. Peter Mandelson (2011), former EU trade commissioner, states that African 
countries over the last 50 years have become ‘professional beggars’. By the 1990s, various 
development theorists such as Parfitt (2002) heralded ‘the end of development’. Further, 
development studies started to be replaced by discourse about the strategies of emancipation, 
such as ‘new social movements’ theory, originating in groups such as the Zapatistas of 
Mexico.  
 
The collapse of the Soviet bloc created a new politico-economic scenario. In 1995, GATT 
was replaced by the WTO and the Uruguay Round came into effect. Policymakers the world 
over increasingly adopted a neo-liberal mind-set, moving away from state ownership and 
direct intervention in the economy. Both academics and practitioners came to view the state 
as inefficient and corrupt. Government’s role was no longer perceived as being that of a doer 
but rather as a facilitator and regulator. New states also felt obliged to embrace market 
economics and liberalise their economies. Meseguer (2009, p. xi) remarks that this change in 
economic paradigm ‘marked one of the most important socioeconomic changes in recent 
                                       
1 By its very nature, ‘development’ should be sustainable as that which is not sustainable is 
simply growth. The need to refer to sustainable development indicates the degree of 
confusion that started to permeate the academic development thinking. 
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decades’. Subsequently, the ‘development project’ was projected as a blueprint outlining a 
linear transition towards a modern, market-oriented, private-sector led economy which offers 
a standard of living comparable to that of advanced economies. This simplistic approach 
confused the issues and failed to account for the sociocultural complexities of the new states 
and the multi-dimensional nature of development (Baldacchino, 1998). What is left of the 
development discourse now assumes secondary importance. Storey and Murray (2001, p. 
291) state that ‘a clear disjuncture pervaded the study and practice of development which 
became inspired by a range of perspectives, including post-modernism, post-colonialism, 
feminism and ecology. Development practice regressed to post-war techno-centric and 
modernization philosophies’. 
 
By the dawn of the new millennium, the new states started to realise that globalisation was no 
panacea. The WTO accepted that the next round of multilateral negotiations (The Doha 
Round) would be a ‘round for development’. Although a partial agreement has been reached 
in Bali in late 2013, the finalisation of the Doha Round still seems far away. The biggest 
hurdle is the reluctance of the more advanced countries to stop subsidising the export of their 
agricultural produce. Weiss (1998) challenges the view that globalisation has rendered the 
state powerless and argues that countries such as Singapore have managed to deepen 
economic interdependence by forging sophisticated and flexible ties with domestic and 
international groups. Meseguer (2009) questions whether the 2007 financial meltdown, and 
subsequent economic crisis in much of the developed world, will lead to the decline of the 
neo-liberal paradigm. The ‘Washington Consensus’ is proving to be a mirage just like the 
‘development project’. Cooper Ramo (2004, p. 4) remarks that ‘The Washington Consensus 
was a hallmark of end-of-history arrogance; it left a trail of destroyed economies and bad 
feelings around the globe’.  
 
An alternative proposition is emerging, which Cooper Ramo (2004) terms the ‘Beijing 
Consensus’: China is marking a path for other nations around the world which are trying to 
‘figure out not simply how to develop their countries, but also how to fit into the international 
order in a way that allows them to be truly independent, to protect their way of life and 
political choices in a world with a single, massively powerful centre of gravity’ (Cooper 
Ramo, 2004, p. 3). The ‘Beijing Consensus’ acknowledges that it is no blueprint, emphasises 
the importance of geo-politics and the need for a pro-active approach to development. It 
 47 
 
highlights the fact that development entails not only higher GDP per capita but also 
sustainability of the economic system and an equitable distribution of wealth. 
 
Conventional economic development thinking failed owing to the blind imposition of 
‘western’ modernisation schemes on societies, ‘whose traditions, values, habits, social strata, 
and concepts of economic activity were fundamentally different’ (Piasecki & Wolnicki, 2004, 
p. 312). It is unfortunate that mainstream development thinking seems to be at a dead end. 
Development is a complex, multi-faceted and multi-speed phenomenon and western 
academics have generally failed to fully understand its nature. If a new lease of life is to be 
injected into development thinking, a holistic approach needs to be adopted. In the age of 
globalisation, ‘the past is an exceptionally poor guide to the future’, obliging small states to 
think differently about their economic development trajectory (Williamson & Hu, 1994, p. 
52).  
 
Development theory offers various explanations as to why many states, including a great 
number of small ones, have failed to reach the level of prosperity of more advanced 
economies. Western economists tend to interpret the lack of development as a special case of 
cyclical economics, a sort of permanent slump. Other explanations are often framed from an 
ideological perspective. As a process, economic development became equated to 
industrialisation, with the government being given a primary role in driving it forward. 
However, since the early 1990s, neo-liberal thinking (as incorporated in the Washington 
Consensus) led to the rolling back of the state. The government was expected to take a back 
seat and its role was confined to that of regulator and facilitator. 
 
Economic development theory seems to have come to a dead end. The development paradigm 
is fast being replaced by a competitive one. Its major constraint has been that while 
emphasising the key factors hindering countries from developing, it has been unable to offer 
pragmatic guidelines as to how countries (including small states) can develop their 
economies.  Politicians find it convenient to speak in terms of competitiveness rather than 
development as it shifts the focus (and reasons underlying policy failure) to exogenous 
factors. Storey and Murray (2001) state that although the conditions created by pursuing 
competitiveness may be unfortunate, they are not as bad as those of being uncompetitive. 
Small states are presented with little option: they either manage to compete or fall behind. 
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The issue remains the same as that addressed by economic development: how can 
‘competitive’ thinking help a small state achieve ‘superior performance’? 
 
3.1.3 Competitiveness 
 
Scholars and analysts of competitiveness try to root their work in the thinking of Adam Smith 
(1776); in reality, competitiveness represents a paradigm shift given that international trade 
(and business) is no longer presented as a win-win proposition. Competitiveness implies that 
some win, while others lose. The study on national competitiveness is rooted in business 
studies and not economics. The concept of comparative advantage is being replaced by 
competitive advantage owing to ‘[a] growing awareness that the assumptions underlying 
factor comparative advantage theories of trade are unrealistic in many industries’ (Porter, 
1998, p. 12). What does not change is the importance of specialisation. Porter (1998) asserts 
that productivity and competitive advantage in an economy require specialisation. He 
distinguishes between ‘lower-order’ sources of competitive advantage (e.g. low labour costs 
or cheap raw materials), which are easy to imitate, and ‘higher-order’ advantages (e.g. 
proprietary process technology and product differentiation), which are more defendable and 
sustainable. 
 
In ‘The Competitive Advantage of Nations’, Porter (1998) studies the ten most successful 
economies in the world to determine whether there are a set of key factors underpinning the 
‘superior performance’ of these economies. The ‘diamond of national competitiveness’ 
model is the result of his research. Porter’s diamond represents ‘a theory of investment and 
innovation’ (Porter, 1998, p. 173), with innovation growing ‘out of pressure and challenge’ 
(Porter, 2008c, p. 585). Porter’s (1998, p. 8) quest was to find out why nations ‘can or cannot 
compete in sophisticated industries and activities involving high productivity’. He remarks 
that competitiveness is not about having a trade surplus, a cheap currency or low unit labour 
costs and that the particular mix of industries that are exporting is more important than a 
nation’s average export share. Despite globalisation, nations have become more, not less, 
important as ‘competitive advantage is created and sustained through a highly localised 
process’ (Porter, 2008b, p. 155). The national environment is of critical importance in 
shaping competitive advantage (Kovacic, 2007). Porter (1998) notes that differences in 
national values, culture, economic structures, institutions and histories all contribute to 
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competitive success. ‘These determinants create the national environment in which 
companies are born and learn to compete’ (Cho and Moon, 2000, p. 62). The basic unit of 
analysis in understanding competition is the industry’s structure, even though ‘[u]ltimately 
only companies themselves can achieve and sustain competitive challenge’ (Porter, 1998, p. 
191).  
 
All industries can use high technology and be knowledge intensive (Porter, 1998d). ‘The 
diamond of national competitiveness’ (figure 4) has four interrelated components which are 
mutually reinforcing: (1) factor conditions (2) demand conditions (3) related and supporting 
industries and (4) firm strategy, structure and rivalry. In addition, there are two exogenous 
factors: chance and government.  
 
 
Figure 4: Porter’s Diamond Model for the Competitive Advantage of Nations 
(Reproduced from Value-Based Management) 
 
Governmental policy influences, but does not determine, national advantage (Porter, 1998). 
Appropriate public policy shifts as nations progress to successive stages of competitive 
development which includes four distinct stages: factor driven, investment driven, innovation 
driven and wealth driven. Government’s proper role is that of a catalyst and challenger; it 
needs to involve an industry in determining the specialised factors to be created. Given that 
‘[i]t often takes a decade for an industry to create competitive advantage...but in politics a 
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decade is an eternity’ (Porter, 1998, p. 185), there emerges an inherent conflict between 
competitive time for companies and political time for governments. 
 
Porter (2008d) emphasises the importance of clusters in boosting productivity. A firm can no 
longer be seen as a stand-alone unit but as part of a value chain. Porter (2008d, p. 221) 
defines a cluster as ‘a geographically proximate group of interconnected companies and 
associated institutions in a particular field linked by commonalities and complementarities’. 
Clusters capture important linkages, technology spill over, skills, information, marketing and 
customer needs. Enterprises in a cluster cooperate among themselves while competing (co-
petition). Identifying paths of interrelationships outside a firm is a creative task as most 
organisational structures in firms work in the opposite direction. Linkages and synergies are 
of critical importance since they create critical mass and promote specialisation and 
reputation.  
 
Innovation drives differentiation and higher value added. Innovation requires the right milieu 
and institutional capacity to be able to flourish (Porter, 1998). Porter argues that while 
clusters have long been part of the economic landscape, their depth and breadth have 
significantly increased with the intensification of competition. Conventional agglomeration 
economics emphasises input cost and specialisation benefits arising from proximity and 
linkages, whereas Porter’s places emphasis on innovation and learning. Equally important is 
the capacity and flexibility that clusters provide for enterprises to act rapidly. 
 
Competition and rivalry between value chains or clusters at a domestic level is of critical 
importance in Porter’s approach. Domestic competition helps enterprises shape up and 
prepares them to face competition in the global market. It is Porter’s merit that ‘nations’ are 
back on the centre stage of ‘superior’ performance. However, Rugman (1991) criticises 
Porter’s diamond model on the basis that it does not properly account for the role of FDI and 
multinational enterprises. Rugman (1992) further argues that a more relevant concept prevails 
in small open economies, namely the double diamond model. Moon et al. (1995, 111) build 
on Rugman’s (1992) work to propose their own model, which emphasises two issues: a 
country’s sustainable value-added results from both domestically and foreign-owned firms 
and that sustainability requires a value-added configuration spread across many countries.  
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Moon et al.’s (1995) double diamond model for small economies is re-produced hereunder 
(figure 5): 
 
 
 
 
   
                                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Generalised Double Diamond  
(Reproduced from Moon et al., 1995) 
 
The outside diamond represents the global system, while the inside diamond represents the 
domestic system. The dotted diamond in between is a country’s ‘international diamond’ and 
represents the interface of the other two diamonds. A comparison of the size and shape of the 
domestic and international diamonds reveals major strategic differences (Moon et al., 1995). 
 
Governments occupy a central role in Moon et al.’s model since it significantly impacts the 
four factors of the diamond model. The authors deems that ‘the government in small 
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economies as Korea and Singapore is more important than anything else in affecting the other 
variables’ (Moon et al., 1995, p. 130). Small states’ dependence on imported technology and 
overseas demand makes it imperative that they link selectively to the ‘diamonds’ of other 
countries. In addition, FDI plays a key role in the economic growth and integration of small 
economies. Porter (1998, p. 160) states that ‘[i]nternational trade and foreign investment can 
both improve a nation’s productivity as well as threaten it’ as they expose a nation’s 
industries to the test of international standards of productivity. In the case of small states, 
trade and FDI are not an option.  
 
Although competitiveness is well-defined at a micro level and sufficiently meaningful at the 
sector level, it is nebulous at the national level. Cho and Moon (2000, p. 25) argue that ‘[t]he 
concept of national competitiveness is elusive as countries do not compete against each other 
in the same way as corporations such as Coke and Pepsi do’. The number of rankings of 
national competitiveness prepared by governments, consultants and research organisations is 
growing and becoming increasingly influential in policy formulation (Wignaraja, 2003, p. 
15). The World Economic Forum (2010, p. 4) defines competitiveness as ‘the set of 
institutions, policies, and factors that determine the level of productivity of a country’, while 
the IMD (2011) looks at competitiveness more in terms of the ability of nations to create and 
maintain an environment in which enterprises can compete. Both these institutions produce 
annual competitiveness reports, whose results vary owing to the different methodologies 
used, including the weighting given to individual variables. The main problem of existing 
competitiveness reports is their lack of a strong theoretical background (Moon & Cho, 2000, 
p. 195). The World Economic Forum (2011) launched the concept of ‘sustainable 
competitiveness’, which it defines as ‘development that satisfies the needs of the present 
without compromising the ability of future generations to meet their own needs’. The Forum 
specifies that sustainability entails the ability to meet society’s economic, social and 
environmental needs. The Report remarks that ‘there is not yet a well-established body of 
literature on the link between productivity (which is at the heart of competitiveness) and 
sustainability’. The index takes a 20-year perspective and emphasises that in the long run, an 
economy should be socially cohesive, live within its financial means and ensure the correct 
and efficient use of its resources (The World Economic Forum, 2011). 
Wignaraja (2003) distinguishes between three primary approaches to competitiveness: 
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1. The macroeconomic perspective which deals with internal–external balance and focuses 
on real exchange rate management as the principal tool for competitiveness 
2. The business strategy that focuses on rivalries between firms and countries and assigns 
public policy a limited role  
3. The technology and innovation approach that brings together the enterprise and national 
levels and active public policies for competitiveness. 
 
The technology and innovation approach considers technology to be an important 
determinant of competitive advantage. This is evidenced by the work of various analysts on 
the absorption capacity of enterprises in developing countries. The technology and innovation 
perspective associates the concept of competitiveness with the accumulation of technological 
capabilities at enterprise level and collective learning within the National Innovation System.  
 
Wignaraja (2003) proposes his own competitiveness index for developing economies on the 
basis of their manufactured exports. This index is built around three sub-components 
 
• Current manufactured exports per capita 
• Long-term growth in manufactured exports 
• Share of technology-intensive exports  
 
National competitiveness approaches emphasise that competitive advantage is created and not 
inherited. Porter was instrumental in bringing about this paradigm shift (Cho & Moon, 2000). 
By linking national competitiveness to the structure of specific markets, Porter shifted the 
focus of competitiveness from factors which were internal to the firm to external ones. 
 
Not all analysts agree about the merit of studying competitiveness at the national level. Paul 
Krugman (1994) holds that it is a meaningless concept and what really matters is 
productivity. He warns that the obsession with national competitiveness is both wrong and 
dangerous. Howes and Singh (1999, p. 21) disagree with Krugman and argue that at the 
national level ‘the notion of competitiveness is analytically meaningful and useful to 
policymakers’. Whatever its rationale and quality, the analysis of national competitiveness 
clearly responds to a growing policy need (Lall, 2001). The continued popularity of national 
competitiveness among academics and practitioners is evidenced by the numerous reports on 
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the subject that are published on a regular basis. The primary merit of national 
competitiveness is in highlighting the fact that, on international markets, the prospects of a 
country depend as much on its own performance as on that of its competitors.  
Cho and Moon (2000) find that Porter’s diamond model is not relevant to small economies 
because their domestic variables are limited. In particular, it can be argued that this model is 
of limited value to small states because of the following reasons: 
 
1. Domestic demand is negligible and customers can hardly be expected to be global trend-
setters. For small states, demand arises out of global/regional markets. 
2. They need to import most of their raw materials and components. Small states typically 
lack the critical mass necessary to create specialised factors to successfully compete on 
external markets.  
3. The scope for upstream and downstream industries in small economies is limited.  
4. While firm rivalry is equally intense and personalised, firm strategy is mostly ‘emergent’, 
lacking sophistication and a business planning culture. 
 
Another critical assumption made by Porter in his diamond model is that countries have the 
market power to manoeuvre and manipulate the global market structure to their advantage. In 
his model, Porter relates market power to a country having  substantial/sustained exports to a 
wide array of nations and/or significant outbound foreign investment. 
 
Competitiveness theories too give no special consideration to small states. Rather they tend to 
focus on the degree of sophistication reached by an economy. They generally fail to provide 
guidelines as what it takes, for example, for ‘factor-driven’ economies to move up the 
economic development ladder. Where a prescription is offered (such as with Porter’s 
diamond model) the basic tenet (manipulating market power) is hardly relevant to small 
states. 
 
 
 
3.1.4 Explanations from Political Economics 
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The relationship between state and society is not merely a relationship between the central 
state and the whole of society; ‘both are subdivided on the vertical and horizontal levels with 
different levels and organisations having different capacities’ (Heberer, 2003, p. 1).  
State capacity relates to the ability of the state to get things done in pursuance of defined 
objectives and goals (Cheung, 2008). It is difficult to identify states with a high degree of 
capacity in all policy areas (Sorensen, 1993), such that ‘an “overall” state capacity does not 
exist and is impossible to measure’ (Weiss, 1998, p. 7).  
 
Heberer (2003) explains that state capacity entails the following:  
 
1. Legitimacy: the acceptance of the political system by its citizens  
2. Regulation: its capacity for regulation and social control 
3. Resources: they enable enforcement, especially finance and personnel 
4. Bargaining: the ability to incorporate new social groups into bargaining processes and 
find a balance between various interests  
5. Learning capacity: the ability to learn from mistakes and failures.  
 
3.1.4.1 Democratic Corporatism 
 
Democratic corporatism is a form of ‘social capital’ that hypothesises why certain states 
perform better than others. It entails ‘[t]he voluntary, cooperative regulation of conflict over 
economic and social issues through highly structured and interpenetrating political 
relationships between business, trade unions, and the state, augmented by the political 
parties’ (Katzenstein, 1985, p. 32).  
 
Katzenstein adds that both liberal and social democratic corporatism are distinguished by 
three traits: 
 
1. An ideology of social partnership expressed at the national level 
2. A relatively centralised and concentrated system of interest groups and 
3. Voluntary and informal coordination of conflicting objectives through continuous 
political bargaining between interest groups, state bureaucracies and political parties  
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Weiss (1998, p. 25) criticises the corporatist approach for being ‘too narrow’ or ‘too fleeting 
to allow sustained analysis of transformative capacity’. She adds that this approach tends to 
overplay tri-partite arrangements at the expense of government–industry relationships.  
3.1.4.2 Strong State thesis 
 
Similarly, the strong state approach seeks to explain differences in state capacity which lead 
to diverse economic performances by countries. States can have strong or weak capacity 
depending on the historically formed balance of power between state and society (this, 
however, is not a reflection of the degree of democracy). A strong state is not necessarily a 
highly interventionist one. State capacity is measured in terms of its coercive capacity. A 
strong state is seen as having high capacity to complete four tasks: penetrate society, regulate 
social relationships, extract resources and allocate them in determined ways (Migdal, 1988). 
According to Weiss (1998), a strong state requires that the national political executive and the 
bureaucracy possess three core capabilities: 
 
• Formulate policy goals and strategies for implementation independent of societal 
pressures 
• Alter the behaviour of important domestic groups to get them to further its policies 
• Restructure the domestic environment in the pursuit of goals  
 
Strong states are equated with the power they have over society. Such a view of state power 
makes it virtually impossible to apply to modern states. As mentioned, neither is a state’s 
strength equally applicable across all issues, nor is its capacity necessarily built on the state’s 
hard authority to impose its will top-down on society. Rather, it depends on ‘its power to 
mobilise social and economic support for the achievement of state goals’ (Fritz, 2003, p. 5). 
Instead of a ‘strong state’, it makes more sense to refer to a ‘functional’ or ‘capable’ state, 
that is, ‘a state that enables society to respond continuously and dynamically to a changing 
international environment’ (Fritz, 2003, p. 5). 
 
Rodrik (1999, p. 94) observes that in times of great change, flexibility and adaptability 
require ‘insulated, autonomous executives who can act speedily and decisively’ and 
democracy ‘even when not hostile to reform, complicates it’. Democracies are notoriously 
bad at producing credible bargains that require political commitments over the medium term 
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(Rodrik, 2011b). Katzenstein (1985) disagrees with this reasoning and deems that although 
authoritarianism in the short term can achieve results, it is not conducive to longer-term 
development. 
3.1.4.3 Finance 
 
A third approach from political economics emphasises national finance as a primary 
instrument that enables the implementation of policies. Goal formulation requires the 
capacity to be implemented, and there exists a causal relationship between a country’s 
financial resources and the capacity of the state to deliver. This approach assumes that there 
exists an autonomous capacity on the part of the state which insulates it, while at the same 
time, generating the ability for it to act on relevant groups. Weiss (1998) asks whether this 
approach really explains or merely restates the problem of differential state capacities. 
3.1.4.4 Embedded Autonomy 
 
Originally conceived by Evans (1989), ‘embedded autonomy’ proposes that an effective state 
is not only ‘sufficiently’ autonomous but also sufficiently entrenched in particular networks, 
which enable it to implement policies. For Evans, the key question is not how much state 
intervention is necessary for development, but the nature of intervention. States are embedded 
in a dense network of social ties that enable political elites to negotiate goals, policies and 
implementation strategies with business actors. These are not personal clientele-type ties, but 
connections between constituencies and the state as an organisation. A state needs to possess 
the capacity to combine two apparently contradictory aspects: ‘Weberian bureaucratic 
insulation’ and ‘intense immersion in the surrounding social structure’(Evans, 1989, p. 561). 
3.1.4.5 Governed Interdependence 
 
While agreeing with Evans about ‘embedded autonomy’, Weiss (1998) emphasises the 
existence of a formally institutionalised environment of cooperation between a strong 
government and a well-organised business sector that ensures the delivery of the state’s 
economic goals. ‘Governed interdependence’ is achieved through political exchange between 
the state and societal actors (Weiss, 1998). National variations in political institutions 
determine the capacity of states to offset the effects of external pressures. Weiss (2000) 
defines ‘transformative capacity’ as the ability of a state to adapt to external shocks and 
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pressures by generating new means of governing the process of industrial change. Weiss adds 
that transformative capacity is most successful in an environment of ‘governed 
interdependence’, which requires both a strong state and private sector. Both the state and 
private sector maintain their autonomy, but it is up to the state to set broad developmental 
goals and monitor business performance. The state receives the information and cooperation 
it needs from societal organisations to transform the economy. In return, the state legitimates 
those organisations, ameliorates social risks surrounding investment and provides a focal 
point to resolve struggles among firms and sectors.  
 
Cheung (2008) synthesises much of the above thinking and proposes a framework that brings 
together the primary existing notions of modern state capacity building. His framework, 
which is re-produced hereunder, brings together four key players:  
 
• political society : strong leadership, legitimacy and authority  
• bureaucracy: organisational strength and insulation  
•  economy/industry link: as per governed interdependence linkages  
• society: drawing on ‘social embeddedness’ 
 
 
 
 
Figure 6: Modern State Capacity Building 
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(Reproduced from Cheung, 2005) 
 
Cheung (2008, p. 122) notes that ‘[w]hat makes a state effective are its linkages to all these 
spheres and its ability to inculcate and mobilise social and economic support for the 
achievement of its goals’. The presumptions behind this framework are as follows:  
 
(a) a complex and multi-interest society is making governance more challenging 
(b) governance problems cannot be dealt with by the state, society or market, each on its own 
(c) the ‘state’ has the role, as well as the competence, to ‘steer’ and ‘regulate’  
 
These approaches emphasise the importance of social partners working together to help 
achieve established economic goals. This is true irrespective of large or small states. The 
importance of state capacity is closely related to the ‘social capital’ perspective emerging 
from small state studies, which will be dealt with further on in this research. 
 
Political economists generally emphasise the role of the state in driving economic 
transformation and associate competitive advantages with state capacity. State intervention 
should enable ‘society to respond continuously and dynamically to a changing international 
environment’ (Fritz, 2003, p. 5).  
 
‘The proposition that state capacities for domestic transformative strategies provide a 
competitive advantage’ lies at the heart of such approaches (Weiss, 1998, p. 5). Although a 
United Nations (2006) report highlights the serious challenges faced by small states in 
building state capacity, approaches from political economics largely fail to make reference to 
the peculiar realities of small states. Although explanations offered by theories from political 
economics generally offer valid understandings impacting on the ability of states to achieve a 
superior economic performance, these are not presented in a holistic manner and are not 
sensitive to the specific conditions of small states. 
 
3.2 Enterprise Level 
 
The limitations of these approaches to adequately account for the ‘superior economic 
performance’ of small states induced the researcher to explore explanations relating to 
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superior economic performance from approaches focusing on the firm. There are essentially 
two reasons for this. The first was to explore the possibility of learning from such 
explanations and gather insights which could be extrapolated to the state level. The second 
relates to the fact that in a small state ‘proximity’ is not just about physical closeness but is 
also ‘relational’ implying that the impact of the state’s policies, decisions and actions on 
enterprises (and vice-versa) tend to be greater and faster.  
 
Neo-classical economic philosophy refutes the concept of superior performance at the 
enterprise level, which it interprets as a ‘temporary’ distortion of market conditions. 
Williamson (1981) laments the tradition in economics to view with disrespect all market 
structures that depart from perfect competition. Economists acknowledge that firms are able 
to reap ‘rents’ out of market imperfections (monopolistic) or innovative initiatives. 
Innovation is incorporated as variable in the supply or production function, equating it ‘with 
independent technological and less frequently organisational changes’ (Fonseca, 2002, p. 12). 
Over a longer period, however, competing firms catch up with innovative ones, creating a 
new supply–demand equilibrium which eliminates higher returns. Schumpeter (1934) 
attributes superior performance to scientific and technological innovation as well as the role 
of the entrepreneur. Unlike neo-classical economists, Schumpeter places innovation inside 
the economic system. For him, the impact of innovation is on-going and this renders the 
future unpredictable. Superior business performance can also result from the capability of 
certain firms to exploit ‘external’ advantages arising from their operating environment. Since 
the 1980s, the importance of these advantages have been given new life through the extensive 
work on value chains, networks and clusters conducted by various academics (especially 
Michael Porter). Externalities are considered to be of vital importance for competitiveness, at 
both the enterprise and state level. 
 
A firm is a unique entity in time and space as well as a product of its history (Hunt & 
Morgan, 1995). Ultimately, it is firms which create value and compete (Porter, 1998). 
Superior performance at the firm (enterprise) level is gauged through higher profits, higher 
sales, a dominant market share and any other objective which an enterprise sets for itself. 
Achieving competitive advantage does not imply that a company must out-perform its 
competitors in all areas all the time (Asikhia, 2006). Deciding which areas to exploit is the 
central issue in setting competitive priorities for an organisation. The objective of strategic 
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management is to build sustainable competitive advantage (Amis et al., 1997). There is no 
generally accepted theory, and much less systematic evidence, on the origins and dynamics of 
competitive advantage (Cockburn et al., 2000). The processes by which competitive 
advantages are generated and sustained are complex and continue to attract the interest of 
scholars in various fields, including organisational economics, strategic management and 
marketing (Fahy et al., 2004).  
3.2.1 Environmental View 
 
According to Cockburn et al. (2000), Michael E. Porter transformed the study of ‘imperfect 
competition’ into a theory of ‘competitive advantage’ and in the process, shifted the focus of 
strategy research outward, towards the analysis of the firm’s microeconomic environment. 
During the 1980s, the competitive forces framework of Porter (1980) became the dominant 
paradigm. It focused on a firm’s actions to create defensible positions against competitive 
forces. A superior performing firm enhances its ‘market power’, commands better prices and 
creates ‘entry’ barriers into the industry. Market power can, and does, shift over time. The 
approach taken by Porter (1980) has its roots in industrial economics, which is primarily 
concerned with consumer welfare and intra-industry competition. Industry structure is seen as 
a key determinant of profitability as expressed in the structure-conduct-performance (S-C-P) 
maxim: industry structure determines conduct, which in turn determines profitability 
(O’Keeffe et al., 2009). Many of a company’s competitive advantages lie outside the firm 
(Porter, 1998). An industry’s market structure is both a consequence and determinant of 
competitive rivalry (Witteloostuijn & Boone, 2006). 
 
The number of firms (density) as well as their size and distribution (concentration) determine 
the competitive conditions of an industry. Theories of market structure have generally 
focused on three key questions:  
 
(1) What determines market structure features?  
(2) How does market structure influence competitive behaviour (and vice versa)?  
(3) How does market structure evolve over time? 
 
The strategic conflict approach became prominent in the late 1980s and focuses on product 
market imperfections, entry deterrence and strategic interaction. Shapiro (1989) utilises game 
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theory to analyse the nature of competitive interaction between firms. Shapiro’s work paved 
the way for the game-theoretic school, which views superior performance as resulting from 
better strategizing. Some managers are able to ‘play the game’ more effectively than others. 
The strategic conflict approach holds that ‘rents’ will flow from privileged market positions 
resulting ‘from strategizing’ and ‘limitations on competition which firms achieve through 
raising rivals’ costs and exclusionary behaviour’ (Teece, 1984, p. 528). 
 
Competitive models are criticised for presenting competition as a zero-sum game; firm 
profitability seems to depend on developing a position of power over suppliers, customers 
and competitors. This causes problems, especially with policymakers, who come to view 
superior firm performance and profitability as taking place at the expense of consumer 
welfare (O’Keefe et al., 1996). Hamel (1991) observes that Porter’s notion of competitive 
advantage, while providing the means to compute product-based advantages at a given point 
in time (in terms of cost and differentiation), provides little insight into the process of 
knowledge acquisition and skill building.  
3.2.2 Efficiency view 
 
The resource-based view (RBV) of the firm has its origins in economics, with Penrose (1959) 
being one of the pioneers (Metais & Meschi, 2004). The notion that firms are fundamentally 
heterogeneous in terms of their resources and internal capabilities has long been at the heart 
of the field of strategic management (Peteraf, 1993). The RBV approach gained popularity 
with both academics and practitioners after the publication of ‘The Core Competence of the 
Corporation’ by Prahalad and Hamel (1990). Since then, the RBV framework has been 
extensively used in marketing, management, economics and business studies. RBV 
proponents (Table 1) hold that strategic investments should be directed towards developing 
internal ‘activities’ and ‘resources’ because this is more productive and sustainable than 
developing market advantages to out-perform competitors. 
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Table 1: Studies on Firms’ Performance 
(reproduced from McGahan, 1999) 
 
Firms are portfolios, or bundles, of distinctive and difficult-to-trade ‘resources’ (Teece, 2007) 
which persist over time (Eisenhardt & Martin, 2000). Firms achieve superior performance by 
developing and leveraging resources that are valuable, rare, inimitable and non-substitutable 
(Barney, 1991).  
 
Competitive advantage stems from individual attributes as well as linkages among resources. 
Not all resources are of equal importance or possess the potential to be a source of sustainable 
competitive advantage (Fahy et al., 2004). Resources are developed over time, and hence, 
‘history matters’ (Freiling, 2004, p. 30). Nooteboom (2005, p. 67) proposes that ‘firms 
compete not by striving to do the same thing most efficiently but by trying to offer 
differentiated products on the basis of firm-specific competencies’. RBV theories of 
competition require units of selection that are relatively durable and which can be transmitted 
to successors (Freiling, 2004). The most potent proprietary resources are intangible and tacit 
and include company and/or brand image and reputation (McGarth et al., 1995). The RBV 
approach is an inside-out perspective of the firm that seeks to identify the characteristics of 
firms achieving superior performance and which enables management ‘to reconceptualise 
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what their businesses are, do, and can be’ (Rouse & Daellenbach, 2002, p. 492). RBV 
presents an enactment-based view of strategy formation and implementation, in which firms 
are seen to proactively manage and shape their environments and not to simply respond to 
exogenous uncontrollable forces. Bingham and Eisenhardt (2008) classify RBV strategic 
logics into three categories: leverage, position and opportunity. Each logic potentially leads to 
competitive advantage; different logics may be useful at different stages of market evolution 
and each addresses distinct objectives.  
 
The nature of competition influences resource accumulation and hence, the competitive 
advantage of individual firms (O’Keeffe et al., 1996). To be strategic, moves must entail 
resource commitments which are irreversible (Teece et al., 2000). Resources can be 
dissipated, atrophied or simply squandered by several internal factors, including failing to 
adapt and reinvest as well as the presence of causal ambiguity (Fahy et al., 2004). Causal 
ambiguity is the most effective barrier to imitation as competitors find it difficult to 
understand the competencies on which the advantage is based. Wilson (2008) criticises the 
RBV approach for failing to give an adequate account of how firms identify and use unique 
‘resources’ and for not being sufficiently dynamic to adequately explain competitive 
advantage in situations of rapid and unpredictable change. RBV is vague and tautological 
(Priem & Butler, 2001).  
3.2.2.1 Competencies 
 
An off-shoot of the RBV school, the competencies approach emphasises the role of a firm’s 
competencies, rather than its resources, in determining competitive advantage. Hamel and 
Prahalad (1994, p. 199) define competencies as a ‘bundle of skills and technologies that 
enables a company to provide a particular benefit to customers’. Freiling (2004, p. 34) 
describes competencies as ‘inter-personal patterns of action which rest upon the division of 
work and which support a goal-oriented social interaction of persons in a non-random 
manner’.  
 
In contrast to RBV, this approach views the firm as an ‘open’ organisation with strategically 
monitored boundaries, creating a state of ‘permeability’. Assets, and sometimes even 
resources, can be transferred between economic actors (Freiling, 2004) with possible 
competitive advantages through the assets or resources of a network of firms and the blending 
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of a firm’s capabilities with those of ‘partner’ firms (Dyer and Singh, 1998; Lorenzoni & 
Lipparini, 1999). 
 
One of the strategic capabilities of the firm is its ability to integrate knowledge (Grant, 1996) 
and transform dispersed, tacit and explicit competencies into a wide body of organisational 
knowledge (Nonaka, 1994). The ability to integrate knowledge, residing both within and 
outside the firm’s boundaries, emerges as a distinctive organisational capability (Lorenzoni & 
Lipparini, 1999). Competences are embedded in interfirm resources and routines and can 
provide an effective way to organise knowledge transfer (or access) in dynamically 
competitive domains or in contexts wherein complex knowledge is scattered or specialised. 
Nooteboom (2005, p. 67) sees competencies as a special kind of resource and asserts that 
‘tacitness of knowledge, organisational structure and culture form an important part of the 
reason that competence does not spill-over easily’. A firm’s competitiveness is a function of 
its pace, efficiency and extent of knowledge accumulation (Hamel, 1991). Competences have 
a long-term character, implying that they are planned and built into strategic perspectives 
(Hulsmann & Wycisk, 2008). 
 
3.2.2.2 Dynamic Capabilities 
 
The dynamic capability (DC) approach is another branch of the RBV school. It seeks to 
incorporate dynamic and temporal elements (Teece et al., 1997). Dynamic capabilities are an 
eclectic paradigm drawing from multiple disciplines that are emerging as the paradigm of 
modern business firms (Teece & Pisano, 2004). The dynamic capabilities approach maintains 
that in turbulent environments, firms need to develop and nurture a unique set of constantly 
evolving ‘resources’. Eisenhardt and Martin (2000, p. 1116) describe dynamic capabilities as 
‘the organisational and strategic routines by which firms achieve new resource configurations 
as markets emerge, collide, spilt, evolve, and die’. The value of dynamic capabilities for 
competitive advantage lies in their ability to alter the resource base. The term ‘dynamic’ 
refers to the firm’s capacity to renew competences to achieve congruence with the changing 
business environment, while ‘capabilities’ emphasise the key role of strategic management in 
appropriately adapting, integrating and reconfiguring internal and external organisational 
skills, resources and functional competences to match the requirements of a changing 
environment (Teece et al., 1997).  
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The capacity to reconfigure and transform is itself a learned organisational skill. The more 
frequently practiced, the easier it is accomplished. ‘Change is costly and so firms must 
develop processes to minimise low pay-off change’ (Teece et al., 1997, p. 522). Dynamic 
capabilities thinking seeks to combine strategic decision making with a set of specific and 
identifiable processes (e.g. product development). Dynamic capabilities are embedded in 
organisational processes and are considered more important than assets since they are seen as 
a major driver that gives operational sense to a firm’s tangible and intangible assets. Teece 
and Pisano (2004) argue that the very essence of capabilities or competences is that they 
cannot be readily assembled through markets. Firms develop capabilities through learning 
and building knowledge (Slater & Narver, 1995). The literature on capabilities has placed a 
lot of emphasis on market orientation, organisational learning and strategic flexibility. 
 
Teece (2007, p. 1347) states that the dynamic capabilities framework goes beyond traditional 
approaches and seeks to understand competitive advantage in that ‘it not only emphasises the 
traits and processes needed to achieve good positioning in a favourable ecosystem, but it also 
endeavours to explicate new strategic considerations and the decision-making disciplines 
needed to ensure that opportunities, once sensed, can be seized; and how the business can be 
reconfigured when the market and/or the technology inevitably is transformed once again’. 
Effective dynamic capabilities depend on the inherent flexibility of the resources available to 
a firm and its flexibility in applying these resources (Sanchez, 1995). To transform dynamic 
capabilities into organisational innovativeness, a firm has to provide flexible structures, 
operations and strategic posture. Eventually, dynamic capabilities translate into strategic 
flexibility. 
 
Teece (2007) observes that maintaining dynamic capabilities requires entrepreneurial 
management. He adds that entrepreneurship is about sensing and understanding opportunities 
(and not about analysing and optimising), getting things started and finding new and better 
ways of putting things together. Firms, at various points in time, make long term, quasi-
irreversible commitments to certain domains of competence (Teece & Pisano, 2004). What a 
firm can do and where it can go are constrained by its positions and paths (Teece et al., 
1997). The strategic alternatives (paths) available to the firm are determined by its existing 
socio-technical processes (routines) and are shaped by its resource and capability position. In 
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the short run, the capabilities approach sets definite limits on strategic options, as capabilities 
have to be developed since they cannot easily be bought. From the capabilities perspective, 
strategy ‘involves choosing among and committing to long-term paths or trajectories of 
competence development’ (Teece et al., 1997, p. 529).  
 
In a rapidly changing environment, firms need to balance exploration and exploitation. 
Operational effectiveness demands continuity, whereas dynamic capabilities emphasise 
‘adaptation’ and ‘innovation’. Related diversification builds on or extends existing 
capabilities and is the only form of diversification that a resources or capabilities framework 
is likely to view as meritorious (Teece et al., 1997).‘Given that the functionality of dynamic 
capabilities can be duplicated across firms, their value lies in the resource configurations that 
they create, not in the capabilities themselves’ (Eisenhardt & Martin, 2000, p. 1118). Here, 
the emphasis is on developing and exploiting distinctive configurations, not specific products 
or sectors. The dynamic capability approach supports growth and diversification that builds 
on or extends existing capabilities. The capacity of a firm to transform itself is a learned skill; 
practice renders managing change as less demanding and less costly (Hulsmann & Wycisk, 
2008). 
 
Long-term competitive advantage is not easily achieved in dynamic markets and ‘managers 
seek to compete by creating a series of temporary advantages’ (Eisenhardt & Martin, 2000, p. 
1117). These authors add that the strategic logic of dynamic capabilities has to be a 
combination of the leverage logic (enhancing existing resource configurations in the pursuit 
of long-term competitive advantage) with the opportunity logic (formulating new resource 
configurations in the pursuit of temporary advantages). Dynamic capabilities may create 
sustainable competitive advantage in fast-changing markets through a series of temporary 
competitive advantages. D’Aveni’s (1994) ‘New 7S Framework’ deals with the fleeting 
nature of competitive advantage. Porter (1998) concludes that ultimately the only way to 
sustain a competitive advantage is to upgrade it. Core capabilities, which produce significant 
value, could later hinder the firm if they develop into core rigidities (Leonard-Barton, 1992). 
Dynamic capabilities are linked to the concept of bounded rationality which deems that 
managers do not have complete information regarding future events, alternatives or 
consequences and are only able to consciously process a limited amount of information 
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(Gavetti, 2005). Wilson (2008, p. 88) proposes that ‘strategic decision-making does not rest 
on “all-knowing” rationality but on satisfying and approximation’. 
 
Although the concept of dynamic capability has become an important strategic analysis tool, 
its definition and usage is still relatively nebulous. Coh (2005, p. 11) notes that ‘[g]eneral 
consensus on nature and properties of dynamic capabilities has not yet emerged’. 
 
Rouse and Daellenbach (2002), following an RBV approach, propose the following 
framework: 
 
(a) resources (tangible and intangible) which are bundled, linked, incorporated, converted and 
organised  
(b) socio-technical processes (e.g. knowledge, routines, structures of relationships and 
cultures) some of which are rare, inimitable (or costly to duplicate) and non-substitutable that 
form 
(c) capabilities and core competencies which become sources of competitive advantage when 
leveraged into products and services  
(d) value and competitive advantage indicated by their performance consequences 
 
 
 
 
 
 
 
Figure 7: RBV Framework Leading to Competitive Advantage 
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(Adapted from Rouse & Daellenbach, 2002) 
 
 
 
3.2.3 Convergence of the Two Schools 
 
The efficiency and environmental paradigms are often presented in juxtaposition to one 
another. Teece et al (1997) note that these paradigms should be seen as being 
complementary, rather than in competition, with one another. 
The external forces for change and complexity are re-enforced by equally important 
transformations occurring within many organisations (Barlett & Ghoshal, 1998). Barney 
(1991, p. 100) finds it odd that most research has focused either on external or internal 
factors, given that ‘since the 1960s ‘the SWOT framework’ (figure 8) has been used to 
consider both external and internal phenomena in determining competitive advantage’. 
 
Figure 8: SWOT Analysis, RBV and Market Power Models 
(Reproduced from Barney, 1991) 
 
Hill and Westbrook (1997, p. 47) note that good strategy involves the ‘fit between the 
external situation a firm faces (threats and opportunities) and its own internal qualities or 
characteristics (strengths and weaknesses)’. Amit and Schoemaker (1993) and Cockburn et 
al. (2000) agree that the two approaches are essentially complementary, but Teece et al. 
(1997, p. 526) emphasise that ‘in several important respects the perspectives are also 
competitive’. Table 2, I re-produces a comparative analysis of both approaches. 
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Table 2: Perspectives on Competitive Strategy 
(Reproduced from O’Keefe et al., 1996) 
 
Porter (1998, p. 67) suggests that ‘sustaining and improving competitive position ultimately 
requires that a firm develops its internal capability in areas competitive to advantage’.  
 
From the above, it can be concluded that the two schools essentially complement each other: 
the relative importance of either being context-specific. Ajitabh and Momaya (2004) suggest 
that a key reason for low usage of both theories by practitioners is the weak understanding of 
the proposed frameworks and models. 
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3.3 State and Enterprise Level 
3.3.1 R-A Theory 
 
R-A theory proposes to be ‘a general theory of competition’ (Hunt & Morgan, 2005, p. 154). 
Although the theory emerged from marketing, it draws on various disciplines, ‘not only with 
regard to its pedigree—its ancestors comprising eleven different research traditions—but also 
with regard to its implications for an understanding of firms, industries and markets’ (Hunt, 
2000, p. 385).  
 
Among the theories and research traditions on which R-A theory draws, and with which it has 
affinities, are evolutionary economics, ‘Austrian’ economics, historical tradition, industry–
organisation economics, resource-based tradition, competence-based tradition, institutional 
economics, transaction cost economics and economic sociology (Hunt & Morgan, 2005, p. 
385) 
 
Table 3 synthesises the development of R-A theory and the central issues treated.  
 
Table 3: Development of R-A Theory 
(Reproduced from Hunt & Derozier, 2004) 
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Although R-A theory is founded in different disciplines, ‘it is not precisely the same thing as 
any of the works in its pedigree’(Hunt, 1999, p. 47).  
 
R-A theory combines heterogeneous demand theory with the RBV of the firm (Hunt, 2012). 
It sees resource creation, not allocation, as driving productivity and economic growth (Hunt 
& Morgan, 2005). RBV and R-A theory are similar in their viewing of a firm combining 
heterogeneous, imperfectly mobile resources; there are significant differences between the 
two.  
 
RBV is a theory of the firm, which views  
 
a) innovation as being exogenous to the firm,  
b) competition among firms as being equilibrating and  
c) demand as being outside the scope of the theory.  
 
RBV makes no reference to the relevance of public policy. By contrast, R-A theory is a 
theory of competition, which includes a theory of the firm, and which views  
 
a) innovation as endogenous,  
b) competition to be evolutionary and dis-equilibrating and  
c) demand as an integral part of the theory.  
 
R-A theory deems that public policy significantly impacts competitiveness. It holds that 
comparative advantages in resources lead to market position advantages, which result in 
competitive advantage in specific market segments.  
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Table 4 outlines the foundational premises of R-A theory, which are then explored in detail. 
 
Table 4: Foundational Premises of R-A Theory 
 (Reproduced from Hunt & Madhavaram, 2012) 
 
3.3.1.1 Demand is heterogeneous and dynamic 
Inter- and intra-industry demand is posited to be both substantially heterogeneous and 
dynamic. ‘Consumers’ tastes and preferences differ greatly within a generic product category 
and are always changing’ (Hunt & Morgan, 2005, p. 165). To the extent that demand curves 
exist at all, they exist at a level of (dis)aggregation that is too fine to be an ‘industry’ (Hunt & 
Morgan, 2005, p. 165). R-A theory views industries as ‘collections of market segments’, with 
the latter being defined as ‘intra-industry groups of consumers whose tastes and preferences 
with regard to an industry's output are relatively homogeneous’ (Hunt, 2012). Products are 
seen as bundles of attributes, with different market offerings (or ‘bundles’ of attributes) for 
different market segments within the same industry (Hunt, 2012). 
3.3.1.2 Consumer information is imperfect and costly 
While neo-classical theory assumes that consumers have perfect and costless information 
about the availability, benefits and prices of all products in the marketplace, R-A theory holds 
that they have imperfect information and often face considerable search costs. These search 
costs are reduced by societal institutions such as trademarks, patents and licenses, which 
signal ‘the attributes of market offerings’ (Hunt & Morgan, 2005, p. 165). 
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3.3.1.3 Human motivation is constrained self-interest seeking 
Etzioni (1988) argues that people have two intricate sources of value: pleasure (P-utility) and 
morality. People, as consumers as well as managers of firms, are motivated by constrained 
self-interest rather than profit maximisation. R-A theory follows this line of thought and 
argues that as a result, firms are not able to maximise profit or wealth. ‘Agency’ problems 
‘associated with ethical egoism thwart maximization and because of ethical code mismatches 
between (and among) owners, managers, and subordinate employees which may result in 
non-maximising behaviours’ (Hunt & Morgan, 2005, p. 172). 
3.3.1.4 Firm’s objective is superior financial performance  
R-A theory acknowledges that the pursuit of ‘profits and efficient modes of performance 
drives much of organizational choice’ (Zald 1987, p. 6). The firm’s overall objective is to 
seek superior financial performance and not maximisation (Hunt & Morgan, 2005, p. 17). 
Such performance is indicated by measures such as profits, earnings per share, return on 
investment and capital appreciation. R-A theory equates ‘superior’ with both ‘more than’ and 
‘better than’ (Hunt & Morgan, 2005). This implies that firms seek a level of financial 
performance exceeding that of some referent. ‘The referent against which the firm’s 
performance is compared can be the firm’s own performance in a previous time period, the 
performance of rival firms, an industry average or a stock-market average’ (Hunt & Morgan, 
2005, p. 170). 
 
From an R-A theory perspective, it is difficult to use ‘normal’ industry profits as a referent 
for comparison purposes since in reality, long-run equilibrium is a rare phenomenon. Given 
this limitation, superior financial performance cannot be said to lead to ‘abnormal profits’ or 
rents. By positing superior financial performance as the primary goal of firms, R-A theory 
implants dynamism into its framework, with the actions of competing firms being dis-
equilibrating rather than equilibrating. ‘Activities that produce turmoil in markets are 
societally beneficial because they are the engine of economic growth’ (Hunt & Morgan, 
2005, 170). This ‘accords well with the extant dynamism of competition in market-based 
economies’ (Hunt & Morgan, 2005, p. 170). 
3.3.1.5 Firm’s information is imperfect and costly 
R-A theory holds that firms are not able to maximise profit or wealth because of imperfect 
information and often costly measures to obtain information about customers and 
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competitors. R-A theory not only refutes that firms have full information and knowledge but 
also adds ‘that occupying marketplace positions provides a major source of organizational 
learning’ (Hunt & Morgan, 1997, p. 79).  
3.3.1.6 Resources of the firm 
According to R-A theory a firm’s resources can be physical, financial, legal, human, 
organisational, informational and relational (Hunt & Madhavaram, 2012). International trade 
theory explains the benefits of trade by postulating that countries have heterogeneous and 
immobile resources. Similarly, R-A theory argues that the resources available to firms within 
the same industry are heterogeneous and relatively immobile. ‘Therefore, analogous to 
nations, some firms will have a comparative advantage and others a comparative 
disadvantage’ (Hunt, 1997, p. 431). At an enterprise level, a comparative advantage in 
resources exists when its ‘resource assortment (e.g. its competencies) enables it to produce a 
market offering that, relative to extant offerings by competitors, (1) is perceived by some 
market segments to have superior value and/or (2) can be produced at lower costs’ (Hunt & 
Morgan, 1995, p. 7). 
 
The neo-classical school considers land, labour and capital as resources, but for R-A theory, 
resources are the firm’s tangible and intangible entities that enable it to produce efficiently 
and/or effectively a market offering that has value for some market segment(s). The value of 
a resource is, therefore, measured in terms of its potential to yield competitive differentiation 
and/or customer value delivery that enhances the firm’s performance outcomes (Hunt, 2000). 
Certain types of resources are more valuable than others. Individual resources may have 
direct, indirect, mediating or moderating effects (or a combination of all four effects) on firm 
performance (Hunt & Morgan, 2005, p. 187). R-A theory also posits that there are ‘non-
resources’, which do not enable and/or inhibit the firm, as well as ‘contra-resources’ that 
actually inhibit the firm from producing efficient and/or effective market offerings that have 
value for certain marketing segment(s) (Hunt & Madhavaram, 2012). Different bundles of 
resources may be equally efficient or effective in producing value for certain market 
segments (Hunt & Morgan, 1995).  
 
The processes by which various resource types influence the ability of the firm to create 
unique comparative advantages are complex, and R-A theory emphasises the importance of 
understanding the role of organisational competencies. R-A theory views competences as 
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higher-order, socially complex, highly interconnected, combinations of tangible and 
intangible resources that fit coherently together and enable a firm to efficiently/effectively 
produce valued market offerings. R-A theory merges with the ‘dynamic capabilities’ 
approach by delineating the process by which a competence that enables firms to respond 
creatively to changing market conditions can be successful in achieving superior financial 
performance. Hunt and Madhavaram (2012) conclude that R-A theory’s concept of ‘higher-
order resources’ provides the foundation to understand both marketing and overall business 
competences and capabilities.  
3.3.1.7 Resources are heterogeneous and imperfectly mobile 
The development and leveraging of heterogeneous and imperfectly mobile resources enable 
firms to achieve competitive advantages through greater effectiveness and efficiency. 
Resource heterogeneity suggests that every firm has an assortment of resources that is in 
some way unique. Given the interconnectedness and complexity of competences, ‘they are 
likely to be significantly heterogeneous and asymmetrically distributed across firms in the 
same industry’. Imperfectly mobile implies that resources, to varying degrees, are not easily 
or readily bought in the marketplace. Resources may be available, and not necessarily owned, 
by the firm. Resource heterogeneity can persist through time despite attempts by firms to 
acquire the same resources of successful competitors (Hunt & Morgan, 2005, p. 173). Given 
resource heterogeneity and immobility, strategic choices must be made to influence 
performance. ‘Different firms in an industry will adopt different strategies based on different 
resource assortments. This suggests that they will target different market segments and have 
different competitors’ (Hunt & Morgan, 2005, p. 176). 
 
‘Rivals will fail (or take a long time to succeed) when an advantaged firm's resources are 
either protected by such societal institutions as patents or the advantage-producing resources 
are causally ambiguous, socially or technologically complex, tacit, or have time compression 
diseconomies’ (Hunt & Madhavaram, 2012, p. 586). Heterogeneity and immobility indicate 
that resources, unlike what RBV proposes, are ‘replicable, not scarce’ (Hunt & Morgan, 
1997, p. 79). Moreover, given that R-A theory ‘recognizes that technologies or competencies 
can be replicated by other firms, it acknowledges that they are non-rival’ (Hunt, 1997, p. 
434). The life span (sustainability) of a particular comparative advantage in resources is 
determined by both internal and external factors and can be neutralised by the actions of 
consumers, government or competitors (Hunt and Morgan, 1995). 
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3.3.1.8 Role of management and strategy making 
R-A theory is a general theory of competition that provides an integrative, positive and 
theoretical foundation for business and marketing strategies (Hunt & Derozier, 2004). It 
demonstrates to managers how these strategies ‘fit into’ the broader issues of competition 
(Hunt & Madhavaram, 2012). Specifically, the role of management (both owner and non-
owner) is ‘to recognise and understand current strategies, create new strategies, select 
preferred strategies, implement the strategies selected, and modify strategies through time, 
focused on creating competitive dynamics that are disequilibrium-provoking’ (Hunt & 
Morgan, 2005, p. 174). 
 
Hunt and Madhavaram (2012) note that the firm’s overall business strategy involves the 
following four higher-order resources that facilitate managerial action: 
1. absorptive capacity 
2. market-focused strategic flexibility 
3. learning platform capability 
4. organisational learning capability  
3.3.1.9 Competitive dynamics and innovation 
R-A theory is an evolutionary theory of competition, in which each firm in an industry is a 
unique entity in time and space as a result of its history (Hunt & Morgan, 1997, p. 78). 
Theorists agree that the firm’s strategic imperative should be sustained, superior financial 
performance, sought through competitive advantage in the marketplace (Hunt, 1999, p. 155). 
In contrast to Porter’s industrial economics approach, R-A theory does not perceive an 
industry’s structure and a firm’s conduct (strategy) to be the sole determinants of superior 
performance. Firms do not just passively respond but seek to influence or shape their 
changing environment and improve themselves through renewal competences and proactive 
innovations. ‘Resource advantage theory cannot restrict itself to only one resource for 
competitive advantage because it is first and foremost a positive, general theory of 
competition’ (Hunt & Morgan, 1996, p. 108).  
 
The constant struggle among firms for comparative advantages in resources leads to 
increased knowledge (Hunt & Morgan, 1997). Competitors attempt to neutralise and/or 
leapfrog the advantaged firm through acquisition, imitation, substitution or major innovation. 
‘This enables them to surpass the previously advantaged competitor in terms of either relative 
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costs (i.e. an efficiency advantage), or relative value (i.e. an effectiveness advantage), or 
both’ (Hunt, 2012). Firms learn through competition. ‘As Hayek (1948) stressed, competition 
is a knowledge discovery process’ (Hunt, 2002, p. 12). The process of competition itself 
becomes ‘a major source of organisational learning as firms learn from the feedback loop 
from relative financial performance’ (Hunt & Morgan, 1997, p. 79). 
 
R-A theory is non-consummatory in that it involves a continuous process of change with no 
end-stage. ‘Although R-A competition is a process that is moving, it is not moving toward 
some ideal point (such as a Pareto-optimal, general equilibrium)’ (Hunt, 1999, p. 147). R-A 
theory is inherently dynamic. Innovation plays a critical role in R-A theory. ‘The renewal 
competence of firms, motivated by the quest for superior financial performance, contributes 
to the proactive innovations that result in societal productivity’ (Hunt, 1999, p. 154). The 
quest for superior performance results in innovation which in turn stimulates productivity and 
constitutes ‘the technological progress that results in economic growth’ (Hunt, 1999, p. 156). 
Innovation can be either proactive or reactive. Proactive innovation is motivated by the 
search for superior financial performance and is not prompted by specific competitive 
pressures. ‘When proactive innovative activities successfully produce innovations that 
contribute to efficiency and/or effectiveness, firms will be rewarded by…superior financial 
performance’ (Hunt, 1997, p. 435). 
 
The concept of ‘dynamic capabilities’ is central to proactive innovation by enabling firms to 
do the following:  
 
(1) anticipate potential market segments (unmet, changing and/or new needs, wants and 
desires) 
(2) envision market offerings that might be attractive to such segments  
(3) foresee the need to acquire, develop or create the required resources, including 
competences to produce the envisioned market offerings (Hunt & Arnett, 2003, p. 9) 
 
Reactive innovation includes imitating the resource, finding (creating) an equivalent resource 
or identifying (creating) a superior resource and is directly prompted by the learning process 
of firms’ competing for the patronage of market segments (Hunt & Arnett, 2003, p. 9). Both 
proactive and reactive innovation can be ‘radical’ or ‘incremental’, and both contribute to the 
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dynamism of R-A competition (Hunt, 2012). Evolutionary theories of competition require 
entities that can serve as the units of selection in an evolutionary process. These entities must 
be relatively durable (they can exist, at least potentially, through long periods of time) and 
heritable (they can be transmitted to successors). Within R-A theory, both firms and 
resources are proposed as the heritable, durable entities of selection, with competition for 
comparative advantages in resources constituting the evolutionary selection process (Hunt, 
2012). 
 
The list of nine foundational premises of R-A theory has remained unchallenged and there 
seems to be agreement that they accurately convey the descriptively realistic general case of 
competition (Hunt, 2012). Figure 9 illustrates how firms achieve superior financial 
performance.  
 
 
Figure 9: Comparative Advantage Theory of Competition 
(Reproduced from Hunt, 2012) 
The above figure also demonstrates that the competitive process is significantly influenced by 
five environmental factors: 
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• societal resources on which firms draw 
• societal institutions that form the ‘rules of the game’ (North,1990) 
• actions of competitors 
• behaviours of consumers and suppliers 
• public policy decisions (Hunt & Morgan, 2005, p. 157) 
 
Figure 10 demonstrates that firms with a comparative advantage in resources can occupy 
marketplace positions of competitive advantage (i.e. cells 2, 3 and 6). Cell 3 represents the 
best marketplace position for a firm with a resource portfolio that enables it to produce an 
offering for some market segment(s), which is perceived to be of superior value and is 
produced at lower costs. The various market segments indicate the heterogeneity of an 
industry and is intended to help managers’ analyse their firms’ and competitors’ positions, 
understand the history of the firm and/or industry and develop new market offerings.  
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Figure 10: Competitive Position Matrix 
(Reproduced from Hunt, 2012) 
 
As emphasised by the ‘good governance’ school, R-A theory perceives economic action to be 
embedded in social structures, institutions and culture (Hunt & Arnett, 2003). R-A theory 
holds that the process of competition is significantly influenced by societal institutions. Given 
its strong emphasis on innovation, R-A competition requires institutions that protect the 
property rights of innovators such as patents, copyright laws and laws protecting trade secrets 
(Hunt, 1997). Poirot (1993, p. 892) states that ‘[i]n order for an existing institutional structure 
to direct economic activity along a path that is conducive to economic growth, individuals 
must be able to reap the gains from innovation’ (Hunt, 1997). 
 
R-A theory asserts that successful systems have evolved flexible institutional structures that 
can survive shocks and changes. Depending on the type of institutions that prevail and their 
enforcement characteristics, the creation, diffusion and division of knowledge will occur with 
either high or low transaction costs. The extension of R-A theory to the individual level 
provides a different way of conceptualising where competitive advantage lies within the firm 
(Griffith, 2010). Intangible resources of the firm are, to a certain degree, embodied within the 
employees of the firm and are only firm resources to the degree to which the firm aggregates 
the resources embodied within employees (Griffith & Lusch, 2007). For example, R-A theory 
contends that business skills and experience are a key firm resource, but these ‘are resident in 
firm employees, not the firm itself’ (Griffith, 2010, p. 20). By including institutions, R-A 
theory broadens its focus to include national comparative systems. R-A theory proposes to 
provide ‘a theoretical framework for understanding the ‘superior performance’ of firms as 
well as national economies’ (Griffith, 2010, p 28). 
 
R-A theory seeks to provide an explanation for ‘market-based economies keep getting more 
efficient and more abundant’ (Hunt & Morgan, 1995, p. 8). The superior productivity of 
market-based economies is attributed to the fact that ‘superior rewards in such economies 
will flow to those firms…that engage in specific kinds of innovative activities’ (Hunt & 
Morgan, 1997, p. 79). These innovative activities are those that lead to the discovery, creation 
or assembling of resource assortments that enable the innovating firms to efficiently and/or 
effectively produce valued market offerings (Hunt & Morgan, 1997, p. 79). R-A theory 
provides a theoretical foundation for formal models of endogenous economic growth (Hunt, 
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1997b): economies grow due to ‘vigorous, on-going, dis-equilibrating struggles among firms’ 
(Hunt, 1999, p. 154). This results in innovation that promotes increases in firm productivity 
throughout the economy, technological progress and economic growth. In contrast to 
neoclassical economics, R-A theory makes technological growth a result of the specific, 
profit-driven actions of firms (Hunt, 1999, p. 155).  
 
For R-A theory, superior economic performance is determined in particular by the search for 
comparative advantage by firms and their propensity to engage in both proactive and reactive 
innovation. This explains how a country may be poor in natural resources but can still do well 
economically. R-A theory agrees that history is important even at the state level. A key factor 
distinguishing wealthy from non-wealthy societies is trust-promoting institutions. The 
process by which such institutions contribute to (or from) firm-level, superior financial 
performance can be explained by the fact that societies having moral codes based on 
deontological ethics (the moral content of an action is not wholly dependent on its 
consequences) reduce transaction and transformational costs, rendering their competitive 
processes more efficient and effective. Societies become wealthy over time ‘because the 
underlying institutional framework persistently reinforced incentives for organizations to 
engage in productive activity’ (North, 1990, p. 9). The most important deficit of non-wealthy, 
market-based economies is the lack of certain types of societal institutions that foster 
productivity and economic growth (North, 1990). For North (1990, p. 9), ‘in many Third 
World countries today as well as those that have characterised much of the world’s economic 
history, the opportunities for political and economic entrepreneurs are still a mixed bag, but 
they overwhelmingly favour activities that promote redistributive rather than productive 
activity, that create monopolies rather than competitive conditions, and that restrict 
opportunities rather than expand them’.  
 
‘R-A theory allows for the possibility that social relations and social structures can (and often 
do) affect competition. The thesis that social structures (i.e. networks of social relations) can 
be pro-competitive is foreign to neoclassical economic theories’ (Hunt & Arnett, 2003, p. 2 ). 
Although the works of early scholars (e.g. Max Weber and Emile Durkheim) in economic 
sociology recognised that economies are embedded in broader social structures, the concept 
of ‘embeddedness’ is often credited to Polanyi et al. (1971), who argued that ‘[t]he human 
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economy...is embedded and enmeshed in institutions, economic and noneconomic’ (quoted 
by Hunt & Arnett, 2003, p. 2).  
 
R-A theory proposes to be a general theory of competition which is evolutionary and dis-
equilibrating. Superior performance is determined by the search for comparative advantage 
by enterprises (and states) and their propensity to innovate. This theory builds on the RBV 
approach and considers competencies as higher-order, socially complex resources. R-A 
theory perceives economic action to be embedded in societal structures, institutions and 
culture. 
 
This research finds that R-A theory offers the most comprehensive and relevant theoretical 
framework to its area of study, given that it 
1. is a ‘general theory of competition’ (Hunt & Morgan, 2005) linking the dynamics of 
competitiveness at the individual, micro and macro levels  
2. offers an explanation as to what constitutes ‘superior performance’ 
3. re-defines resources to include tangible and intangible entities available to the firm that 
yield competitive differentiation and/or customer value delivery  
4. holds that it is a key task of management to build a competence in strategic management 
5. embeds the economy within a broader societal framework. R-A theory allows for the 
possibility that social relations and social structures can (and often do) affect competition 
(both negatively and positively).  
 
From the perspective of this research, the main limitation of R-A theory lies in the fact that 
the process of competition is essentially seen as a ‘local’ process. It tells us little about an 
economy’s or enterprise’s interface with international business in developing ‘resources’ 
(especially technology) and in pursuing innovation. In small states, the competitive process is 
inevitably impacted by ‘exogenous’ forces, with technology being often sourced from 
overseas (especially through FDI). Also, R-A theory, while acknowledging the impact of 
societal resources and societal institutions on the competitive process and allowing for the 
availability of non-rival technologies and competencies to competitors, ignores the possibility 
of enterprises working together. In the literature, there is growing awareness about the 
importance of inter-linkages between firms, as well as between economic sectors, in shaping 
competitiveness at the national level. An advanced economy is perceived as encouraging and 
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supporting alliances and networking that enable its organisations and enterprises to reap 
externalities and facilitate the diffusion of knowledge. Little research has been conducted on 
the scope and nature of such inter-linkages in small economies. In a small economy, the 
scope of clustering and networking is conditioned by the limited number of players as well as 
geophysical considerations.  
 
In concluding the review on mainstream theories explaining ‘superior economic 
performance’ it can be stated that while they offer various explanations, they generally fail to 
provide a convincing  account of what drives superior economic performance in the case of a 
small state.  At the state level, international trade theory makes the case for specialisation 
and free trade, and development studies generally highlight the state’s responsibility in 
creating the ‘right’ operating environment, while competitiveness approaches emphasise that 
competitive advantage is created and not inherited as resource endowment.  
 
At the enterprise level, the neo-classical school dismisses the very concept of superior 
performance seeing it as a mere ‘passing’ situation, which sooner or later will lead to 
supply–demand equilibrium. Superior performance results in ‘rents’, which can arise out of 
market imperfections, technological innovation and entrepreneurship. Both the 
environmental and efficiency schools seek to explain superior performance. While the 
environmental school emphasises the ability of an enterprise to use strategy and market 
power to manipulate the structure of an industry to its advantage. Porter(1998) extended this 
line of thought to nations in his work on national competitiveness, the efficiency school 
perceives competitive advantage as primarily arising from the ability of the firm to exploit 
unique resources, competencies and dynamic capabilities.  
 
Although these two schools have often been presented as being in opposition to one another, 
good strategy involves a ‘fit between the external situation a firm faces (threats and 
opportunities) and its own internal qualities or characteristics (strengths and weaknesses)’ 
(Hill and Westbrook, 1997, p. 47). In a dynamic environment, competitive advantage can 
only be sustainable, if it is consistently re-created. The individual enterprise was the unit of 
study of both approaches. What is more important for the purpose of this research is that 
while the environmental approach with its emphasis of market power is not  relevant to small 
states and their enterprises, the efficiency view offers a plausible alternative that can be the 
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basis for further study. R-A theory is an off-shot of the efficiency school and its logic and 
insights were instrumental for the course of this research. 
 
 
 
  
 
4. Research Methodology 
 
This chapter outlines the research design of this thesis highlighting the methodology that has 
been followed with particular attention being given to defining the research setting as well as 
elaborating on the data collection and data analysis processes.  
 
Given the nature of the research problem of this thesis which seeks to understand a complex 
economic phenomenon embedded in broader social change, it was deemed appropriate to 
follow a qualitative approach, which tends to generate words, rather than numbers, as data for 
analysis. Gephardt (2004, p. 455) states that ‘[q]ualitative research starts from and returns to 
words, talk, and texts as meaningful representations of concepts’. A valid contribution to 
theory and practice requires a methodological fit as ‘an overarching criterion for ensuring 
quality field research’ (Edmondson & McManus, 2007, p. 1155). A methodological fit relates 
to the fit of research design and subsequent execution with the state of prior relevant theory 
(Said, 2013). A qualitative approach permits exploring dynamics across different levels of 
analysis (Bansal & Corley, 2011).  
 
This qualitative approach is complemented by quantitative analysis, given that the researcher 
collected and analysed the statistics available on the performance of the pharmaceutical 
industry in Malta around the period of EU accession. The objective of gathering and 
assessing this data was to obtain a numerically-based assessment as to the success of the 
pharmaceutical industry in Malta during the period being investigated.  This assessment is 
based on conventional economic criteria including the industry’s output, gross value added, 
employment and exports. 
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This research is based on social constructionism, which acknowledges that the social 
researcher is a product of a particular context (time and space) and is part of the phenomenon 
being investigated. Evaluation research is intended to present a meaningful reconstruction of 
the real world and this is shaped by the researcher’s own values and experience as an insider.  
‘Social constructionist epistemologies dismiss the notion that researchers are passive 
observers or knowers, but rather that social researchers make sense out of meanings, drawing 
from reflexive approaches to generate understandings as a basis for theory creation’ (Said, 
2013, p. 8). Researchers’ orientations are influenced by ‘their socio-historical locations, 
including the values and interests that these locations confer upon them’ (Hammersley & 
Atkinson, 2009, p. 551 cited by Said, 2013). According to social constructionism, knowledge 
is built through selection and structuring on the basis of an interchange between actors in a 
social system. Research should be sensitive to not only the researcher’s bias but also 
interpretation, understanding and constructions of all those contributing, directly or 
indirectly, to the gathering of information and data.  
 
Social constructionism as a paradigm has three primary concepts: 
 
(a) researchers make subjective meanings of their experiences  
(b) meanings are diverse and multiple  
(c) meanings are formed by interaction with others and shaped by historical, social and 
cultural contexts 
 
The researcher’s mind-set tends to take a systems view of reality and it is this orientation 
which led to perceiving a small state as an organisation, with well-defined but permeable 
boundaries. Such an organisation has been termed as an ‘open system’ and a schema (figure 
12) developed so as to help define the research setting of this thesis. Such a schema follows 
the logic of systems approach and  is considered appropriate owing to the constructs of inter-
relatedness of the features of the ‘open-system’, acknowledging the central importance of the 
external environment and its dynamic and evolving nature. Systems thinking characterises 
also the proposed theoretical framework relating to the role of arch-RCDCs in determining 
competitive advantage. A basic postulate of the framework (Figure 14) is that its components 
have to be always present as their inter-relationships are essential for the final outcome. A 
systems approach embraces complexities in a holistic but pragmatic way. Godet (2006, p. 14) 
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points out that a systems analysis ‘is a way of thinking’ and ‘an act of epistemological faith 
since it supposes that the observer is capable of self-observation and observation 
simultaneously’. In an increasingly dynamic and complex world, a systems approach leads to 
not only learning but also effective decision making (Sterman, 2000). Systems analysis 
involves moving beyond gathering facts, attempting to make sense of the ‘myriad human, 
political, social, cultural and contextual elements involved’ (Wallman, 2005, p. 119). 
According to the US National Defence University (2011), the systems paradigm is to be 
viewed as a tool which leaders can use to improve an organisation’s capability to 
  
(1) analyse tactical and strategic environments,  
(2) develop and enact strategies in response to environmental demands and  
(3) sustain an adaptive and productive organisational culture. 
 
According to Stacey (2003, p. 30), the systems approach tries to ‘understand phenomena as a 
whole formed by the interaction of the parts’. A system as a whole comprises two or more 
parts (Bierema, 2003). It consists of sub-systems that are inter-related and interdependent. 
Each sub-system within the system, and the system itself, has a boundary separating it from 
other sub-systems and systems. Systems’ thinking is based upon ‘a spatial metaphor of inside 
and outside’ and follows a linear notion of time (Stacey, 2003, p. 313). This research adopts a 
temporal development perspective, where the process triggered by external change is seen as 
a sequence of events, with meanings and perceptions changing over time. Multiple parts tend 
to create multiple relationships. Enhancing one aspect of the system largely depends on the 
interaction of a specific sub-system with other parts of the total system (Rhydderch et al., 
2004). Systems analysts tend to believe that the ‘whole’ is greater than the sum of the sub-
systems. A system relies on its relationships and holistic principles to achieve optimal 
performance (Rhydderch et al., 2004). 
 
A case study research is sympathetic to the principles of systems analysis (Stake, 1995). 
Given that the rationale for choosing a case study  is its ability in explaining  the presumed 
causal links in complex, real life interventions, it was deemed to be the most appropriate 
approach  to study the impact of the changes generated by EU membership on the Maltese 
pharmaceutical industry. This choice is further due to the fact that changes generated by EU 
membership are unlikely to have well-defined outcomes. Case studies “are the preferred 
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strategy when ‘how’ and ‘why’ questions are being posed, when the investigator has little 
control over events and when the focus is on a contemporary phenomenon within some real-
life context” (Yin, 2003, p 1). A case study is a detailed, holistic empirical investigation into 
a complex entity that emphasises the uniqueness and context of the case and typically draws 
on various data sources (Ridder et al, 2009). “It copes with the technically distinctive 
situation in which there will be many more variables of interest than data points” (Yin, 2003, 
p.13). A case study is ‘an empirical inquiry that investigates a contemporary phenomenon 
within its real-life context, especially when the boundaries between phenomenon and context 
are not clearly evident’ (Yin, 2003, p. 13). Case studies offer an in-depth evaluation, making 
it ideal for new or poorly researched fields. Case studies represent a comprehensive research 
strategy which “comprises an all-encompassing method-covering the logic of design, data 
collection techniques and specific approaches to data analysis” (Yin, 2003 p. 14). Case study 
research relies on well-established criteria including a clear definition of the case, appropriate 
allocation of resources and varied and multiple data sources. Deconstructing and 
reconstructing the case leads the researcher to ‘new meaning’. The ‘case’ has both uniqueness 
and commonality that is relevant and interesting and advances knowledge within the field 
being studied (Stake, 1995). This research’s case study follows an ‘instrumental’ approach, 
given that its focus is on learning about the validity of the proposed theoretical framework on 
the role of arch-RCDCs in determining the strategic flexibility and competitive advantage of 
an ‘open system’ rather than learning from the case itself (Stake, 1995).  
 
Collecting multiple sources of data enhances the trustworthiness of a case study research and 
can provide richer contextual information for the cases (Yin, 2009).This research’s case study 
relies on secondary data (collected from various sources including statistics from government 
sources, newspapers and the internet) as well as primary data compiled through personal 
interviews conducted by the researcher. Katzenstein (1985, p. 12) notes that ‘using 
newspapers is not without risks’. Given the timeframe of the selected case study, newspapers 
are seen as a valid source in capturing the ‘immediacy’ of the moment, even if this may be 
shrouded in a non-technical approach. One of the main challenges in a case study is to 
balance description, analysis and interpretation (Yin, 2009). Case study has long been 
stereotyped as a weak sibling among social science methods and denigrated as having 
insufficient objectivity, precision and rigour (Yin, 2003). However, a case study is not meant 
to represent a ‘sample’. Its purpose is to “expand and generalise theories not to enumerate 
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frequencies” (Yin, 2003, p.10). Given that the literature review did not yield an appropriate 
knowledge base on the subject in hand, it was inevitable that this research proposes an 
alternative theoretical framework related to the competitive advantage of small states (figure 
14).   
 
The primary field research of this thesis entails two types of interviews, those with 
policymakers and other stakeholders, which follow an open-ended approach and subsequent 
interviews with the top management of pharmaceutical enterprises operating in Malta 
conducted on a semi-structured basis. The intention of holding preliminary open-ended 
interviews (Table 5) is to enable the researcher to learn more about the subject matter, keep 
the interview as flexible as possible so as to learn as much as possible on the interviewees 
perceptions on the subject matter. The advantage of having a semi-structured interview (see 
Annex 1 for an illustrative list of questions) is to help the interviewee understand better the 
subject matter, enable some probing by the researcher without upsetting the rapport with the 
interviewee. Interviews have the advantage of being versatile and highly specific, especially 
when the number of interviews being held is relatively small. The disadvantages associated 
with interviews include reliance on interviewees’ memory and bias and are generally directed 
to reflect the researcher’s own interests and reactions to the information from the interviewee. 
This is especially the case with open-ended interviews. Constructionism views the interview 
as an engagement in constructing meaning. Experience is never ’raw’ but embedded in a 
social web of interpretation. It is not just what is said which is important but how it is said. 
 
Table 5. Interviews with Relevant Public Institutions in Malta 
 
Organisation  Interviewee Position Date 
Malta Enterprise Galea, M. Advisor to Chairman 26.06.2012/10.03.2013 
Chemistry Dept. UoM Farrugia, C. Senior Lecturer 10.11. 2012 
Chemistry Dept. UoM Sinagra, M. Professor 19.11.2012 
Malta Medicines Authority Vella Bonanno, P. CEO 03.07.2012/20.07.2012 
National IP Office, Commerce Dept. Warr, G. Director General 03.07.2012 
Institute of Applied Science, MCAST Rizzo, A. Head 25.07.2013 
Malta College Science & Technology Castillo, N. Director, Policy & FP7 23.07.2013 
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The semi-structured interviews are meant to help test the validity of the theoretical 
framework. Given the small number of enterprises involved (Table 6), interviews were held 
with each one of them.  
 
 
 
 
 
In total twenty six face-to face interviews were held.  All of the interviewees were very open 
and willing to discuss the various issues raised during the discussion (the researcher was 
known to many of them) but they were less willing to give specific information relating to the 
financial performance of their company. The illustrative list of interview questions helped to 
guide discussions, which at times did not keep with the researcher’s line of inquiry as the 
Pharma Manufacturers Section CoC Farrugia, C. Chairman 12.07.2013 
Table 6. Interviews with Pharmaceutical Companies Operating in Malta 
 
Company Interviewee Position Date 
Actavis Ltd. Cachia, P. General Manager 17.07.2013 
Acatvis Group Vella, S. VP Manf. West Europe 26.07.2013 
Amino Chemicals Ltd. Antonio, S. Managing Director 11.06.2013 
Siegfried Generics Malta Ltd. Giromini,V. Managing Director 13.07.2013 
Combino Pharm Ltd. Allegrucci, P. Managing Director 09.08.2013 
Medichem Malta Ltd. Mangion, D. Managing Director 18.06.2013 
APL Swift Services Ltd (Aurobindo) Schembri, F. Managing Director 20.06.2013 
Starpharma Ltd. Galea Kenely, M CEO 05.07.2013 
Institute of Cellular Pharmacology Ltd. Saliba, C Managing Director 22.08.2013 
Solea Pharma Ltd. Martin, P. CEO 06.08.2013 
Pharmadox Healthcare Ltd. Seychell, P. Managing Director 23.07.2013 
Pharmacare Premium Ltd. Khour, B. Managing Director 29.06.2013/11.09.2013 
Alpha Farma Ltd. Debono, M. Managing Director 17.06.2013 
Actavis Ltd. Zammit, J. Group HR Manager 09.01.2013 
Pharmamed (Actavis) Grioli, J. Managing Director 21.01.2013 
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respondents felt it opportune to comment on issues  which they felt important for the 
conversation. As can be expected, the contribution made by interviewees differed 
significantly. This was due to such factors as whether the company was already operating in 
Malta prior to EU membership. the number of years they were personally involved in the 
pharmaceutical industry in Malta and the level of autonomy of the local operation from the 
parent company. 
 
 
 
 
Data collection and analysis is organised in two phases: A first phase involving gathering and 
analysing information and data resulting from the secondary data and a second phase which 
relates to obtaining and assessing information  through field research. In the first phase the 
researcher  seeks to ensure that Malta qualified as an ‘open system’. EU membership has 
blurred the real state of the Maltese economy and  there is a popular tendency to assume that 
since Malta now forms part of an advanced economic group, it automatically shares the same 
strengths and advantages. Indeed, despite EU membership, Malta’s share of world exports as 
well as trade with the EU has been showing a downward trend since 2000. Malta’s terms of 
trade have also been worsening indicating that the prices that Malta obtains for its exports are 
declining relative to the prices it pays for its imports. 
 
The researcher  had to obtain the official data relating to the pharmaceutical industry in Malta 
so as to get a better understanding of the performance of the pharmaceutical industry in Malta 
around the time of the country’s accession into the EU.  Unfortunately, there are no sector 
studies on the pharmaceutical industry in Malta and the official statistics are not published at 
this level of detail. The statistics were made available to the researcher by the National Office 
of Statistics. These were then charted and assessed along conventional criteria which 
included: output, gross value added, employment, gross value added per employee, exports, 
exports per employee and exports related to output. The statistics help show the rapid growth 
that the Maltese pharmaceutical industry achieved between 2000 and 2011. Data was also 
obtained from the both  National Intellectual Property Office of Malta as well as the National 
Office of Statistics with regards to the number of patents being filed by the pharmaceutical 
industry and the amount of investment it was making into R & D respectively. This was 
 92 
 
deemed important as it could help indicate the extent to which the pharmaceutical industry is 
dependent on R & D for its success. 
 
To get additional information on the local pharmaceutical industry, the researcher managed to 
find some theses on the industry at the University of Malta. These were mostly presented by 
law students and focused on the legislative changes involving the pharmaceutical industry 
that Malta had to implement as part of  its obligation to transpose the EU’s ‘acquis 
communitaire’. This led to an extensive analysis of the European pharmaceutical industry as 
its policies, institutions and structures impacted on local legislation (such as the Medicines 
Act of 2003) and the creation of new institutions (such as the Medicines Authority). 
Secondary data was generally collected from open sources especially the internet (including 
newspaper reports).  This was deemed necessary as some key individuals who were operating 
in the Maltese pharmaceutical industry at the time of its accession to the EU were no longer 
available for interview (mostly expatriates who had returned home). This material helped in 
formulating the illustrative list of interview questions  and to fill some of the deficiencies in 
information obtained from the primary research.  
 
The second phase focuses on interviews with both policymakers involved directly or 
indirectly with the local pharmaceutical industry as well as with top management of local 
enterprises. The interviews with the policymakers are opened ended and are intended to help 
the researcher obtain as much relevant information on the industry. When needed (in two 
instances) a follow-up meeting was organised so as to obtain additional information or 
clarifications to points discussed in the first interview. The information gathered together 
with the proposed theoretical framework helped to prepare a set of illustrative questions 
which are used to guide discussion in the interviews with the enterprises. The idea of having 
such a list of questions is to have a semi-structured interview with the management of local 
pharmaceutical enterprises so as to ensure that sufficient attention is given to  the research’s 
line of inquiry, there is still the possibility of the interviewee making comments which (s)he 
deem important and which could be missing from the proposed model. The illustrative list of 
interview questions proved invaluable not only in gathering information but also in coding 
and assessing the data collected.  
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The first three questions are intended to get the interviewee to express his (her) opinion on 
the impact of Malta’s EU membership on the local pharmaceutical industry, its operating 
environment as well as on his enterprise. These questions help to establish clearly the general 
line of enquiry but are vague enough so as to allow the interviewee to give his own ideas on 
the matter. The fourth question  relates to the perceived primary challenges currently facing 
the pharmaceutical industry in Malta. Once this is answered, the interviewee is asked how 
these challenges have changed since 2004 (the year Malta) joined the EU. This question links 
with the previous three questions and indirectly seeks to re-affirm the impact of EU 
membership, especially at an industry level. The fifth question seeks to establish what the 
interviewee deems to underpin the competitiveness of local pharmaceutical enterprises and to 
what extent they are still dependent on charging low prices as they are mainly competing on 
costs. The sixth question attempts to determine the operating philosophy of the enterprise and 
whether it had a clear plan as to how to increase value added. (Value added is generally 
associated with increasing output and/or lowering unit costs, but it can also result from the 
enterprise capitalising on its market power and push up its prices). Question seven is closely 
linked to the previous one and directly asks as to the perceived ability of the enterprise to 
influence the prices it gets for its products. Question eight goes back to the impact of EU 
membership on local enterprises and seeks to gauge whether the interviewee believes that 
they have enough power to play a role in influencing EU directives and policies. (This given 
that impact rises out of a dyadic relationship and can work both ways). Question nine seeks to 
test the propensity of local pharmaceutical enterprises to collaborate and network (alliance 
capability). The is an open-ended question as it does not specify with whom they collaborate 
or network. Question ten attempts to determine how the interviewee perceives the strengths 
of his enterprise: is it its assets (such as technology, machinery, marketing, finance and 
human resources) or is it in its competencies (such as market sensing, alliance capability, 
managerial know-how and flexibility). Question eleven too is an open-ended one and seeks to 
conclude the interview by asking about the perceived future of the pharmaceutical industry in 
Malta. 
 
The researcher did not record the interviews as it was felt that this could condition 
interviewees and work against having an atmosphere conducive to open discussion. Hand-
written notes were taken during the interview and these were then re-written and expounded 
shortly after the interview to ensure that salient points emerging from the discussion were still 
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fresh in the researcher’s mind. Following the termination of the field research it was decided 
to add another component (other RCDCs) to capture those factors which interviewees felt 
were critical for the development of the pharmaceutical industry in Malta. 
 
As mentioned, the involvement of a researcher as the primary instrument of data collection 
presents limitations owing to subjectivity and bias. The limitations of a research based on a 
single case study are obvious, and attempts to generalise the results to a diverse population 
are inevitably over-simplistic (Lorenzoni & Lipparini, 1999).  
 
 
This chapter outlined the methodology followed by this research. Given the complexity of the 
subject matter a qualitative, case-study approach was adopted. The research is an exercise in 
social constructionism and follows systems thinking. The proposed theoretical framework 
relating to the relevance of the identified arch-RCDCs for competitive advantage helped in 
the preparation of an illustrative list of questions for interviews with the top management of 
pharmaceutical companies in Malta, to gather information as well as for data analysis. 
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5. Research Findings 
 
This chapter presents the results of the secondary and primary research of this thesis. In the 
first part of the chapter the research setting is delved by applying the proposed schema 
(figure 12) to the development of the pharmaceutical industry in Malta following EU 
membership. The credentials of Malta as an open system are established as well as an outline 
of the EU pharmaceutical industry with a focus on legislation which had to be transposed by 
Malta and impacted on the country’s public policy as well as institutional set-up dealing with 
the pharmaceutical industry. An analysis of the sector’s economic performance follows. In 
the second part of the chapter, the findings arising from the field research are presented. The 
theoretical framework (figure 14) relating to the arch-RCDCs and the competitive advantage 
of an open system helped guide the field research and the analysis of findings at both the 
sector and enterprise level. 
 
This research has proposed an alternative approach which views a small state as an 
organisation, with well-defined but permeable boundaries. Such an organisation has been 
termed as an ‘open system’ and a schema (figure 12) developed so as to help define the 
research setting of this thesis.  
 
When this schema is applied to the pharmaceutical industry in Malta we get figure 18 which 
proposes to capture the impact of Malta’s membership in the EU on the pharmaceutical 
institutions (including enterprises) in the country, leading to their development, improved 
sector performance and competitive advantage.  
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Figure 18 : Impact of EU membership on Malta’s Pharmaceutical Industry 
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5.1 Malta as an Open System 
 
The two criteria set by this research for an open system are that the country and its enterprises 
generally lack ‘market power’ and population does not exceed 1.5 million. Malta has a 
population of 420,000 and despite the country’s relatively high GDP per capita (€17,000 in 
2014), most Maltese enterprises still compete on costs. They are ‘price takers’ with 
practically no market power. Malta is an archipelago of three inhabited micro islands with a 
total area of 316 square kilometres. The islands are 93 kilometres south of Sicily and almost 
300 kilometres north of Libya (figure 19). Malta’s terrain is low and rocky with coastal cliffs.  
 
The history of the country goes back some six thousand years and the islands are a true 
melting pot of civilisations. Malta’s strategic location and natural harbours attracted military 
powers in the Mediterranean which wanted to control this important trade route.  
 
Malta achieved political independence from Great Britain in 1964 and became a Republic ten 
years later. Today, Malta is a member of the EU, the UN and the Commonwealth. Malta 
ranks 36th out of 187 countries on the UN Human Development Index (2011). 
 
Figure 19: Malta’s Geographical Location 
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Malta’s aridity and poor soil do not permit the development of extensive agriculture (even 
though there were times in the past when the country thrived on olive oil and cotton exports). 
Malta is highly dependent on the importation of food and other essentialities. Over the 
centuries, the country prospered as a trade hub, especially in times of war, when it capitalised 
on the increased military spend of its foreign rulers. 
 
Malta boasts a long tradition as a centre for healthcare. During the time of the Knights of St. 
John (1530–1798), the country had one of the most advanced hospitals in Europe. The 
Knights set up a medical school which eventually evolved into a multi-faculty university. The 
British built upon this tradition and exploited Malta’s strategic location to house their military 
medical centre in the Mediterranean. The British ruled Malta between 1800 and 1964. Prior 
to WWII, Malta had already achieved a degree of industrialisation which involved a complex 
division of labour supporting the British military services on the islands (Brincat, 2009). In 
the 1950s, the British government was desperately cutting its military expenditure. The run-
down of the British military presence on the islands led to significant economic hardships for 
the local population. Malta had to quickly diversify its economic activities to create jobs and 
maintain its standard of living (Brincat, 2005). A large number of Maltese were obliged to 
migrate to the United Kingdom, United States, Australia and Canada, and immediately after 
WWII, their remittances kept many local families from falling into extreme poverty.  
 
                               Fact Sheet: Malta  
  Population ’000 (2012)  425 
  
Territory Size 316 km2
 
  
Population Density 1250 per km2 
  
GDP (2013) €7.02 b 
  Per Capita GDP  ‘000 (2013) €17,000 
  
GDP (PPS): %,  EU 27 (2012) 83% 
Life Expectancy 79.6 years 
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Brincat (2005) refers to the ‘Maltese Model’ of industrialisation: export-oriented activities 
driven by FDI. ‘The only practical course is to direct every effort, of investment, 
administrative measures and legal machinery, and of the skills of the people, towards the 
achievements of a self-supporting and viable economy’ (Development Plan for the Maltese 
Islands, 1959-64 quoted by Brincat, 2005). Industrialisation was made possible through ‘a 
process that was assisted by certain legacies of the colonial period. These included a ‘reserve 
army of labour’ created by the British military rundown, which ‘disposed of skills 
accumulated over one and a half centuries of servicing naval and other military hardware’ 
(Brincat, 2009, p. 36). During the 1960s, Malta promoted itself in a structured way as a ‘sun 
and sea’ tourist destination. Relying mostly on mass tourism (initially through packaged 
tours, and more recently, through low cost carriers), Malta annually attracts four times as 
many tourists as it has inhabitants.  
 
The country achieved remarkable economic growth rates. The Commission on Growth and 
Development (2008) identified Malta as one of thirteen countries which registered impressive 
growth over a sustained period of time (Table 7). 
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Table 7: Success Stories of High, Sustained Growth 
(Reproduced from World Bank, 2008b) 
The technical skills nurtured at the local military shipyard proved invaluable in supporting 
Malta’s industrialisation process. The country had an abundance of non-agrarian, English-
speaking, cheap labour which attracted a significant number of textile, electronic and light 
engineering operations. Initially, the United Kingdom was the main source of foreign direct 
investment, but this changed in the 1970s when Germany took over. Industrial growth led to 
the creation of a dual economy; a foreign-owned, internationally competitive segment which 
utilised relatively sophisticated imported technologies and an indigenous domestic market-
oriented segment that generally relied on ‘dated’ technology and machinery. Gradually, the 
importance of manufacturing declined from some 35% to 13% of GDP. The Maltese 
economy is now service oriented and relies on activities such as financial services, remote 
gaming and the information and communication industry.  
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To meet the challenge of globalisation and help overcome some of the perceived limitations 
of small size and peripherality, forty years after independence, Malta joined the EU. The 
primary challenge for the country at the time was to liberalise and restructure its economy 
(especially indigenous operations) to meet the challenges of integration into the sophisticated 
European market. Bonello (2009, p. 1), the Governor of the Central Bank of Malta, argues 
that he favoured the EU membership because, given Malta’s small size and lack of natural 
resources, it was ‘Malta’s only viable option’ that guaranteed access to foreign markets. The 
EU membership was also perceived as being ‘the solution to the prevailing economic 
problems...lack of discipline in public budgeting, lack of enforcement, etc’ (Mizzi, 2004, p. 
7). 
 
Malta–EU relations go back to 1970, when the country entered into an association agreement 
with the EEC. This agreement was intended to lead to a customs union, but successive local 
governments were reluctant to go the full way as they feared that local enterprises would not 
be able to compete head-on with European enterprises (Mizzi, 2004). The association 
agreement with the EEC was generally a favourable one for Malta. The country not only 
secured financial assistance from the EEC to help it modernise the physical infrastructure, but 
also practically offered access to all locally manufactured goods (except textiles, clothing and 
food products) to its markets, without any tariff or quota barriers. Though Malta formally 
joined the EU in 2004, the change process began in 1990, when Malta first applied for 
membership. The application sent a strong signal to all the local stakeholders of government 
intentions, but their reactions varied between, and among, themselves. Some were sceptical 
about the EU’s willingness to accept tiny Malta as a full EU member. Others doubted 
whether Malta would be prepared to make all the necessary changes for its membership. In 
June 1993, the European Commission published a favourable opinion (‘Avis’) on Malta’s 
membership, however, it pointed out that extensive restructuring had first to be implemented.  
 
The 1993 Avis finds that membership ‘depends on a thoroughgoing overhaul of the Maltese 
economy’s regulatory and operational systems’ (Bonello, 2009, p. 1). Important reforms 
included the liberalisation of the financial system and the import tariff regime, gradual easing 
of exchange controls, partial deregulation of interest rates and introduction of value-added tax 
and lower direct taxation. Significant restructuring ‘could only be met if we were prepared to 
question the way we had managed the economy in the past and resolved to make the 
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necessary changes to institutions and mind-sets, policies and work practices’ (Bonello 2009, 
p. 1). The fact that politically there was no national consensus on the EU membership 
complicated the situation. In 1996, the PL came to power and decided to ‘freeze’ Malta’s 
application. This naturally sent a contradictory signal to stakeholders and increased 
uncertainty. The ‘adaptation’ process at the national level started in earnest in 1999, when 
after a change in government Malta’s application was reactivated. The European Commission 
updated its 1993 opinion on Malta’s membership and recommended that the Council gives 
the go ahead to screen Malta’s legislation with a view to opening negotiations. 
 
‘As from the year 2000, Malta as a candidate country started receiving technical and financial 
support for the transposition of the Community acquis, for participation in Community 
Programmes and certain Community agencies and for increasing the Maltese administrative 
and judicial capacity’ (EU Commission, 2013). The EU membership entailed the 
transposition of the ‘acquis communitaire’ (the cumulative body of European Community 
laws, comprising the EC’s objectives, substantive rules, policies as well as the primary and 
secondary legislation and case law) into local legislation. It is a pre-condition set by the EU 
that all countries seeking membership must first adopt, implement and enforce all the acquis. 
‘As well as changing national laws, this often means setting up or changing the necessary 
administrative or judicial bodies which oversee the legislation’ (EU Commission, 2012). 
Geographically, Malta is the smallest state within the EU and has the second smallest 
population (after Luxembourg). The EU membership brought with it an obligation for Malta 
to join the euro. With an average trade-to-GDP ratio of 82%, Malta has the second most open 
economy in the Union (Bonello, 2010). The EU is Malta’s major trading partner, accounting 
for 61% of its exports of goods and services and 70% of its imports. 
 
The EU itself is not a homogenous entity and there are significant economic differences 
between its member states and regions. Malta’s aspiration remains that of achieving ‘superior 
performance’ that will enable it to move closer to the standard of living enjoyed by the more 
advanced EU economies. Membership triggered a deep change process which is transforming 
not only the country’s economy but also its political, social, technological, environmental and 
legal scenes. Today, Malta’s economy is specialised in technology-driven industries which 
account for 71% of total exports (this is the highest in the EU). Trade specialisation in 
technologically advanced sectors, however, is not leading to high productivity and high 
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incomes. A recent study commissioned by the MCST finds that ‘[t]he competiveness of the 
Manufacturing Industry is gradually eroding as manufacturing firms are faced with declining 
profits, lower employment levels and reduction in the overall turnover being generated in the 
process’ (BEAT Consulting, 2011, p. 6). Malta is in the same group of EU countries as the 
Czech Republic, Hungary, Poland, Slovakia and Slovenia with a trade specialisation in high 
technology sectors, but having a lower GDP/person than the EU average. This group ‘looks 
like shifting towards becoming an assembly powerhouse for the more technologically 
advanced countries’ within the EU (EU Commission, 2011a, p. 22). The local manufacturing 
sector is still ‘predominantly based on the production function with a limited focus on 
research and development activities’ (BEAT Consulting, 2011, p. 7). Most enterprises 
continue to compete as ‘price-takers’ and are failing to achieve market power through 
innovation and strategic marketing. The majority of Maltese exports are ‘generated by 
Foreign Direct Investment set up in Malta which in most cases have their marketing and sales 
functions located in other destinations worldwide’ (BEAT Consulting, 2011, p. 6). 
 
As a percentage of world exports, local exports show a significant decline since 2001 (even 
though there has been a small improvement from 2009 to 2010). 
 
(Source: European Commission, AMECO database) 
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Chart 1: Malta share of world exports (2000-2011) 
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Despite EU membership, there has been little change in the direction of trade. 
Percentagewise, exports to the EU increased slightly in 2005–2006, but have been falling 
ever since. Similarly, imports from the EU peaked in 2004–2005 and have also been 
declining. 
 
 
(Source: National Statistics Office. Malta) 
 
The terms of trade for Malta have been declining since 2000; the trend has accelerated post-
EU membership (even though in 2010, there was a small rebound).  
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(Source: European Commission, AMECO database) 
 
5.2 EU Pharmaceutical Industry 
 
‘The pharmaceutical industry is concerned with all aspects of the preparation and use of 
medicines’ (Anderson, 2005, p. 3) and is considered to be a ‘strategic’ sector for Europe 
(Gambardella et al., 2000). It is a highly sensitive industry ‘in terms of the debate it arouses 
and the regulations it invites’ (Ballance et al., 1992, p. 140). Health is a universal human 
right (WHO charter) and has become a critical political issue that impacts the local, national 
and global levels. ‘In an era of globalization, governments are expected to provide safety and 
welfare for citizens while ensuring a level playing field and boosting competitiveness for 
businesses’ (WHO, 2011, p. 343). ‘Good health and the opportunity to seek health care are of 
intrinsic value for making progress in international relations between states and between 
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conflicting groups within states’ (Quirke, 2005, p. 1). The international harmonisation of 
pharmaceuticals ‘was formally initiated through the creation of the International Conference 
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use in 1989’ (Zammit, 2010, p. 48). 
 
OECD countries account for 20% of the world’s population, but spend 90% of the global 
expenditure on health; about ‘80% of the world’s population lives without access to essential 
medicines’ (Quirke, 2005, p. 161). In western societies, a major concern is the over-
consumption of medicines for dubious benefit (O’Donovan & Glavanis-Grantham, 2007). In 
Third World countries, international players such as non-governmental organisations (NGOs) 
and global corporations play a critical role. NGOs influence ‘global health governance’ 
through their funding priorities, since they exert considerable influence on the ‘type of health 
programmes and initiatives that are promoted in many aid-recipient states’ (Quirke, 2005, p. 
58). Given the pharmaceutical industry’s importance to public health, its high level of 
regulation, dependence on legal ‘concessions’ and the fact that the government is a main 
purchaser of its products, should lead the industry to be regarded as a ‘public utility’ (Marcia, 
2004).  
 
The aspirations of people for a healthier life are increasing across the world. ‘The 
globalisation of pharmaceuticals illustrates the sheer scale and complexity of our inter-
connected world and its uncertain social and biological outcomes in local and national 
settings’ (Petryna & Kleinman (2007) quoted by Zammit (2010, p. 42). Although the 
pharmaceutical industry has an excellent track record ‘(it) is a victim of its own success’ 
(Farrugia & Savvas, 2009, p. 30) as the industry is characterised ‘by a number of 
contradictions’ (Zammit, 2010, p. 25). ‘Politics and health; fundamental rights of persons, 
medicines and welfare; innovation and development; politics of solidarity, intellectual 
property, innovation and patents and world government are some of the facets in which 
pharmaceutical innovation and effective and equitable use of medicines are involved’ 
(Valverde (2007) cited by Zammit (2010, p. 25).  
 
The industry’s controversial reputation arises from its independent-minded enterprises and 
their secretive method of operation, exceptional profitability and high level of innovation 
(Ballance et al., 1992). The mass production of drugs dates back to 1813, with the 
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establishment of the first specialised pharmaceutical plant (Panda et al., 2011). Over the last 
century, there has been a vast increase in the number of therapeutic innovations (Quirke, 
2005). ‘Parallel with product innovation we clearly see major developments in process 
technology’ (Panda et al., 2011, p. 1). The period of 1950–1970 is considered the ‘golden 
age’ of the drug industry. The invention of genetic engineering in 1973 opened up new 
research possibilities and is leading to significant growth in biotechnology. ‘This marked the 
start of a new era in drug R&D and also the coming of a new R&D trajectory’ (Panda et al., 
2011, p. 2). The life sciences are transforming drug discovery and development. ‘The advent 
of the so-called “molecular biology” revolution since the mid-Seventies has introduced 
drastic changes in the relevant knowledge base, in the processes of discovery and in the 
organisation of research, with the emergence of a new technological regime and new 
technological and organisational capabilities as a key source of competitive advantages’ 
(Gambardella et al., 2000, p. 37). 
 
The pharmaceutical industry is driven by complexity; the companies that succeed are simply 
those that can handle complexity more efficiently (Vella, 2011). The industry is obliged to act 
quickly and in a flexible way. ‘Complexity and speed are becoming fundamental to 
development. If a company does not possess the intrinsic flexibility to address complexity 
effectively, it will be forced out of the market’ (Research & Markets, 2006). The big divide 
within the pharmaceutical industry is between patented (originator) pharmaceuticals and 
generics. There is no one internationally accepted definition of generics, although the term 
generally refers to medicines that are no longer protected by patents or non-patentable 
(Ballance et al., 1992). As per Article 10 paragraph 2 (b) of Directive 2001/83/EC, the EU 
defines a generic medicinal product as one having ‘the same qualitative and quantitative 
composition in active substances and the same pharmaceutical form as the reference 
medicinal product and whose bioequivalence with reference medicinal product has been 
demonstrated by appropriate bioavailability studies’ (Azzopardi & Zarb Adami, 2012, p. 1). 
Equivalent generic medicines may contain different non-active ingredients (such as 
colourings, starches and sugars) and they may differ in size, colour or shape, but none of 
these have an impact on the therapeutic effect, that is, the way they work in a patient’s body. 
The term ‘generic’ also includes biosimilars. Generic medicines are identified either by their 
International Non-proprietary Names (INNs) or their own brand name. INNs are overseen by 
the WHO. Understandably, producers of generic medicines tend to focus on ‘blockbuster’ 
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drugs, many of which generate an annual turnover of more than €1billion and which lose 
their exclusivity status. These drugs ‘are the backbone of many originator companies’ 
(Boldrin & Levine, 2007, p. 16). Pharmaceuticals is a large, high-growth, globalised, and 
innovation intensive industry: its fundamental sources of competitive advantages are R&D 
and innovative competencies, marketing and distribution capabilities (Gambardella et al., 
2000). Globally, the industry is undergoing enormous change characterised by increased 
pressures on the big players, the advent of biotech and the global expansion of the generics 
industry (Singh, 2006, p. 194).  
 
Pharmaceuticals are traded in both their intermediate and finished form. Global 
pharmaceutical corporations sell patented medicinal chemicals and preparations to their 
affiliates, licensees and appointed distributors, while non-patented ingredients are sold on the 
open market as fine or speciality chemicals (Ballance et al., 1992). The internet is fast 
becoming an important channel to purchase medicines as well as leading to the increased 
sales of counterfeit drugs and increasingly challenging state control over the distribution of 
medicines (Ballance et al., 1992). According to Deutsche Bank (2010), the global market for 
pharmaceutical products is about €700 bn and has been recording an average 10% annual 
sales growth in the last thirty years. Global pharmaceutical markets are being shaped by two 
broad demographic trends: population growth and age structure. Advances in drug-based 
treatment research, increased investment in healthcare and consumer-driven private health 
coverage are all boosting the demand for pharmaceuticals. By contrast, in Third World 
countries, the population is relatively young and the main demand for medicines is for acute 
or infectious diseases. The industry is characterised by a high level of concentration, with 
some fifteen dominating multinational companies (Davidson & Greblov, 2005, p. 2). Market 
entry is difficult due to a combination of strict regulations and the need for extensive research 
and development, which involves time-consuming, expensive clinical trials. There are three 
main types of pharmaceutical producers: large integrated corporations, innovative companies 
and reproductive firms. ‘The ethical (prescription–only) pharmaceutical industry has been 
one of the fastest growing, most consistently profitable, of the world’s major industries’ 
(Rickwood & Southworth, 1994, p. 1). Large pharmaceutical firms have been repeatedly 
accused of enjoying a substantial or excessive degree of market power (Ballance et al., 1992). 
Zammit (2010, p. 91) remarks ‘[t]he industry’s ability to influence legislation cannot be over-
estimated’. Estimates of concentration can, however, be misleading since ‘the markets for 
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pharmaceuticals tend to be much more fragmented than those in other industries...Industry 
wide estimates therefore understate the extent to which a few companies dominate certain 
submarkets’ (Ballance et al., 1992, p. 111). Panda et al/ (2011, p. 2) explain that although the 
market structure ‘is oligopolistic at the level of therapeutics’ it is highly ‘competitive for 
OTC and generic categories’.  
 
EFPIA claims that it can cost €1 billion or more to develop a new medicine in the period 
between discovery and marketing, which is normally a duration of 12–13 years. Only around 
one-fifth of new products ever recover the cost of development. Only one or two of every 
10,000 substances synthesised in laboratories successfully pass all stages to become 
marketable medicines, and from these, one in five will produce revenues that match or exceed 
the costs of R&D before losing patent protection (EFPIA, 2012). For bio-pharmaceuticals, 
the costs of R&D tend to be higher than those of traditional pharmaceuticals. Producers of 
originator drugs depend for their profitability on the monopolistic rights arising out of the 
patent system and marketing authorisation procedure. Exclusivity is the lifeblood of the 
industry because it means that no other company may sell the same drug for a set period 
(Marcia, 2004). The cost of bringing a new medicine to the market is subject to wide debate 
and calculations. Critics of the industry point out that R&D is a relatively small part of the 
budget in major pharmaceutical corporations and it is a fraction of their spending on 
marketing and administration. The number of new important drugs is falling despite the 
contribution being made by public research at academic institutions, small biotechnology 
companies and national healthcare institutes, all of which are funded by taxpayers’ money 
(Marcia, 2004). As the number of blockbuster drugs began to fall, ‘firms have turned to 
mergers and acquisitions as a means of achieving economies of scale and scope’ (Quirke, 
2005, p. 197), Although in the past, the size and scope of operations have tended to go hand 
in hand, this is now changing (EC, 2009). The industry also comprises a wide variety of 
SMEs which tend to be national in scope and specialise in niche activities. These companies 
have ‘thrived through imitation and generic competition after patent expiration as well as 
through production and marketing in local markets and product niches’ (Gambardella et al., 
2000, p. 37). These reproductive firms generally lack any in-house research capacity and the 
drugs they produce are not protected by patents (Ballance et al., 1992). The generics market 
is fast moving and subject to volatile prices and small margins (Cassar, 2006).  
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Research-intensive SMEs generally spring off from the life sciences. These companies are 
specialised in the new biotechnologies, and their activities range from the discovery and 
development of new drug compounds to the development of new drug screening or research 
tools and technologies in fields such as genomics and bioinformatics. Many of these 
companies are dependent on investor capital for survival as they are still developing their first 
products (Biotechnology is one of the most research-intensive industries in the world.). 
Originator companies are increasingly resorting to ‘branded generics’, that is, ‘generic drugs 
that carry a big pharmaceutical name...branded generics are likely to reach up to 75 per cent 
of sales growth within the next 10 years’ (Branded Generics, 2011). The EC (2009) 
pharmaceutical enquiry finds that several generic companies are also involved in the 
production of prescription medicines. Generic firms also engage ‘in the development of new 
formulations, dosage forms and methods of delivery (so-called “line extensions” of existing 
products)’. They are also expanding into new areas of pharmaceutical development, such as 
new formulations and biosimilar medicines, and are moving onto new and fast-growing 
pharmaceutical markets such as China, the Middle East and Russia (Grooten, 2008). 
Although generic producers are mostly SMEs, there is an evident shift towards consolidation 
and increased concentration. A few, such as Sandoz, the generics arm of Novartis and Israel’s 
Teva Pharmaceutical Industries have become global players and represent the world’s top 
two generic firms. ‘The gap between them and smaller players keeps growing’ (Hirschler, 
2005).  
 
In today’s fast-moving world, ‘time is money’. Generics take the shortest time possible to 
copy, licence, produce and stockpile a drug. Any time gained gives a competitive edge in the 
relatively low margin industry. Jack (2005) points out that ‘The first into the market often 
wins and keeps the greatest share’. The bottom line in generic pharmaceuticals is all about 
having a strong pipeline of new products coming out (Vella, 2011). The cost structure of 
generic companies is fundamentally different from originator companies. On average, 
manufacturing costs account for 51% of turnover. The European generic medicines industry 
is operating under increasing cost pressures as a result of higher regulatory requirements for 
bioequivalence, added GMP requirements and stricter pharmacovigilance rules (EGA, 2007). 
The future of generics is in biosimilars, as the high prices of biopharmaceutical products is 
likely to lead to important cost savings. Given the high cost of developing biosimilars, ‘these 
cost savings are likely to be less than for chemical molecules’ (EC, 2009, p. 41). While joint 
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research projects and strategic alliances facilitate the exchange of knowledge, ‘network 
externalities’ are also supported by the rapid movement of scientists and technicians across 
firms 
 
Innovation in the pharmaceutical industry can be divided into two distinct categories: 
 
• Fundamental innovation which leads to the discovery of new medicines containing novel 
pharmaceutically active substances (NCEs)  
• Incremental innovation which results from the development of existing medicinal 
products and may include major innovations such as the novel use of existing products in 
new therapeutic areas, development of a new formulation or mode of delivery, 
combination of previously disclosed active substances and use of a new salt or derivative 
of the original product.  
 
Gambardella et al. (2000, p. 1) note that ‘[e]ver since the XIX Century, pharmaceuticals has 
been a stronghold of the European industry, and it still provides by far the largest contribution 
to the European trade balance in high-technology, R&D intensive sectors’. As a result of 
‘some big and many small steps in biomedical research’ (The European Federation of 
Pharmaceutical Industries and Associations, 2008), Europeans live up to thirty years longer 
than they did a century ago. In accordance with the principle of subsidiarity, the delivery of 
healthcare services and medical care in the EU remains the prerogative of each member state. 
Pharmaceuticals account for 24.1% of the EU’s high-tech exports. It is the sector with the 
highest value add per person as well as the highest ratio of R&D investment to net sales. 
Pharmaceuticals represent about 3.5% of total EU manufacturing value (EFPIA, 2008, p. 10). 
Generics account for 18% (by value) and almost 50% (by volume) of the European market. 
The level of generic penetration in the EU is influenced by the different public policy choices 
made by the member states. Generic penetration rates tend to be higher in member states, 
where the prescription of active substances (INNs) instead of brands is encouraged. The slow 
rate of acceptance in some member states is partly due to opposition from industry 
representatives and the medical profession (Ballance et al., 1992, p. 47). EGA (2007, p. 4) 
remarks that ‘variations in the level of generic penetration is significant, due not only to 
different historical and economic backgrounds, but also to the public policies employed to 
promote them’. Apart from budgetary considerations, generics are growing faster than 
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patented drugs owing to the fact that ‘a large number of top-selling medicines are currently 
approaching patent expiry in both the USA and Europe’ (EC, 2009, p. 38). This will open up 
unique opportunities for generic producers.  
 
Table 8 outlines data prepared by EFPIA relating to the EU pharmaceutical industry. 
 
  
Table 8: Key Data for EU Pharmaceutical Industry 
(Reproduced from EFPIA, 2008) 
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The United States accounts for almost half all health-related patents (pharmaceutical products 
and medical technologies) in the world. Within the EU, Denmark, the Netherlands, Sweden 
and Germany are technological leaders in this field (EC, 2011b). The 2008 financial crisis, 
the subsequent economic recession and the euro crisis have convinced the EU of the need to 
boost its manufacturing sector, especially through increased R&D and innovation-driven 
activities. It is encouraging that Europe’s biotechnology sector is growing at a significant 
pace and now accounts for about 20% of new medicines launched on the market (EFPIA, 
2009). The Europe 2020 strategy follows on the Lisbon Agenda and is intended to guide 
Europe’s economic recovery while presenting a comprehensive agenda towards becoming a 
more competitive, sustainable and inclusive economy (EC, 2011b). The Innovation Union 
Flagship Initiative is at the core of this strategy. It outlines how Europe will tackle the 
‘innovation emergency’ it is facing through a strategic approach that integrates research and 
innovation instruments and actors. 
5.3 Societal Structures and Resources 
 
This research follows R-A theory in perceiving economic activity as being embedded in 
broader social activities and assigns importance to the nature of societal resources and 
structures as well as the quality of public policymaking of the open system. The overall goals 
of public policy in the sphere of medicines are availability, affordability and rational use. If 
drugs were ordinary consumer goods, ‘the high level of legal regulation...would hardly be 
justified’ (Zammit, 2010, p. 22). 
 
Extensive regulation has significantly influenced the behaviour of pharmaceutical enterprises 
(Boldrin & Levine, 2007). The European Community plays an active role by legislating 
measures which cannot be taken by individual states. EU regulation seeks to support public 
health, the free movement of goods and people, compliance with legal requirements and the 
concepts of harmfulness and therapeutic efficacy. Unless a medicinal product is authorised, it 
cannot be made available to patients (Vella Bonanno & Flores, 2011, p. 346). Medicines in 
certain categories are authorised through a single marketing authorisation that is valid in all 
EU and European Economic Area countries. At the national level, pharmaceutical regulation 
has various components covering R&D, authorisation, production, distribution and the use of 
medicinal products (figure 20). Local authorities regulate within the public interest to 
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stimulate innovation, encourage a competitive market and protect the environment (WHO, 
2011).  
Figure 20: Framework for Medicines Regulation within the EU 
(Reproduced from Vella Bonanno and Flores, 2011) 
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5.3.1 The Bolar provision 
 
In the United States, up to 1984, experimenting on a patented pharmaceutical prior to the 
expiration of the patent was considered an infringement (L’Ecluse et al., 2005). That year, in 
the Roche v Bolar case, the New York district court found that Bolar had not breached patent 
rights because of the ‘de minimis’ and experimental nature of its use of Roche’s flurazepam 
HCl. This decision was subsequently reversed by the Court of Appeals. This induced the US 
Congress to legislate the Hatch–Waxman Act, which permits the copy (or import), use or sale 
offer of a patented invention within the United States, provided that this is solely ‘for uses 
reasonably related to the development and submission of information under a Federal law 
which regulates the manufacture, use, or sale of drugs or veterinary biological products’ 
(L’Ecluse et al., 2005:113). This exemption is technically referred to as the § 271(e)(1) or the 
Hatch–Waxman exemption (In patent law, it is generally referred to as the ‘research 
exemption’ or ‘safe harbour exemption’). The US Congress also expedited market entry by 
establishing the Abbreviated New Drug Application process. Generic producers were allowed 
to use research material already submitted to the Foods and Drugs Agency (FDA) by the 
manufacturer of the originator product, provided they prove bio-equivalency and the generic 
drug will be used for the same purpose and in the same conditions and dosage as the original 
patented product. In compensation, prescription drugs were granted a five-year patent term 
extension (SPC).  
 
Initially, it was feared that such an exemption would lead to a drop in R&D, but results have 
shown otherwise. Today, even though the generic industry has over 60% (in volume) of the 
market, the R&D expenditure financed by pharmaceutical enterprises has been rising 
significantly since the 1990s (Figure 21).  
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Figure 21: US R&D Expenditures Financed by Firms (1970-2000) 
(Reproduced from EGA, 2008) 
The Hatch–Waxman exemption allowed the United States to make significant progress in the 
development and manufacturing of generic drugs. The EU lagged behind in this area hindered 
by a heavy public policymaking process, which sought to bring together too many 
stakeholders with conflicting interests. It was only in 1996, that the European Parliament 
passed a resolution on the pharmaceutical industry meant to give the production of generics a 
boost. This resolution was rejected by many EU member states which held that ‘such an 
exemption would not comply with Article 30 of the WTO’s TRIPS’ (Cassar, 2006, p. 38). 
The Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement seeks to 
harmonise international rules and covers a broad range of intellectual assets, including 
copyright, trademarks, industrial designs and patents. The WTO (then known as GATT) 
members agreed that, as of 1 January 1995, they will offer a twenty-year protection period for 
medicine patents registered from then onwards. In exchange, the agreement affirmed the right 
of a country to protect its public health by ensuring ‘access to “affordable” pharmaceuticals, 
and to have patent rights removed in cases of “epidemic’ and emergency proportions”’ 
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(Quirke, 2005, p. 69). TRIPS also provides for special transitional arrangements for least 
developed countries to implement new intellectual property legislation by 2016. Davies 
(2010, p. 165) argues that ‘The real impact of TRIPS was not the strict conditions under 
which TRIPS could permit generic production but that TRIPS made it prohibitively 
expensive for a developing country to advance its own pharmaceutical industry, because of 
the cost associated with the licensing system’. 
 
In 2000, a report commissioned by the Enterprise Directorate-General of the EC entitled 
‘Global Competitiveness in Pharmaceuticals - a European Perspective’ confirmed the EU’s 
concern over the competitiveness of the European pharmaceutical industry. The report notes 
that ‘the 1990s have shown an acceleration of the competitiveness of the US pharmaceutical 
industry as a whole in the innovation-intensive segment of the industry’ and that ‘[t]he 
competitive advantage of the US companies in innovation relies both on higher internal 
capabilities and on a higher reliance on collaboration’ (Gambardella et al., 2000, pp. 83–84). 
The Report finds that ‘Europe as a whole is lagging behind in its ability to generate, organise, 
and sustain innovation processes that are increasingly expensive and organisationally 
complex’. In 2000, the WTO confirmed that the Bolar provision was in line with TRIPs 
(ruling in favour of Canada vs. EU). This ruling came at a time when a number of central and 
east European countries were negotiating accession into the EU membership. Many of these 
countries had a flourishing generics industry as they practically had no track record in 
intellectual property law prior to the early 1990s. ‘Although the EU-enlargement offers 
greater market opportunities, the implementation of harmonised intellectual property and 
regulatory provisions has raised particular concerns in the pharmaceutical industry. In the 
CEE states which have a flourishing generic industry, IP protection for pharmaceuticals has 
traditionally been relatively poor’ (von Uexküll, 2006). As explained, the Accession Treaty 
requires that new member states transpose the ‘acquis communautaire’ (EU legislation) into 
national legislation. After protracted negotiations between the Central East European (CEE) 
states and the EU, a compromise was reached which necessitated a comprehensive reform of 
the EU’s pharmaceutical legislative framework (von Uexküll, 2006).  
 
These amendments included new rules on data exclusivity and the introduction of the Bolar 
provision (CMS, 2011). Under the EU law, the US Hatch–Waxman exemption is referred to 
as the Bolar (or Roche-Bolar) exemption, and was put into effect in 2005. In compensation, 
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patented medicines started to benefit from an eight-year period data exclusivity regime and 
an additional two years of marketing protection, which effectively extended the overall 
gestation period before generic manufacturers can register their products (EGA, 2008).  
 
Other important implications of the legal changes are as follows:  
 
• allowing the marketing of generics where originator pharmaceuticals have been 
withdrawn for commercial reasons  
• a more efficient system for the registration of generic medicines (especially through the 
introduction of the European reference product and single market authorisation) 
• greater harmony between newly approved generic medicines and older approved 
originator products 
• clearer scientific and legal definitions of generic and bio similar medicines 
 
The revised regulatory framework is meant to strengthen European competitiveness through 
‘a proper balancing of interests’ (L’Ecluse et al., 2005, p. 113). Cassar (2006, p. 74) remarks 
‘[u]nfortunately the wording used in the Directive means that some ambiguity remains in 
terms of the extent and type of such development work’. Because of this, EU member states 
(through their national legislation or the decisions of their national courts) have different 
interpretations of the Bolar provision, with some adopting a much broader approach (Lovells 
& Whiting, 2011). EGA (2007, p. 7) regrets this lack of harmonisation and concludes that 
‘the EU does not as yet constitute a safe harbour for developing generic and biosimilar 
medicinal products’. 
5.4 Other Societal Institutions 
 
The transposition of the EU’s directives relevant to the pharmaceutical industry into local 
legislation led to the Medicines Act (2003). This Act includes provisions relating to ‘good 
manufacturing practice, importation and parallel importation, marketing authorisations, 
packaging and labelling, wholesale distribution, reimbursement and selection of medicines, 
clinical trials, pharmacovigilance and advertising’ (Bugeja, 2008, p. 34). The Manufacture of 
Medicinal Products for Human Use Regulation (Art. 458.36) of the Medicines Act stipulates 
that, to be manufactured in Malta, a medicinal product needs to be covered by a 
manufacturing licence (Good Manufacturing Practice), ‘even though the medicinal / 
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pharmaceutical is manufactured for export-purposes only’ (Cassar, 2006, p. 89). GMP 
certification ensures ‘that the production of medicinal products is carried out at correct 
potency levels recommended for use in safe doses or to the correct category of patient’ 
(Zammit, 2010, p. 23). The EU’s GMP certificate assesses both process and product. ‘Such 
activities and certification serve to confirm the quality of the medical sector in Malta and re-
enforces the image of the country on international markets’ (Galea, 2012).  
 
In 2008, Malta acted, for the first time, as a Reference Member State. In cases where an 
authorisation for a medicinal product does not yet exist in any of the EU member states, 
identical dossiers are submitted to all member states, for which a marketing authorisation is 
being sought. The reference member state prepares the draft assessment documents, which 
once approved, leads to authorisation in all the member states where the dossier is submitted. 
In 2009, Malta also became involved as a rapporteur for centralised products (Vella Bonnano 
& Flores, 2011). The Medicines Act (2003) delineates the role and responsibilities of the 
Licensing Authority, the Medicines Authority and the Medicines Review Board. The 
Licensing Authority (or the ‘Superintendent of Public Health’) has the ultimate responsibility 
of setting standards, taking the final decision on marketing authorisations for medicinal 
products and licensing manufacturers and wholesale dealers. The Medicines Authority 
assesses medicines, issues marketing authorisation certificates and acts as the enforcement 
agency in the field. Its services include conducting inspections of manufacturing plants and 
laboratories in accordance with EU principles and guidelines for GMP. The Authority’s GMP 
audits are recognised throughout the EU, and it has built a reputation for efficient and timely 
services. ‘The Medicines Authority is committed to support innovation and competitiveness 
through effective, efficient, proportionate and consistent regulation and provision of scientific 
and regulatory advice’ (Vella Bonnano & Flores, 2011, p. 353). The Medicines Authority has 
helped local pharmaceutical companies to develop their quality/GMP perspective (Vella, 
2011).  
 
The Authority involves the private sector in consultation processes relating to the 
introduction of EU legislation. The Medicines Review Board is responsible for hearing all 
appeals against recommendations made by the Medicines Authority. In such cases, the 
Licensing Authority has the final decision after giving due consideration to the opinion put 
forward by the Review Board. In 2010, the government announced its plans through a draft 
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bill, that is, to incorporate the Medicines Authority into a Medicines Institute as one entity 
within the Malta Competition and Consumer Affairs Authority. This proposal was criticised 
by the Pharmaceutical Manufacturers Business Section of the local Chamber of Commerce, 
Enterprise and Industry, which expressed concern that the move would not be positively 
received by the European Medicines Agencies and the US Food and Drug Administration. 
ME too played an important role in the growth of the local pharmaceutical industry. During 
the accession negotiations with the EU, ME realised that the Bolar exemption and lack of 
locally registered medicinal patents could help attract foreign producers of generics to branch 
their operations to Malta. At the time, the Industrial Development Act (1988) was being 
amended to make its compliant with EU State Aid regulations. The Business Promotion Act 
(2001) identified pharmaceuticals as a priority sector eligible for an extensive incentive 
package which included various tax incentives, the provision of finance at special rates for 
the purchase of equipment and/or the construction of custom-built factories. 
 
Other critical institutional developments took place in local education. The Maltese education 
system is slowly adapting to the needs of this growing industry and providing highly skilled 
employees (Kelleher, 2006). Malta enjoys a reputation for good standards of education. Over 
10,000 students attend the local university, whose history goes back over four hundred years. 
Presently, the University has some 450 pharmacy and chemistry undergraduates. To meet 
industry’s needs, the curriculum is updated on a regular basis. To meet a gap in the 
availability of the necessary expertise, some years ago, the University introduced a 
postgraduate diploma for Qualified Persons (warranted signatories who take responsibility for 
the release of medicines from the factory). Vella (2011) points out that ‘[t]he university 
courses offered here expose our graduates increasingly to both the practical and the academic 
side of the subject’. In 2004, MCAST, in collaboration with industry and the Malta 
Laboratories Association, introduced a Higher National Diploma (HND) course for 
laboratory technicians. The ETC, in co-ordination with ME, also seeks to ensure the 
availability of the required skills. ETC runs day and evening courses for assistant laboratory 
technicians and a course for chemical operators, specifically targeting unemployed youths 
(Galea & Mckenna, 2004).  
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5.5 Public Policy 
 
The EC (2009) pharmaceutical sector report identifies three areas of public policy which are 
of particular importance to the industry:  
 
a) patents 
b) marketing authorisations  
c) pricing and ‘reimbursement’ of products 
5.5.1 Patents  
 
R-A theory considers the patent system to be a key institution that promotes social trust and 
facilitates economic growth by fostering efficiency and/or effectiveness of innovation, as well 
as a key societal resource which protects the investment made by firms. Robust intellectual 
property protection is the cornerstone of innovation in the pharmaceutical industry (EFPIA, 
2008). Patent systems were designed to encourage and reward innovation (Wildman Palmer 
& Soames, 2009). It is widely acknowledged that patents are a fundamental incentive to 
innovative activities in pharmaceuticals and biotechnology (Gambardella et al., 2000). 
However, it is only since the 1960s that patents assumed critical importance for 
pharmaceuticals (Quirke, 2005). A patent is a legal title protecting an invention, which can be 
a product or a process, granting its holder the right to prevent third parties from making, 
using, offering the sale of, selling or importing the product without the patent holder’s prior 
consent (WTO, 2012). An EC (2009) sector report on pharmaceuticals finds that a single 
product may have a number of patents. There is also a degree of competition between 
originator medicines for the same therapeutic use. The information contained in the patent 
application, in return for the protection extended, is published and becomes public 
knowledge. This allows third parties (including competitors) to seek to improve the originally 
patented product and obtain a patent on the improvement.  
 
Patent rights are not designed to fence off the holder from competition. ‘The patent system is 
thus designed to foster innovation, not only by the patent owner, but also by competitors’ 
(EC, 2009, p. 169). Since the 1990s, there has been a trend towards increased protection for 
pharmaceuticals (EGA, 2007) as shown in Figure 22: 
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Figure 22: Increase in Protection for Originator Medicines 
(Reproduced from EGA, 2007) 
 
Pharmaceutical patent holders practise ‘total product ’ or ‘lifecycle maximisation’ strategies 
by seeking to obtain as many patents as possible during the development and marketing cycle 
and extend them for new uses of established products. Prior to the European Patent 
Convention in 1973, applications for patents across Europe had to be separately made in each 
country (Cassar, 2006, p. 79). Patents in the EU can now be obtained either by filing an 
application at each national patent office or a single application at the European Patent Office 
(EPO). The EPO was established in 1977 as an inter-governmental organisation. Although all 
the EU countries are signatories (Malta joined in March 2007), the EPO is independent of the 
European Community. A EC (2009, p. 461) pharmaceutical sector inquiry report notes that 
‘[a]ll stakeholders expressed strong support for the urgent creation of a single Community 
patent and a unified and specialised patent litigation system in Europe’. In 2012, the 
European Council agreed on the unitary patent and the setting up of the European patent 
court, which will complement the work of the EPO in granting and administering patents. 
 
Once the period of protection expires, no authorisation from the original patent holder is 
required for anyone to commercially exploit the invention. In the case of pharmaceuticals, 
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this paves the way for the market entry of generic medicines, which are free (provided that 
they get marketing authorisation) to enter the market with ‘copied’ versions of the original 
drug.  
5.5.1.1 Supplementary Protection Certificates 
 
Towards the end of the 1980s, the European pharmaceutical industry argued that the effective 
protection period for a patented medicine was about ten years, or half of the targeted 
harmonised period for patents (twenty years). The effective patent protection period is 
significantly less due to the time ‘lost’ between the discovery and approval of a new drug 
(Boldrin & Levine, 2007). In 1993, the EU emulated the United States and introduced the 
Supplementary Protection Certificate (SPC) (Council Regulation (EEC) No. 1768/92). The 
SPC extends the patent right for a maximum of five years to compensate for the reduced 
protection period. This results in about fifteen years of market exclusivity for patented 
pharmaceuticals (EFPIA, 2008). The application for an SPC must be lodged in each EU 
Member State within six months of the date on which marketing authorisation is granted. 
This requirement is meant to create legal certainty for potential generic competitors, since it 
allows them to know expiry period for the protection of the medicinal product.  
 
According to Galea and McKenna (2004, p. 63), ‘[t]here are two reasons of overriding 
importance for the recent expansion of the generic pharmaceuticals sector in Malta, namely: 
the inclusion of the Bolar provisions in the country’s patent legislation and the very limited 
number of patents that have been registered to date in Malta’. As a former British colony, 
Malta’s commercial law closely follows the UK model, offering extensive protection to 
patent proprietors. Malta’s intellectual property laws date back to the 1960s, making Malta 
among the earliest of the EU member states in this regard (Galea & McKenna, 2004). The 
failure to locally register medicinal patents was the most important differentiating factor in 
attracting generics producers to Malta. Given the smallness of Malta’s domestic market, 
historically, the ‘well-heeled brand name manufacturers overlooked our islands and did not 
register their innovative medicines (nor New Chemical Entities - NCEs) with our patents 
office’ (Galea & McKenna, 2004, p. 65). Given that patent registration cannot take place 
retroactively (the novelty criterion allows one year from the date of first filing to protect an 
innovation), there exists a significant list of internationally patented medicines, medicinal 
ingredients and production processes, which are not covered by a Malta patent.  
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Warr (2012) explains that, prior to 1994, intellectual property in Malta was mostly about the 
registration of trademarks rather than patents. At the time, Malta was participating in the 
Uruguay Round of negotiations at GATT. The global trade agency in 1995 entered into an 
agreement with WIPO, as part of its drive on TRIPS. Because of these developments, a 
separate unit for intellectual property was set up locally within the Ministry of Trade. At the 
time, Malta was still considered a developing country and was given a five-year derogation to 
implement the obligations arising out of TRIPS and bring in line intellectual property 
legislation and policies. ‘Given that there was no harmonised international patent law, the 
local IP department had been advised to shape the changes in a way which would be most 
beneficial to the local economy. This is when we realised the potential benefits of introducing 
the Bolar exemption, and it was subsequently incorporated in the Patents and Designs Act of 
2002’ (Warr, 2012). As part of these arrangements Malta also introduced the SPC. Malta 
does not have any case law to fully perceive the extent of its Bolar provision. ‘This is 
primarily because there has never been to date a patent trial to fully explore the boundaries 
set out by our provision’ (Cassar, 2006, p. 73).  
 
It is notable that under Article 10(6), only generic marketing authorisation applicants within 
the EU are able to benefit from the exemption, so that the same research conducted solely for 
a marketing authorisation outside the EU would not be covered (Cassar, 2006). The changed 
operating environment in Malta led to an explosion in locally registered patents. The majority 
(85%) of all locally registered patents during 2000–2010 were in pharmaceuticals (table 
below). This growth in the number of registered patents continued until 2007. Malta then 
acceded to the European Patent Convention and Treaty, and it became possible to cover 
Malta by applying with the European Patent Office in Munich (Anchor Corporate Services, 
2012). 
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Table 9: Malta Patent Filings (2000-2011) 
 TOTAL FOREIGN no. 
LOCAL 
no. 
% FOREIGN PHARMA no. % PHARMA 
2000 116 93 23 80 69 59 
2001 133 107 26 80 83 62 
2002 202 180 22 89 109 54 
2003 297 275 22 93 197 66 
2004 471 452 19 96 416 88 
2005 659 648 11 98 641 97 
2006 810 802 8 99 790 98 
2007 178 170 8 96 165 93 
2008 23 17 6 74 18 78 
2009 30 21 9 70 20 67 
2010 19   7     12 37 2 11 
2011 16 4 8 0 0 0 
TOTAL 2,954 2,776 174 94 2,510 85 
(Source of Data: National IP Office of Malta, 2012) 
Warr (2012), the Director General of the Commerce Department and Comptroller of 
Industrial Property, explains that local IP legislation does not permit stockpiling. Stock-piling 
is a practice that generic drug companies undertake, whereby they build up an inventory of 
patented drugs in the six month period leading to the expiration of the patent so that they are 
ready to go to market as soon as the patent expires. However, Galea and McKenna (2004, p. 
65) note ‘the local Patents Act includes an early working clause but not a stockpiling 
provision and is, in other words, in line with the WTO judgment’. Cassar (2004, p. 76) 
concludes that ‘[s]tockpiling is not specifically implanted in Maltese law...if the law does not 
forbid it, then for all intents and purposes it is there’.  
5.5.2 Marketing Authorisation 
 
Marketing authorisation (MA) procedures verify if the medicines are safe, effective and of 
good quality. MAs are issued on the basis of scientific criteria of the medicinal product 
concerned as well as detailed results of clinical tests and clinical trials. ‘MA procedures are 
regulated by EU law, set out in Regulation (EEC) 2309/93 and Directive 2001/83/EC 
(Medicinal Products Directive)’ (Cassar, 2006, p. 20). To obtain an MA, there is a centralised 
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EU application procedure as well as a national one. The centralised procedure (which is also 
available for generics) involves a single application, evaluation and authorisation. Once an 
MA is granted under the centralised procedure, the medicinal product may be put on the 
market in all EU member states. A national application may also be valid in other EU 
member states through mutual recognition arrangements. The MA has an initial duration of 
five years and may be renewed on the basis of a re-evaluation of the risk-benefit balance 
upon application by the holder at least six months before the expiry of the five-year period. 
 
In the case of an MA for a generic product, it is possible for the applicant to file a so-called 
‘abridged’ application, whereby the applicant is exempted from the requirement to prove 
safety and efficacy through preclinical tests and clinical trials. Such abridged applications are 
only permitted once the originator company’s data relating to the pre-clinical tests and 
clinical trials is no longer protected.  
 
5.5.2.1 Data exclusivity  
 
Data exclusivity relates to the regulatory data protection, whereby an innovative 
pharmaceutical company can keep information submitted confidential to obtain marketing 
approval for a medicinal product. Data exclusivity is a separate and additional provision to 
patent protection for the originator medicine. It was introduced in 1987 to compensate for 
insufficient product patent protection in some countries. Data exclusivity implies that MA 
bodies are not allowed to process an abridged application to market a generic drug before a 
certain period of time has elapsed, since the first marketing authorisation for the originator 
product was granted. Data exclusivity rules were harmonised within data exclusivity periods 
ranging from six to ten years (von Uexküll, 2012). The EU data exclusivity period was set at 
eight years (EU Directive 2004/27/EC) and has been effective since 2005. The implication is 
that generics may not be placed on the market until ten years after the original; this provides a 
two-year window during which bioequivalence testing may be carried out. A further one year 
of protection for the originator drug is available if authorisation is obtained for a new 
therapeutic indication that brings significant clinical benefits in comparison with existing 
therapies.  
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This system is commonly referred to as the 8 + 2 (+ 1) formula (Figure 23). Prior to its EU 
membership, Malta’s legislation provided for a six-year data exclusivity period. In its 
membership negotiations, Malta requested a fifteen-year derogation, but this was not granted. 
Malta adopted the EU exclusivity formula with effect from 2006. 
 
 
Figure 23: EU’s Data and Marketing Exclusivity Formula 
(Reproduced from European Commission, 2009) 
 
‘EU accession brought with it what has been called a cumbersome bureaucratic registration 
process’ (Bugeja, 2008, p. 5). Until 2002, Malta had 7020 products placed on the market and 
it was sufficient for an importer to present a CPP issued by the WHO. The EU does not 
recognise the CPP and stipulates that all medicines sold domestically must have a local 
marketing authorisation. Malta obtained a derogation (up to 2006) whereby medicines could 
be sold through a provisional marketing authorisation issued by the Medicines Authority. 
However, from 2005, the decentralised procedure (the recognition by national authorities of 
an assessment performed by another EU member state for medicinal products which have not 
received a marketing authorisation at the time of application) could also be used to boost the 
range of medicines locally available (Bugeja, 2008). 
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Following EU membership, the number of drugs on the Maltese market fell to 1,500 by 2007. 
In 2006, both Cyprus and Malta put pressure on the EU to amend Directive 2004/27 (which 
governs the decentralised procedure) to allow public healthcare goods authorised in another 
EU state to be sold on their markets, also known as the ‘Cyprus Provision’ (Vella Bonnano, 
2012). Table 10 presents the number of marketing authorisations for medicinal products 
locally issued from 2004 to 2007.  
 
Table 10: Authorisations issued for Medicinal Products in Malta (2004-2007) 
(Reproduced from Bugeja, 2008) 
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Galea and Mckenna (2004, p. 67) point out that ‘[m]arketing authorisation granted by any EU 
member state serves to ensure ease of penetration into South American and North African 
markets’. To verify that the pharmaceutical products meet EU standards, many non-European 
countries (including Malta’s neighbours in North Africa) requested a free sales certificate. 
This certificate was issued by the local Medicines Authority as well. ‘Such a certificate 
usually suffices in having a medicine sold in these countries’ (Galea, 2012). A business 
opportunity arising from Malta’s EU membership relates to the issuing of marketing 
authorisations for English-speaking countries by the local Medicines Authority (Galea, 2012). 
Given that the Medicines Authority enjoys mutual recognition with most EU countries and 
handles relatively few applications, a dossier can be registered in Malta rather than in the 
United Kingdom or the Netherlands perhaps. In these countries, registration can be a 
relatively lengthy process due to the amount of applications handled.  
 
5.5.3 Pricing and Reimbursements 
 
Price controls are the most prevalent form of regulatory intervention on the global 
pharmaceutical market (Ballance et al., 1992). The cost of patented medicines is a problem 
for not only governments but also the general public, especially in Third World countries. 
The demand side of the pharmaceutical sector is unique, as it is characterised by a complex 
interrelationship between patients, doctors, hospitals, insurance providers and reimbursement 
systems. Although patients are the ultimate consumers of medicine, they often rely on a 
doctor’s expertise and recommendations. The average annual EU spending on pharmaceutical 
products is €430 per capita, but ‘there exist significant differences between and within 
countries’ (EC, 2009, p. 46). 
 
Each EU member state follows different policies and schemes, adapted to its own economic 
and health needs. A number of member states apply policies supporting the sale of generic 
medicines by obliging pharmacists to dispense the cheapest product (EC, 2009). The norm, 
however, is for pharmacists to dispense medicines prescribed by the doctor, and they have 
little say in the medicine given to the patient. Because of these factors, and the fact that a 
large proportion of prescription medicines are provided under public healthcare or insurance 
schemes, the price sensitivity of medicines is rather limited (EC, 2009). While ‘policymakers 
are generally sympathetic to the industry’s arguments that increases in prices and profits are 
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essential if research to develop cures for major diseases is to continue’ (Boldrin & Levine, 
2007, p. 139), governments are under pressure to contain their expenditure on health.  
 
Once the protection period is over, ‘generic’ drugs enter the market and the price of a 
‘prescription’ drug significantly falls. Generic medicines are cheaper because they have a 
lower cost-base arising from lower investments in product development. Generics help cut 
the costs of public healthcare, and their growing popularity has generated increased 
competition and lower prices (Hirschler, 2005; Gambardella et al., 2000; EC, 2009). In 
OECD countries, spending on pharmaceuticals has been increasing faster than total 
healthcare spending, with pharmaceutical spending in 2006 accounting for 17% of the health 
budget in the OECD. Generics have come to play a key role in ensuring the affordability and 
sustainability of healthcare systems throughout Europe (EGA, 2007, p. 2). Many 
governments resort to some sort of reference pricing for medicines. EGA (2007) claims that 
reference pricing creates artificial and inappropriate prices for medicines, leading to 
inefficiencies in the supply chain. Linking the price of generic medicines to a constant 
percentage of the originator product (e.g. 25–50% lower than the originator) is deemed as 
being anti-competitive and endangers the security of supply of generics. ‘Such linkage 
enables originators to force generic medicines competitors off the market by constantly 
lowering prices to the point where generic medicines (forced to sell at a fixed percentage 
below the originator) can no longer afford to enter onto-or to stay on-the market’ (EGA, 
2007, p. 6). 
 
The EC (2009, p. 40) sector enquiry finds ‘[t]he ultimate price level of generic products 
depends on many factors including among others the degree of competition’. Average ex-
factory prices of generics are lower in Europe than in the United States (EGA, 2007). Figure 
24 shows that during 2005–2007, the EU ex-factory price index was on average 15% below 
the US benchmark. 
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Figure 24: EU–US Price Comparison of Generics 
(Reproduced from EU Commission, 2009) 
 
The impact of EU accession on the prices of medicines in Malta has been quite strong, with 
many of them increasing ‘drastically as mark-ups for the wholesale dealer and pharmacists 
were no longer regulated’ (Bugeja, 2008, p. 37). On paper, the EU membership should have 
facilitated parallel trading and increased competition. Local consumers did not enjoy lower 
prices from such activities, since generally speaking, any resulting benefits were kept by 
importers and/or pharmacists (retailers). Wholesale dealers play a dominant role in the 
Maltese market, and whenever they feel threatened by parallel imports, they stop delivery of 
other ‘key’ drugs in their product portfolio. A number of wholesale dealers also own 
pharmacies, and this enforces their hold on the local market. In 2007, the government set up a 
Medicines Committee to verify the market prices of medicinal products (Farrugia & Savvas, 
2009). Reference pricing was introduced, whereby local medicinal prices are compared to the 
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average price prevailing in a basket of countries made up of three categories: high, medium 
and low priced.  
 
The medical profession in Malta is not required by law to prescribe drugs by their 
international non-proprietary name (INN). Nevertheless, pharmacists can legally offer 
generic alternatives to the medicines prescribed, ‘unless the doctor specifically indicates on 
the prescription that no substitution is allowed’ (Azzopardi & Zarb Adami 2012, p. 4). 
Farrugia and Savvas (2009, p. 34) argue that low generic prices compared to those of 
originator medicines are unlikely to be sustainable in a small island state such as Malta, 
unless the market penetration is appreciable: ‘this can only be achieved through strong 
generic promotion and a campaign to engender positive public/prescriber opinions of 
generics’. 
Company Name Product Employees 
Actavis Ltd. Generics 559 
Arrow Pharm Malta Ltd. Generics 298 
Amino Chemicals Ltd. Active Pharma Ingredients 53 
Siegfried Generics Malta Ltd. Generics 53 
Combino Pharm Ltd. Generics 41 
Medichem Malta Ltd. Active Pharma Ingredients 30 
APL Swift Services(Aurobindo) Generics 17 
Starpharma Ltd. Generics 12 
Institute of Cellular Pharmacology  R&D and plant extracts  11 
Solea Pharma Ltd. Active Pharma Ingredients 10 
Pharmadox Healthcare Ltd. Generics (Repackaging) 10 
Pharmacare Premium Ltd. Generics 9 
Alpha Farma Ltd. Generics (Repackaging) 7 
 
Table 11: Enterprises in the Maltese Pharmaceutical Sector (Manufacturing) 
(Source: Malta Enterprise, 2012) 
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Table 11 lists all the manufacturing enterprises operating in the Maltese pharmaceutical 
sector. After a period of significant growth upon Malta’s EU membership, the number of 
these manufacturers has not increased. There are also two producers of medical gases and 
two manufacturers of active pharmaceutical ingredients (APIs) which are GMP licensed. 
(Since 2013, API producers are obliged to be GMP certified).  
 
Chart 4 below shows expenditure on R&D by the local pharmaceutical sector.  
 
(Source: National Statistics Office, Malta) 
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Chart 5 relates R&D expenditure to output for 2005–2010. 
 
 
(Source: National Statistics Office, Malta) 
 
The data show that while the level of R&D in the pharmaceutical sector has been significant 
(especially when compared to other sectors of the Maltese economy), the amounts being 
invested relative to output are on the decline. Moreover, in 2013, Actavis gave notice that 
because of the Group’s global restructuring, it would be closing its R&D unit. This is 
expected to further reduce the amount of R&D in Malta. 
 
As BEAT Consulting notes with regard to local manufacturing operations, pharmaceutical 
enterprises also suffer from the same deficiencies of subsidiaries depending on their overseas 
parent company. These enterprises are essentially ‘production units’ and for them, 
operational effectiveness and cost control are critical considerations. This, despite the fact 
that a small number of local pharmaceutical operators have set up sales units responsible for 
African, Middle Eastern and other markets. The width and depth of the local sector is quite 
limited, especially when compared to other European pharmaceutical centres. Mackay (2011, 
0
1
2
3
4
5
6
2005 2006 2007 2008 2009 2010
Pe
rc
en
ta
ge
 
Year 
Chart 5: R&D/Output in Pharmaceutical Industry,  
2005-2010 (%) 
 136 
 
p. 68) points out that ‘[t]he predominant problem encountered by the local generic drug 
manufacturers relates to the unavailability of third party storage facilities for storing 
pharmaceutical waste until this is exported’. Waste resulting from the processing of active 
pharmaceutical ingredients (APIs) has to be exported and is sent to Switzerland to be treated. 
This is rather expensive, especially since the route across Italy has to be monitored by 
satellite. Galea (2012) points out that the provision of good quality water has been a primary 
problem for the industry in Malta. 
 
Figure 25 shows the present composition of the pharmaceutical sector in Malta:
 137 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Composition of the Pharmaceutical Industry in Malta 
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5.6 Sector Performance 
 
The data presented below was obtained from the NSO, because no sector studies or published 
data specific to the Maltese pharmaceutical sector are available. The sector’s output during 
2000–2011 is shown in Chart 6. There is a steady increase in turnover up to 2008, when 
output peaked at €216.6 m. This represents an increase of 423% over an eight-year period. In 
2009, we see a significant dip and since then, the industry has not fully recovered.  
 
–
 
(Source: National Statistics Office, Malta) 
 
In terms of gross value added (Chart 7), there was a similar steady increase in the 2004–2008 
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€112,002 (2008) represents a remarkable improvement. Subsequently, gross value added also 
fell to €65,859 (2011). This is partly because of a shift from manufacturing towards partial-
manufacturing and repackaging operations.  
 
–
 
(Source: National Statistics Office, Malta) 
 
Pharmaceuticals are not a labour-intensive industry. This is evident in Chart 8, which shows 
that while turnover almost quadrupled between 2000 and 2011, the number of employees 
increased from 724 to just 1019.  
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Source: National Statistics Office (Malta) 
 
Combining charts 7 and 8, we get the gross value added per employee (Chart 9) for the local 
pharmaceutical industry. Once again, 2008 is the peak year with gross value per employee 
reaching a high of €135,105. This was a significant improvement compared to where the 
industry stood in 2000, when the relative figure was just €8,718. Nevertheless, by 2011, gross 
value per employee had fallen to €58,864, that is, 56% less compared to 2008. 
 
0
200
400
600
800
1000
1200
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
N
um
be
r o
f E
m
pl
oy
ee
s 
Year 
Chart 8: Full-time Equivalent Employment by Pharmaceutical Enterprises, 2000-2011 
 141 
 
 
(Source: National Statistics Office, Malta) 
 
Chart 10 shows exports by the local pharmaceutical industry for 2000–2011. In this instance, 
it appears that there is steady growth with small declines in 2003, 2009, and 2011. Exports 
peak in 2010 at €212 m, which is an almost tenfold increase over 2000. 
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(Source: National Statistics Office, Malta) 
 
The value of exports per employee (Chart 11) presents a similar picture as in Chart 5, where 
it peaked in 2010 (€209,677 per employee). This represents a 740% increase over 2000. 
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(Source: National Statistics Office, Malta) 
 
 
Chart 12 shows the level of exports compared to output. Interestingly, in 2003, the level of 
exports fell drastically compared to output. This was probably due to stockpiling as the local 
pharmaceutical industry prepared itself for Malta’s entry in the EU from 2004. Exports have 
been consistently less than output, except in the last two years. 
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(Source: National Statistics Office, Malta) 
 
5.7 The Field Research 
 
The field research followed the theoretical framework presented in Figure 14 to evaluate the 
relevance of the identified arch-RCDCs in shaping the competitive advantage of the Maltese 
pharmaceutical industry. Figure 26 illustrates the field findings. 
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Figure 26: Competitive Advantage of the Maltese Pharmaceutical Industry 
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The field research finds that, except for one company (ICP), all other local pharmaceutical 
enterprises produce generics. Nine of these companies are subsidiaries of international 
companies, while four others (including ICP) are Maltese owned. The ‘indigenous’ 
companies have close working relationships, or some form of strategic alliance, with foreign-
owned firms either operating in Malta or overseas. While opening doors to a huge single 
market, EU membership brings with it additional operating costs for local pharmaceutical 
enterprises. These costs arise mainly from legal obligations related to the environment 
(especially waste management) as well as health and safety. Mangion (Medichem) notes that 
‘[E]U membership brings with it additional obligations and costs, especially with regards to 
the protection of the environment’. These costs tend to have a bigger impact on smaller 
enterprises.  
 
Although practically every local pharmaceutical enterprise seems to have its own particular 
operating rationale, local enterprises can be grouped in the following categories: 
 
1. API production 
Malta lacks any chemical synthesis or fermentation process. Most generic APIs are sourced 
in Asia in semi-finished form and are then ‘polished’ in Malta and re-exported. Exports are 
normally intended for both ‘regulated’ markets (such as the Unite States, Canada and Japan) 
as well as non-regulated ones (such as Latin America and Africa).  
 
2. Solid dosage forms 
Generally, these are produced from generic APIs imported either from the EU or Asia. These 
forms (normally tablets) are exported either in bulk or packaged, using own brands and those 
of third parties (under some form of contracting arrangements). These third parties are mostly 
generics companies, but at times, consist of originator firms. 
 
3. Packaging operations 
Generics are imported in bulk from Asia to be packaged in primary and/or secondary 
packaging. These drugs are analytically tested before a batch is released. A marketing 
authorisation has to be obtained before these medicines are exported whether to the EU or 
non-EU markets. The importation of generics is at most times conducted on a ‘parallel trade’ 
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basis (mostly from former East European countries) with bulk or primary packaged 
medicines being repacked into ‘customised’ secondary packaging, using own or third party 
brands. This last type of operation tends to cater to expensive, high-end drugs intended for 
North African and the Middle Eastern markets. 
 
4. Institute of Cellular Pharmacology Ltd. 
ICP is a story of its own. The company produces vegetal extracts for human and animal use 
on an industrial scale for pharmaceutical and related industries. It conducts its own R&D and 
applies for patents on a regular basis (at least one every four months). ICP is the only R&D-
based pharmaceutical operation in Malta. (R&D activities of most other local operators focus 
more on quality assurance rather than molecule or process development). 
 
The next section outlines the main findings of the field research in the light of the illustrative 
list of questions asked during the interviews with top management of local pharmaceutical 
enterprises. 
 
Question one: impact of EU membership on the Maltese pharmaceutical industry.  
 
Interviewees generally agree that EU membership deeply impacts the local pharmaceutical 
industry in a number of ways. Saliba (ICP) states that ‘[E]U membership has a broad and 
deep impact on Maltese society and economy. Membership created extensive ripple effects; 
just like throwing a big stone in a bath’. Mangion (Medichem) argues that ‘[w]hile it is true 
that EU membership facilitates the growth of the local pharmaceutical industry, the 
experience of countries such as Iceland and Switzerland shows that the industry could have 
thrived even if Malta stayed out of the EU’.  Allegrucci (Combino) agrees and points out that 
‘[M]alta’s potential as a launching base for pharmaceutical would have been discovered in 
any case. EU membership merely facilitates this discovery’. This is possibly true, but most 
interviewees agree that EU is a certificate of consistency, reliability and quality for suppliers, 
distributors and consumers and it is not easy for a small country like Malta to build such a 
reputation. Mangion (Medichem) adds that ‘EU membership ‘per se’ is not so important, 
what really makes a difference for Maltese companies is patent law’. Saliba (ICP) opines that 
‘[s]tandards are driven by customers not by EU or other regulators’. The key features of the 
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impact of EU membership on the local pharmaceutical industry resulting from  the 
interviewees are that membership, 
 
a. Offers unhindered access to a huge (more than five hundred million persons), affluent 
market. The single market enables Maltese producers to operate as inside-players and 
technically  they compete on a level playing field with producers from other EU member 
states 
b. Facilitates access to third markets. ‘The EU pharmaceutical industry has a first class 
reputation all over the world. The fact that  Maltese producers form an integral part of the 
European industry opens doors in the rest of the world’ (Debono, Alpha) 
c. Brings price stability as Malta is also a member of the Eurozone. ‘Price stability is 
important as it helps us improve our financial planning. Being part of the Eurozone 
eliminates a lot of fluctuations in the exchange rate market’ (Vella, Actavis) 
d. Attracts foreign direct investment into the local pharmaceutical industry as evidenced by 
the increase in the number of local operators since Malta joined the EU in 2004 
e. Facilitates the sourcing of expertise and skilled personnel from other EU countries, ‘We 
are able to attract manpower from other member states, such as Spain and Italy, whose 
economies are not performing so well, as workers have the comfort of remaining within 
the single market’. 
 
Question two: impact of EU membership on the local operating environment for 
pharmaceutical enterprises.  
 
Debono (Alpha) opines that ‘[m]embership led to a qualitative leap in the operating 
environment. The GMP is generally better regarded than the FDA’. Mangion (Medichem) 
agrees and adds that ‘GMP is very well respected all over the world; the only exception 
possibly being the USA. Even Canada has a higher regard for the GMP than the FDA’. 
Obtaining GMP certification is not subject to EU membership but it is impossible to operate 
within the EU without GMP. (For example, ICP was already GMP certified prior to  Malta 
joining the EU). Allegrucci (Combino) points out that ‘EU membership imparts a sense of 
assurance among foreign buyers…..the operating environment and resulting exports from 
Malta are of the highest standard’. Schembri (Aurobindo) remarks that ‘[t]he EU stands for 
high standards and a high level of regulatory compliance. Member states often offer mutual 
recognition and this is very important for producers of pharmaceuticals’. Saliba (ICP) 
proposes a different perspective, noting that the biggest impact of EU membership is on 
Malta’s tertiary sector, ‘[t]here existed a big gap in subjects relevant to the pharmaceutical 
industry, between the local university and those in the UK. This gap has now been practically 
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closed’. On the domestic market, according to Debono (Alpha) EU membership led to 
‘[g]reater choice, increased competition and lower prices’ and that ‘[c]hanging over to the EU 
proved to be a cumbersome process for local importers many of which represented Swiss 
producers’. He adds that although Swiss pharmaceuticals did not need re-testing or re-
analysis, they still required batch release.  Initially, the number of  pharmaceutical products 
on the domestic market declined from some 7,000 to 1,700 medicines (Table 10) but 
eventually they started to rise again due to the ‘Cyprus provision’ (products having a 
marketing authorisation by an EU member state were allowed to be sold on the local market) 
and the setting up of EPO. 
 
Question three: impact of EU membership on Maltese pharmaceutical firms.  
 
This question ties with the previous two questions as the impact of EU membership on local 
firms cannot be separated from the impact on the industry as well as its operating 
environment. Vella (Actavis) explains that his company ‘[c]ame to Malta for a number of 
reasons. At the time Iceland was already facing a shortage of skills and a steep increase in 
costs. Probably, the company would not have acquired Delta had it not been convinced about 
Malta’s commitment to join the Community. Actavis needed a production base within the 
EU’. Galea Kenely (Starpharma) states that ‘[o]ur company was set up in 2002 specifically to 
tap the opportunities arising from EU membership’.  In a similar vein, Giromini (Siegfried) 
notes that ‘Siegfried came to Malta in 2004 due to the country’s membership in the EU and 
the fact that the country is considered to be ‘patent free’. Since then we have invested a lot in 
state of the art equipment which very few companies, even in the EU itself, can match.’ 
 
Mangion (Medichem) points out that ‘EU membership for our company is not critical as we 
do not sell to EU countries. In my opinion, what is vital for us is international patent law’. He 
adds that EU membership brings with it a lot of obligations and additional costs, with EU 
legislation often being ‘myopic’.  He complains that the EU is too bureaucratic and the costs 
related to environmental protection are ‘prohibitive’. Saliba (ICP) once again offers a 
different perspective explaining that ‘[i]n our industry an enterprise’s operating standards  are 
set by our customers and not by the EU. Customers carry out operational audits on a regular 
basis and GMP or FDA compared to these audits are child play.’ Farrugia (Chamber of 
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Commerce) notes that ‘[t]he impact of EU membership is probably greater on local 
authorities than on operations of the companies themselves’. 
 
Seychell (Pharmadox) notes another advantage that Malta obtained whereby no VAT is 
charged on imported pharmaceuticals, This derogation was negotiated with the EU and is on 
an indefinite basis. This concession ‘implies that local manufacturers do not have to pay VAT 
on the import of materials. For a small enterprise like ours this is important because it eases 
the pressure on our cash flow.’ Seychell (Pharmadox) continues that ‘[i]t is equally important 
that Malta has zero-duty on the importation of active ingredients and other materials provided 
the final products are re-exported to markets outside the EU’. 
 
Question four:  primary challenges currently facing the industry compared to those faced 
upon membership? 
 
In 2004, local industry was generally confident that it would be able to meet the stringent 
operating standards set by the EU. What pre-occupied Maltese pharmaceutical companies 
was the potential competition from former ex-Soviet countries which were joining the EU at 
the same time as Malta. There was also some concern about the lack of technical know-how 
and expertise. At the time, the pharmaceutical industry in Malta was growing very fast and 
‘[t]his was putting a lot of pressure on the availability of personnel, such as qualified persons 
and quality analysts’ (Vella, Actavis).  Saliba (ICP) points out that ‘[a]t the time, companies 
like Actavis, were engaging graduates to do the work of technicians’. The industry was also 
unhappy with the existing physical and institutional infrastructure.  Schembri (Aurobindo) 
states that service providers were not geared for the specific needs of the pharmaceutical 
industry, ‘[i]t was hard for construction companies to abide by the high standards demanded 
by the industry’. 
 
Ten years later, the concern with competition from East European operators remains. ‘Really 
we do not compete directly with Asia. Our competition comes mostly from East Europe, now 
including also Croatia and Serbia’ (Vella, Actavis). Through various measures have been 
taken to increase the local supply of personnel at all levels of the industry, the availability of 
human resources remains a problem. Vella (Actavis) speaks about ‘[a] dichotomy between 
Malta’s industrial strategy and its education system’. Both Saliba (ICP) and Allegrucci 
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(Combino) opine that people are one of the unique selling points (USPs) of the 
pharmaceutical industry in Malta. Allegrucci (Combino) remarks that ‘[s]ecuring the right 
personnel, whether operators, technicians or graduates remains a problem. Luckily, the EU 
serves as a safety valve and presently we are sourcing a lot of manpower from Spain. But this 
tends to raise the cost of labour’.  Vella (Actavis) complains about rising labour costs and 
claims that this is undermining the competitiveness of the industry.  Allegrucci (Combino) 
does not agree, noting that ‘[t]he share of labour costs in total costs in our industry is 
minimal’. Schembri (Aurobindo) points out that ‘Maltese workers are not well prepared for 
the pharmaceutical industry.  Government needs to take a more holistic approach to the 
manpower needs of industry’.  Martin (Crystal) criticises the turnover among operators 
noting that ‘[l]ocal employees are often ready to change jobs even for a marginal increase in 
wages’. Another issue raised by Vella (Actavis) relates to the brain drain. He states that more 
Maltese employees, after gaining experience in the industry, are migrating to other countries, 
‘[i]n Europe as well as far away countries such as Australia’.  
 
Local service providers catering for the industry have risen to the occasion,  ‘[t]ransport 
providers in particular have come a long way. They now operate internationally, playing a 
regional role’(Schembri, Aurobindo).  The physical infrastructure supporting the 
pharmaceutical industry is still far from satisfactory. ‘The airport lacks the necessary 
facilities to handle pharmaceuticals’ (Schembri, Aurobindo). There are also problems in 
disposing with toxic materials (which are transported all the way to Switzerland) as well as 
with the quality of municipal water.  
 
Most interviewees praise the efficiency of the Medicines Authority whose contribution they 
deem critical for the development of the pharmaceutical industry. Schembri (Aurobindo) 
opines that the ‘[t]he Medicines Authority is well respected as it has an excellent track 
record’. Debono (Alpha) states that ‘The level of expertise about our industry in the public 
sector is poor, except for the Medicines Authority’.  Vella (Actavis) agrees that there exists 
limited knowledge about pharmaceuticals in the public sector and so does Farrugia (Chamber 
of Commerce) who states that ‘[t]he poor level of knowledge in the public sector is evident in 
the way that medicines are procured by the government’. 
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Schembri (Aurobindo) points out that ‘[M]E can do a lot more but unfortunately it lacks the 
necessary technical knowledge’. Seychell (Pharmadox) finds that ‘ME has two standards in 
granting assistance one for local players and one for foreign ones’. Allegrucci (Combino)  
does not agree as in his opinion ‘ME does a very good job. It has been instrumental in getting 
our company to come to Malta’. Galea Kenely (Starpharma) complains that ‘[d]ifferent 
institutions have different standards and these vary significantly’. She speaks of ‘regulation 
overkill’ pointing to the policies relating to the construction industry (Malta Environment and 
Planning Authority), waste management (Wasteserv) and health and safety (Occupational 
Health and Safety Authority). Giromini (Siegfried) laments that with regards to waste 
management, ‘MEPA and other institutions continue to churn out studies, but no concrete 
action is taken’. 
 
Another important challenge which the pharmaceutical industry in Malta is currently facing 
relates to patent law itself.  A growing number of foreign patent-holders attempt to register 
them in Malta retrospectively.  Given that the country lacks the necessary expertise to 
professionally assess such requests, they often manage to register them. Local companies are 
then obliged to appeal these patents. This in itself is a pretty straight forward task as the 
necessary evidence is relatively easily available from overseas, but it costs money and is 
time-consuming. The local pharmaceutical industry is lobbing for changes in Maltese patent 
law and requesting the setting up of a patents tribunal. 
 
Question five: to what extent are local pharmaceutical enterprises dependent on costs for their 
competitiveness? 
 
There is general agreement among pharmaceutical companies operating  in Malta that they 
compete primarily on costs. Vella (Actavis) explains that ‘[g]enerics are very price sensitive 
and cost-control is critical for the success of our industry’. He explains that in Malta, 
pharmaceutical companies have high overheads and fixed costs relative to the volumes 
produced, ‘[t]his is why we tend to specialise in short-runs that carry a premium price’. 
Martin (Crystal) states that ‘[o]ur operation in Malta is fully dependent on minimising costs. 
But the costs here in Malta are lower than those of our parent company in Spain’. Allegrucci 
(Combino) remarks that ‘[a]lthough production costs in Asia are lower than in Malta, so is 
the productivity of their workers. Malta offsets its higher costs through higher productivity, 
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by offering easier access to EU markets, especially in carrying out quality assurance as well 
as in obtaining batch release and marketing authorisation’. Giromini (Siegfried) notes that his 
company’s operating costs in Malta are practically at par to those in India. He attributes this 
to ‘[t]he investment made in state-of-the-art equipment, strict process control and the quality 
of our human resources’. As will be explained in question seven, there are a few local 
pharmaceutical operators who are able to influence the price they fetch for their products, so 
that while cost-control is important for them, it is not the only element underpinning their 
competitiveness. 
 
Question six: what can be done to increase the value-added of local pharmaceutical firms? 
 
Given the production-orientation of most local pharmaceutical companies, it is to be expected 
that a good number of them emphasise the role of technology in raising value added. A 
higher value added is closely associated with increased output at the same, or lower, costs. 
Seychell (Pharmadox) points out that to improve value added ‘[w]e need to keep up with 
changes in the market by consistently updating and upgrading our technology’. Vella 
(Actavis) states that ‘[t]o increase the value added of our Malta operation we depend on the 
technology given to us by the parent company and moving towards the higher end of the 
product spectrum’. The need to go for speciality medicines is emphasised also by Mangion 
(Medichem) who notes that ‘[t]he solution is to go for speciality medicines targeting ‘niche’ 
market opportunities, such as using heroin and opiates for medicinal purposes. We need to 
have short-runs, be flexible and be able to respond quickly to customer requests’. Schembri 
(Pharadox) explains that ‘[s]hort runs and niche products enable us to charge a premium 
price’. 
 
Other interviewees emphasise the importance of staying close to customers. Debono (Alpha) 
opines ‘[w]e can enhance our value added by improving our disposition to accommodate 
clients and be flexible’. He adds that this can be achieved through just-in-time delivery and 
being ready to deliver small consignments, thereby minimising the money tied in stocks by 
clients.  Galea Kenely (Starpharma) opines that ‘[o]ur company has to stay in touch with 
clients so as to ‘foresee problems’ and be able to offer timely support’. She adds that 
Starpharma has to offer a ‘[c]ustomised service which is complete and based on patent 
specialisation’. Seychell (Pharmadox) agrees with this saying that ‘[w]e have to become a 
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one-stop shop and be able to offer a complete service to customers exploiting the patent-free 
status of Malta as long as it lasts’. 
 
Question seven: the extent to which Maltese pharmaceutical enterprises are price setters.  
 
Vella (Actavis) states that ‘[w]e absolutely have no control over the prices we charge. That is 
entirely in the hands of the parent company’. Allegrucci (Combino) and  Giromini (Siegfried)  
agree, with the latter pointing out ‘[T]he Malta operation is just a cost-centre. All pricing 
decisions are taken by our Head Office in Switzerland’. Debono (Alpha) remarks that 
‘[g]iven the competition we have, it is practically impossible to charge premium prices’. For 
local operators serving as a mere production base cost-control is critical as they are not in a 
position to fetch higher prices (except by going for niche products requiring shorter runs and 
fast delivery). Local operators that specialise in ‘patent launches’ have more room where to 
manoeuvre and seem to have enough market power to influence the prices they charge. 
Mangion (Medichem) notes that ‘[w]e operate in a patent-free zone and if a contractor wants 
to use our services and expertise, he has to pay for it’. This is shared by Schembri 
(Aurobindo) who states ‘[o]ur company does exploit its advantageous position arising from 
the country’s patent-free status and it does have a degree of leverage on the prices it charges’. 
Seychell (Pharmadox) explains that in the case of launching a new generic ‘[t]ime is of 
essence. We stock-pile the product and then ship out as fast as we can, sometimes even using 
chartered flights, to ensure fast pipeline filling. We have developed a specialisation in such 
launches and get paid well for it’. Saliba of ICP, the only operator in Malta not producing 
generics says that his company ‘[c]harges a significant mark-up. This is the advantage of 
doing our own research.  Research is expensive but rewarding’.  
 
Question eight: the influence of Maltese companies on EU policy-making. 
 
The view of the pharmaceutical industry in Malta is that, with the exception of Actavis, it has 
practically no say on what gets decided in the EU.  ‘Actavis is one of the largest producers of 
generics in the world and it is well-represented in Brussels. In a way Actavis serves as the 
voice of the local generics industry within the EU’ (Galea Kenely, Starpharma).  Local 
operators generally perceive the EGA as being effective in its lobbying.  Saliba (ICP) points 
out that ‘Maltese operators have no say in EU policymaking, and as far as I am concerned 
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even the EFPIA is ineffective’. Giromini (Siegfried) opines that in any case ‘EU 
policymakers are far removed from the real needs of the pharmaceutical industry’. 
 
Question nine: do local pharmaceutical firms collaborate and network? 
 
Giromini (Siegfried) replies that ‘[M]altese pharmaceutical operators operate in silos. We are 
more interested in networking with foreign companies than among ourselves. We do not 
seem to trust each other. We have not even been able to procure a joint electricity backup 
system’. Vella (Actavis) notes that ‘[t]here is an element of collaboration, especially within 
the Chamber of Commerce; but this is mostly a lobby group’. He adds ‘our umbilical cord is 
with our parent company. We make sure to attend for all the important networking events 
such as the World Drug Manufacturing Summit’. Seychell (Pharmadox) finds that 
collaboration within the Chamber of Commerce is weak as most members are importers and 
wholesalers of pharmaceuticals and not manufacturers.  The Chamber has three sections 
representing pharmaceuticals: manufacturers, pharmacists and healthcare (mostly 
wholesalers). Seychell adds that his company has a close working relationship with 
Aurobindo. Allegrucci (Combino)  points out that his company has a close working 
relationship with Siegfried. Saliba (ICP) opines ‘Malta has a very small community and here 
people get to know each other at university, in the village and so on. In cases of need we do 
support each other. There is more collaboration taking place than meets the eye’. Maltese 
operators ‘are not really competing among themselves. They only compete in securing the 
right human resources given that the supply is limited’. Martin (Crystal) while admitting that 
there is little collaboration with other operators notes that ‘[w]e work very closely with local 
suppliers, especially those supplying equipment and materials’.  
 
Question ten: the major assets/competencies of local enterprises. 
 
The pharmaceutical industry in Malta considers its employees as one of its major assets. 
Schembri (Combino) praises the work ethic of the Maltese, especially their productivity and 
flexibility. He explains that his company has manufacturing plants  in such diverse places as 
France and India, and points out that ‘[p]ractically 80% of the problems we face in our 
overseas plants arise out of poor communications. In Malta our employees  have a good 
command of English as they tend to be multi-lingual and are well-disposed to work with 
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foreigners’. Workers are praised for their willingness to learn and good communication skills. 
These employee’ traits can be considered as part of  a ‘bundle of competencies’ which are 
exploited  to cater for the specific needs of the pharmaceutical industry. Galea (Malta 
Enterprise) explains that a good number of employees working in the pharmaceutical industry 
where previously engaged in other manufacturing sectors, such as clothing and electronics. 
‘They were given specific training by ETC so that they would be able to work in the 
pharmaceutical industry’. Giromini (Siegfried) makes a distinction between flexibility and 
adaptability of local workers, ‘[f]lexibility is a mechanical process, whereas adaptability 
results from a disposition to meet customer needs’. Another feature which is emphasised by 
Zammit (Actavis) is what he refers to as ‘managing complexity’. This ‘[e]ntails a capability 
to produce cost-effectively a broad mix of products’. This feature is closely related to the 
concept of flexibility, being able to produce niche products and fast response. Zammit 
(Actavis) explains that ‘[l]ocal production costs are higher than in the other fourteen plants of 
our company across the world which, achieve lower costs due to standardisation; we are 
renowned for our flexibility and adaptability’. It is not unusual for the company’s Malta plant 
to make ten changeovers in a production line within a week. Debono (Alpha) and Galea 
Kenely (Starpharma) both emphasise the importance of their companies staying close to the 
market. The former emphasises the need of ‘[i]mproving our disposition to accommodate 
clients and be flexible’ while the latter stresses that ‘[o]ur company has to stay in touch with 
clients so as to ‘foresee problems’ and be able to offer timely support’.  Both of these 
statements point towards the importance of market sensing (including market orientation).  
 
Question eleven: the future of the pharmaceutical industry in Malta. 
 
Vella (Actavis) states that ‘[t]he consumption of generics is expected to continue to grow 
with the market for pharmaceuticals becoming increasingly competitive’.  He adds that an 
ageing population in Western societies, the increased cost of healthcare and additional 
budgetary constraints of governments are leading to a changed market scenario. The cost of 
new medicines is generally  becoming prohibitive due to increased regulation and this is 
paving the way for generics. As a result a number of originator companies are moving into 
generics generally through acquisitions and vice-versa. Schembri (Aurobindo) notes that 
‘[p]rocurement patterns in the EU are changing very fast. Customers are placing smaller 
orders and expect quick deliveries so as not tie up money in stocks’. Debono points out that 
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‘[a] new cycle is emerging in the pharmaceutical industry built around biosimilars and lower 
prices. This is partly being driven by an ageing population’. He adds that South American 
countries like Argentina and Brazil are very strong in biosimilars due to the legacy of a 
significant German community after World War II ‘Malta could become an important 
stepping stone for these countries into the EU’. Giromini (Siegfried) opines that it is 
impossible for the local industry to move into originator products, ‘[i]t is like moving from 
driving a motor cycle to formula one racing’. Saliba (ICP) warns that the Life Sciences 
project is likely to be a ‘white elephant’ and that if Malta is not careful ‘[t]he pharmaceutical 
industry will have the same fate as textiles’. Table 12 presents the key findings from the field 
interviews categorised by topics emerging from the illustrative list of questions (Annex 1)
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Questions Topic Key Findings 
1+2+3 EU membership impact 
on local 
pharmaceuticals 
Significant especially on public institutions. Enhanced 
reputation facilitated access to global markets. 
Attracted FDI, improved price stability and eased 
sourcing of expertise and manpower. Higher operating 
costs.  
4 Challenges for the 
industry 
2004: competition from East Europe, lack of know-
how and skills, support of local service providers 
2014: first two concerns remain. Limited knowledge in 
public sector about the industry (except for Medicines 
Authority). Improved physical infrastructure not 
enough. Satisfactory improvement by service 
providers 
5+7 Competing on costs 
and influence on prices 
Depends on nature of operations. ‘Subcontractors’ 
fully dependent on costs compensating higher fixed 
costs through ‘premium’ products. ‘Patent launchers’ 
who have a degree of market power and ICP enjoy 
good mark-ups. 
6 Improved value added Primarily through technology up-grades and niche 
products for ‘subcontractors’. Offering a complete 
solution to customers for ‘patent launchers’. 
8 Impact on EU policies Practically non-existent except for Actavis 
9 Collaboration and 
Networking 
Negligible relative to potential. Mostly confined to 
joint lobbying efforts. 
10 Assets/Competencies Human resources deemed primary asset: good 
communications, flexible and willing to learn. Ability 
to ‘manage complexity’ and a customer focus 
11 Future of industry in 
Malta 
Overall positive especially through a growing global 
market for generics and biosimilars 
  
Table 12: Key findings as per illustrative list of interview questions 
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The next sections present the research findings categorised by the arch-RCDCs as per  
theoretical framework proposed in Figure 14 and as referred to in figure 26 .   
 
5.7.1 Market sensing 
 
The field research shows that, in the case of the pharmaceutical industry in Malta, market 
sensing is of critical importance at the national, industry and enterprise level. The EU 
membership led to an upgrading of the country’s operating environment in terms of policies 
and institutions. The EU’s ‘acquis communitaire’ is among the most sophisticated in the 
world, and the membership enables Malta to consistently upgrade its legislation and 
supporting societal structures relating to the pharmaceutical industry. The transposition of EU 
legislation into Maltese law by itself did not guarantee the transfer of the necessary 
knowledge as well as its proper implementation. As explained above a number of 
interviewees lamented that the local public sector still lacks a proper understanding of the 
industry’s specific needs. Also, although the EU’s ‘acquis communitaire’ is constantly being 
upgraded to reflect developments in the global scenario, these changes do not necessarily 
reflect the specific needs of local operators who deem that they are not in a position to 
influence EU’s policies. Actavis is the only exception.  
 
EU membership has been a critical catalyst in creating the ‘right’ legislative and institutional 
operating environment and has been instrumental in fostering a high reputation which 
enhances the market positioning of local pharmaceutical operators. Membership opens the 
doors to European and global pharmaceutical markets, enabling local pharmaceutical firms to 
benefit from the EU’s extensive network of trade agreements. ME also plays an important 
market-sensing role by monitoring global developments and staying close to the 
pharmaceutical market. This is essential for ME in seeking to convince foreign investors to 
branch their operations to the country. (During the field research, it also emerged that two 
other foreign companies have on-going negotiations with ME to open subsidiaries in Malta). 
ME needs to remain close to developments in the pharmaceutical industry to be in a stronger 
position in securing from the government the financial and other resources necessary to 
service the on-going needs of the industry (including the continued development of the 
infrastructure). ME is completing the construction of a Life Sciences Park, which is expected 
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to help create a new dimension to the activities presently undertaken by the pharmaceutical 
industry in Malta. 
 
The research also shows the importance of the National IP Office at the Commerce 
Department within the Ministry for the Economy, Investment and Small Business. While the 
staff at this office are deemed by the research interviewees as being helpful, they lament that 
it lacks the necessary resources to research patent applications internationally and to assess 
them accordingly. This research has already referred to the request by the local 
pharmaceutical industry to change Maltese patent law and the setting up of a patents tribunal 
so as to enable local operators to challenge pharmaceuticals registered retrospectively. This is 
a delaying  tactic by originator companies to protect their market position and delay its being 
challenged by generics. At the enterprise level, market sensing is generally channelled 
through the overseas parent company. This umbilical cord is critical in keeping the local 
operation in touch with international market developments. Many interviewees confirm that 
although they do attend specialised fairs and visit overseas clients regularly, the actual price 
negotiations are handled directly by the parent company. This is confirmed by Vella 
(Actavis), ‘[w]e absolutely have no control over the prices we charge. That is entirely in the 
hands of the parent company’ and  Giromini (Siegfried), ‘[T]he Malta operation is just a cost-
centre. All pricing decisions are taken by our Head Office in Switzerland’ Few local top 
managers are expected to ‘scan’ the market to identify changing customer needs, except in 
those instances where the local operation also serves as a ‘regional’ sales office.  
 
Nevertheless, a ‘unique’ form of market sensing capability is evolving among other local 
operators who are building a competence in scanning the ‘patent’ world to identify medicines 
whose patent will be expiring in the near future. This type of market sensing leads to the 
identification of market opportunities through a thorough understanding of the ‘lifecycle’ of 
medicinal patents.  
5.7.2 Change Management 
 
Although Malta’s decision to join the EU was a highly controversial and protracted one, once 
the PN was returned to power in the 2003 general elections, the PL accepted the people’s 
verdict on the EU membership as being final. Since then, the local political class has 
practically been united in its commitment to EU membership and this sends a strong message 
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to local society as well as potential foreign investors. This commitment greatly facilitated the 
economic restructuring and transformation processes necessary to secure EU membership. 
The government was the primary driver of the change process triggered by this membership 
and provided the necessary leadership to ensure that restructuring takes place without too 
many hiccups. The opposition took a back seat in fear of being accused of still being anti-EU 
membership. As far as the social partners were concerned, they too accepted the inevitability 
of membership and this conditioned their mind-set and attitudes to change. The 
pharmaceutical industry in Malta pays relatively good wages and salaries and this helped it to 
be accepted and be held in high esteem by local workers. 
 
There has, therefore, been societal consensus to promote and support the pharmaceutical 
industry. Given the government’s positive attitude to the generics industry, the EGA twice 
held major conferences in Malta in 2005 and 2012 . Busuttil, a Maltese member of the 
European Parliament, reiterated the government’s commitment to the generics industry which 
‘[h]as shown a commitment to Malta and to the Maltese workforce and I will reciprocate by 
supporting this industry’s interests in Brussels’ (The Times, 2006). The PN government 
consistently projected the growth of the pharmaceutical industry as reflecting its capability to 
win the trust and confidence of overseas investors and attract to Malta a sophisticated 
manufacturing activity. An aura of high technology and high value-added was built around 
the industry at a time when many lower-end manufacturing enterprises were closing down or 
transferring production to lower cost destinations. Saliba (ICP) notes that ‘[i]n its 
membership negotiations with the EU, the government had to take a key decision: whether to 
opt for an environment that favoured originator companies or generics’. He adds that the 
general public was not made aware of the implications of this decision, and Actavis was 
powerful because it had a large workforce. Consequently, the government simply went along 
with the advice and requirements of Actavis and this created the platform for additional 
generics to set up shop in Malta.  
 
As mentioned earlier on this chapter, the transposition of the EU’s directives helped change 
the operating environment of the local pharmaceutical industry by inducing the setting up of 
new structures such as the Medicines Authority. This institution acts as a supervisor of the 
local pharmaceutical industry and has become an important stakeholder. The Authority is the 
link between the local pharmaceutical industry and sector developments within the EU. ME’s 
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role has already been highlighted, especially with regards to its strategic efforts to attract 
pharmaceutical firms to Malta. Pharmaceuticals are classified as a priority sector within the 
Business Promotion Act which regulates the granting of government assistance to enterprise. 
Another critical role which ME plays is in getting the industry’s stakeholders together to 
identify and address the specific needs of the industry. One example of this has been the work 
done by ME to enhance the factory-building know-how of local contractors. These were 
generally used to building standard factories and needed to upgrade their competencies to be 
better able to build the more sophisticated buildings required by the pharmaceutical industry. 
ME also brokers meetings between the industry and other local authorities, as was the case 
with education. Galea(ME) notes that ‘[M]E’s efforts have been instrumental in sensitising 
the local academic and employment institutions with respect to the opportunities that the 
pharmaceutical industry offers and in encouraging them to launch new courses tailor-made 
for the industry’. Changes were also made in the curriculum of existing courses to adapt them 
to the needs of industry. The transformation process was not always a smooth one and 
challenges did arise. For example, while the chemistry department (which forms part of the 
Faculty of Sciences) whole heartedly welcomed the opportunity to introduce various courses 
to address the specific requirements of the pharmaceutical industry, the pharmacy department 
(which forms part of the Faculty of Medicines) struggled to re-orient itself. It was only 
recently that the pharmacy department introduced two undergraduate degrees, pharmaceutical 
technology and pharmaceutical science, intended for the specific needs of the industry. 
 
The situation was rendered more complex through personality clashes, which in a small 
community tend to be more deeply felt. Generally, there has been no real objection by other 
local business interests or social groups to the development of the pharmaceutical industry in 
the country. The industry is pre-dominantly export oriented and not perceived as a threat. 
Bugeja (2008, p. 35) notes that the impact of regulatory change arising from the EU 
membership ‘[w]as multifaceted, triggering reactions from all the main stakeholders’. The 
primary contention that surfaced arose out of considerations relating to sales on the domestic 
market. Prior to the EU membership, ‘[l]ocal importers and wholesale dealers were 
particularly worried about the impact of parallel trading on their business’ (Vella Bonnano, 
Medicines Authority). These enterprises represent a powerful interest group. Individually, 
they act as exclusive local representatives and distributors of numerous originator drugs and 
established brands and have significant market power arising from their exclusive product 
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portfolio and dominion over the local market. At the time, the wholesale dealers took 
advantage of their position to manipulate and control market prices. A controversy broke out 
over the requirement stipulated by EU regulations that the labels of medicines sold on a 
domestic market have to be in the language of the country. In the case of Malta, this implied 
that all medicines had to be re-labelled to have a label in Maltese. Importers saw this as an 
unnecessary expense and the issue was only solved when the government and the EU 
Commission agreed to allow labelling in English (Malta’s other official language). 
 
‘[T]he EU membership brought with it a breath of fresh air into the local pharmaceutical 
sector and medicines market’ (Vella Bonanno, Medicines Authority). The change brought 
about by the EU membership at the enterprise level affected mostly Actavis as at the time it 
already had a sizeable operation in Malta. The Icelandic top management of the company had 
seen EU membership as a unique opportunity to tap the lucrative EU market and move away 
the Malta operation away from the Third World markets it used to cater for. Internally within 
Actavis itself there was little resistance from the management towards this re-orientation, 
‘[e]ven though some managers were disappointed that the enterprise was losing its semi-
philanthropic orientation by no longer producing cheap medicines for poor countries’ 
(Zammit, Actavis). 
5.7.3 Knowledge Capacity 
 
The Medicines Act (2003) incorporates the directives of the EUs ‘acquis communitaire’. This 
Act includes provisions relating to ‘good manufacturing practice, importation and parallel 
importation, marketing authorisations, packaging and labelling, wholesale distribution, 
reimbursement and selection of medicines, clinical trials, pharmacovigilance and advertising’ 
(Bugeja, 2008, p. 34). The Manufacture of Medicinal Products for Human Use Regulation 
(Art. 458.36) of the Medicines Act stipulates that, to be manufactured in Malta, a medicinal 
product needs to covered by a manufacturing licence (Good Manufacturing Practice-GMP) 
‘even though the medicinal / pharmaceutical is manufactured for export-purposes only’ 
(Cassar, 2006, p. 89). A GMP certification ensures ‘that the production of medicinal products 
is carried out at correct potency levels recommended for use in safe doses or to the correct 
category of patient’ (Zammit, 2010, p. 23). The EU’s GMP certificate assesses both process 
and product. ‘Such activities and certification serve to confirm the quality of the medical 
sector in Malta and re-enforces the image of the country on international markets’ (Galea, 
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Malta Enterprise). Agius (2011) remarks the pharmaceutical industry ‘is a very complex 
industry, so you also can’t just wake up one day and decide that you are going to play an 
important role, it takes years and years’. Gambardella et al. (2000, p. 81) state ‘the 
development of competencies and innovative capabilities is a long, cumulative and difficult 
process that does not respond immediately and smoothly to economic incentives’.  
 
Malta boasts a tradition in pharmacy which goes back at least to the sixteenth century to the 
days of the Knights of St. John. This created a degree of knowledge about pharmaceuticals 
but the industrial production of pharmaceuticals in the country started only in the mid-1970s, 
with the setting up of Pharmamed. Eventually, in the early 1990s, the industry got its first 
(and last) indigenous research-driven company (ICP Ltd.). Pharmamed in its first stage 
operated at the basic level of the industry and obtained most of its know-how and technology 
transfer from its Dutch management. The company not only survived but was transformed 
and grew, proving that Malta had the essential knowledge and competencies to run a generics 
pharmaceutical operation. Grioli (Pharmamed) states that ‘[t]he company at the time did not 
have the knowledge and resources necessary to embark on the production of originator 
drugs’. It is only when Delta brought Pharmamed did the company start on a qualitative 
improvement in its operations, even though it remains focused on generics. Pharmamed, and 
especially Actavis when it took over the company, proved to be the cradle of the generics 
industry in Malta When later on, other pharmaceutical companies set up shop, they found 
sufficient knowledge and a skills base which they could build upon. By the time that Malta 
was on its way to EU membership, the country had a pool of experienced managers and 
engineers (most of whom had been employed in other industries) which was available at 
relatively low costs (the cost of specialised personnel in Malta is even more competitive than 
for less skilled employees).  
 
The inflow of FDI in pharmaceuticals that followed Malta’s EU membership quickened the 
transfer of knowledge and this compensated for any limitations that existed. In particular, 
FDI is instrumental in securing the right technology for the manufacturing and related 
activities (including quality assurance) of generics. Malta gradually built a competitive 
advantage in short-run production and other niches. Zammit (Actavis) points out that ‘[w]e 
had become specialists in packaging operations. Our employees used to liaise with foreign 
manufacturers of machinery so as to improve their equipment’. This shows the capability of 
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the Maltese not only to quickly absorb technology but also to adapt and develop it to serve 
their needs. An important consideration that emerged from the field research is that 
knowledge capacity relates to developments not only within the private sector but also within 
the public sector.  This is essential as it conditions the ability of the public sector to 
efficiently and effectively support the development of the pharmaceutical industry. Indeed, as 
noted earlier in this chapter a significant number of interviewees complain that the local 
public sector lacked the desired depth of knowledge about their industry and this is often 
reflected in the way that public officers react to their requirements. While there is a lot of 
truth in this, it has to be appreciated that absorbing and adopting the entire ‘acquis 
communitaire’ in such a short time is a daunting task for any public sector. The knowledge 
incorporated in such directives needs time to be digested (especially for a small country like 
Malta which has limited resources and had to transpose a hefty acquis meant for the needs of 
much bigger and more advanced societies). The challenge of keeping up with extensive 
legislative adjustments is an on-going one and comes at a cost for a small country seeking 
economic integration with a much bigger economic area. A country like Malta has to 
consistently strive to remain on track, even though a lot of these adjustments are costly and 
may be alien to its specific needs.  
 
Knowledge capacity also includes the capability of service providers to meet the needs and 
standards demanded by the pharmaceutical industry. This research has already noted that 
some interviewees commented on the learning curve of service providers such as suppliers of 
testing equipment and materials, transport and waste collectors and construction companies. 
These service providers have been able to upgrade their operations and presently provide  
satisfactory support to the pharmaceutical industry. Another important consideration 
emerging from the field research is that the absorption capacity tends to be partly conditioned 
by the nature of the strategic development of the industry. The growth of the pharmaceutical 
industry in Malta is more the result of an ‘emergent’ strategy than of a ‘deliberate’ one. An 
important implication of this is that the country’s institutions and structures were not 
prepared to cater for the specific needs of the industry. This is evident from the experience of 
local education and training institutions, which adjusted to the industry’s needs in a reactive 
rather than proactive manner. It was only thanks to the flexibility and initiative shown by the 
chemistry department at the local university, which was quick to react and introduce new 
modules and courses, that the required graduates became locally available. In fact, had this 
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department not acted as fast it did to introduce a post-graduate course leading to certification 
of qualified persons, the industry would have continued to suffer from a shortage of 
personnel who are essential for the running of a pharmaceutical enterprise, because without 
their certification, pharmaceuticals cannot be released from a factory. Additionally, in 2005, 
the government realised that there was a need to incentivise the enrolment of more tertiary 
students into science-based faculties. This induced government to change the stipends system 
in such a way that it favoured the study of science subjects. This had a positive effect and the 
intake of students for chemistry and related subjects significantly increased, thereby 
increasing the supply of manpower to the industry, which at times has to resort to poaching 
so as to secure the right personnel. 
 
The primary change agent in education and training has been Actavis which has consistently 
been insisting on ever-higher standards rather than some strategic exercise. Over the years, 
Actavis has continued to demand better qualified students and this helps to meet the growing 
demand for qualified personnel by the pharmaceutical industry. As noted above, 
pharmaceutical operators who did not find the right personnel locally were obliged to get 
them from overseas, either internally from other branches of their group and/or from other 
EU countries. Despite the measures taken to increase the local supply of personnel at all 
levels of the pharmaceutical industry, the availability of human resources is still a problem as 
evidenced by Allegrucci (Combino) statement, ‘[s]ecuring the right personnel, whether 
operators, technicians or graduates remains a problem’.  
 
The fact that the country’s national laboratory does not even qualify for GMP reflects the 
short-comings that persist in Malta in servicing the growth of the pharmaceutical  industry. 
Vella (Actavis) notes that a new phenomenon related to knowledge capacity is emerging. 
‘Individual development is now outpacing the evolution of local enterprises. This is leading 
to a situation where a number of well-trained employees prefer to pursue their career overseas 
as they realise that the way that the industry is operating in Malta offers limited opportunities 
for career advancement’. This ‘brain-drain’ could eventually limit the further development of 
the industry. 
 
Actavis closing down its R&D unit in Malta as part of the rationalisation process following 
the take-over by Watson does not augur well for the pharmaceutical industry in the country. 
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Actavis had built a significant R&D capacity, which at its peak (2007) engaged 45 
employees. The unit worked on product development up to the dossier stage, with the parent 
company subsequently deciding whether to sell the dossier to another manufacturer or 
develop the product itself. Zammit (Actavis) states that ‘[l]ocal R&D favours local 
manufacturing as there is already a familiarity and know-how of what the product entails’. 
Vella (Actavis) agrees, pointing out that ‘[h]aving our development centre situated so close to 
our manufacturing facility, allows the development centre to interface very closely with the 
manufacturing process. This gives us a unique advantage because when one is developing a 
new product it is also a lot about the manufacturing capability’.  Schembri (Aurobindo) 
remarks that ‘[m]any of these employees who lost their jobs from Actavis are finding it 
difficult to take up alternative employment with other local companies, not only due to the 
salary but also because of the ‘title’ of the jobs being offered such as scientific officer as 
against lab analyst’. The setting up of a Life Sciences Park may help solve this problem. 
Schembri adds that in the meantime, ‘[i]t is important for the local university to introduce 
post-doctoral courses to engage specialised personnel in research activities before they are 
lost to the local pharmaceutical industry’. 
 
The field research uncovered another source of knowledge, which is proving invaluable to the 
specialisation of the local pharmaceutical industry: law. The legal profession has a long track 
record in Malta and this knowledge is being exploited to assess the legal standing of patented 
medicines to determine how imminent their expiry is (and in which markets) to embark on 
the development of their generics equivalent. At the national level, one of the spill overs of 
the EU membership is the increased awareness about the role of R&D in driving innovation, 
which is ‘widely recognised as the main engine of prosperity and the key to higher living 
standards’ (Montfort & Mallia 2007, p. 14). Little innovation has been taking place in Malta 
on the basis of structured programmes (Montfort & Mallia, 2007), and the country does not 
perform well in the Innovation Scoreboard, which benchmarks 34 European countries (BEAT 
Consulting, 2011). Malta’s R&D intensity is far below the EU average (EU Commission, 
2011a) and the country has set a national R&D target of just 0.67% of GDP by 2020, arguing 
that it suffers from structural disadvantages (market size, structure and location, and 
absorption capacity). Malta’s limited R&D is partly a result of its fragmented economic 
activities and the pre-dominance of micro enterprises, which operate in isolation and have 
little links with larger foreign-owned enterprises or among themselves. In the period 2000-
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2011, of a total of 2954 patents filed locally 2510 (85%) were submitted by the 
pharmaceutical industry (Table 9). Of these 2796 (94%) were submitted by foreign 
companies which indicates that in most cases these patents did not arise from local research 
but were merely being registered in Malta. The number of patent registrations fell 
dramatically in 2010 and 2011, when probably many foreign operators started to register their 
patents with the European Patent Office. The low level of R & D taking place within the local 
pharmaceutical industry emerges from the fact that whereas around Malta’s accession into the 
EU the research spend relative to output was around 5% (2005) by 2010 this had fallen to less 
than 3%. 
 
According to Farrugia (Chamber of Commerce), ‘[M]alta is still in its infancy in terms of 
R&D’. Instigated by the EU, the MCST recently completed a Research and Innovation 
Strategy for 2014–2020. This strategic process brings together the Chamber of Commerce, 
the University, ME and MCST. This R&D strategy will be financed through structural funds 
made available by the EU. To ensure a more cost-effective use of funds, the Commission is 
insisting that countries adopt an approach known as ‘smart specialisation’. This favours a 
strategy that builds on the strengths of a member state to tap into opportunities rather than 
addressing weaknesses to reduce threats. As part of the process, MCST has undertaken a 
comprehensive exercise to determine existing capacities for further Research and Innovation 
(gauged through such factors as human resources, infrastructure and research and innovation) 
within the local economy. Surprisingly, pharmaceuticals are not included in the ‘smart 
specialisation’ programme. Castillo (MCST) explains that ‘[T]he strategy is meant to be a 
dynamic process and may change should developments justify it’. The reason for this 
exclusion is that MCST (as shown by this research) has found that little ‘real’ research takes 
place within local pharmaceutical enterprises. Castillo (MCST) adds ‘[m]ost R&D activities 
in the local pharmaceutical industry are oriented towards quality assurance, rather than 
product or process development’. Moreover, any Research and Innovation activities within 
local pharmaceutical enterprises are often determined by the parent company overseas with 
the local unit having little or no say. 
5.7.4   Alliance Capability 
 
During Malta’s accession negotiations with the EU, MEUSAC was set up to coordinate some 
130 organisations representing various groups from civil society. ‘In this way, the EU 
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accession was considered not solely as a foreign policy issue but something that encompassed 
the whole society’ (Schembri Aurobindo). MEUSAC managed ‘to introduce an 
unprecedented level of consultation into Malta’s political system’ (Aytaç and Kıratli, 2008, p. 
23). MEUSAC was reactivated in 2008, with the specific scope of engaging civil society in 
the EU consultation and decision-making process to gauge ‘the impact proposed EU 
measures could have on Malta, its institutions, its specific sectors and ordinary citizens’ 
(MEUSAC, 2013). Mizzi (2004, p. 2) remarks that ‘it is only with enhanced coordination and 
co-operation amongst the social partners in Malta that the full economic and political benefits 
of Malta’s EU membership can be exploited’. This is Malta’s own form of ‘democratic 
corporatism’ and has been in place since the early 1990s. The MCESD is an advisory council, 
which brings together government and the social partners, is meant to promote social 
dialogue and formulate recommendations to government on matters of importance to the 
Maltese society. The fact that trade unions and the employers’ organisations sit together with 
the government to discuss issues of national relevance has resulted in practically no industrial 
unrest (especially in the manufacturing sector) over the last two decades.  
 
The MCESD is often mocked as being a mere ‘talking shop’ and a rubber stamp for 
government policy. It is also criticised for having failed to reach, over the last eight years, 
agreement on a social pact. Gambardella et al. (2000, p. 2) point out ‘[t]he competitiveness of 
the industry cannot be assessed by looking only at the individual firms, but also at the broader 
set of institutions, infrastructures, and policies that influence the actions of companies, and – 
even more important – at the dynamic interactions between these levels of analysis’. These 
actors are linked together through a web of different relationships, which include almost pure 
market transactions, ‘command and control’ administrative rules, competition, collaboration, 
and all sorts of ‘intermediate forms’ (Gambardella et al., 2000, p. 2). Modern economic 
thinking emphasises that firms need to collaborate and be part of a ‘network’ or ‘cluster’ 
rather than operate as stand-alone units. The pharmaceutical industry relies heavily on inter-
linkages. The Maltese pharmaceutical industry (as with local industry in general) lacks the 
business sophistication that arises from inter-linkages and networking on a local level. As has 
been explained earlier in this chapter such a disposition to work together is generally lacking. 
Local pharmaceutical firms work with their overseas parent company (or other affiliates) 
rather than with each other. While, as has been noted, FDI has the merit of helping local 
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operations in remaining close to the markets and in facilitating the transfer of knowledge and 
technology, it also prevents them from cooperating with other local enterprises. 
  
This research shows that very few local pharmaceutical companies collaborate with one 
another, even though Saliba (ICP) claims that ‘There is more collaboration taking place than 
meets the eye’. Giromini (Siegfried) notes that ‘Maltese pharmaceutical operators operate in 
silos. We are more interested in networking with foreign companies than among ourselves. 
We do not seem to trust each other’. As already mentioned  in this chapter various 
interviewees note the role of the Chamber of Commerce in getting local operators in the 
pharmaceutical industry together. Seychell (Pharmadox) finds that collaboration within the 
Chamber of Commerce is weak as most members are importers and wholesalers of 
pharmaceuticals and not manufacturers. ME too realises the importance of collaboration and 
set up a ‘Generics Manufacturers Forum’, which brings together local pharmaceutical firms. 
‘Key supporting agencies such as the Medicines Authority, Health Department, Utility 
Services are invited to attend the forum on an “ad hoc” basis’ (Galea & McKenna, 2004, p. 
69). However, this Forum also serves more as a lobby group rather than an institution meant 
to foster collaboration between the sector’s enterprises. 
 
Given the geophysical smallness of Malta, one would expect that local pharmaceutical 
enterprises have a unique opportunity to get to know each other well and explore possibilities 
of collaboration. As Saliba (ICP) puts it ‘Malta has a very small community and here people 
get to know each other at university, in the village and so on’. This even more so given as 
Galea Kenely (Starpharma) points out ‘Maltese operators are not really competing among 
themselves’. Seychell (Pharmadox) finds that living in a small community does not 
necessarily lead to increased collaboration, ‘[p]eople know each other and many are 
suspicious of the credentials of a person entering into a line of business such as 
pharmaceuticals. According to Saliba (ICP) however ‘[t]here is more collaboration taking 
place than meets the eye’. Zammit (Actavis) agrees stating that ‘[t]here is a lot of peer contact 
when we meet overseas during some trade fair or conference. Discussions are informal but a 
lot of information and experiences are shared’. 
 
The local pharmaceutical industry has created few linkages through sub-contracting 
arrangements even though as Martin (Crystal) states ‘[w]e work very closely with local 
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suppliers’. Vella (Actavis) claims that ‘[w]e are definitely keen to pursue opportunities to 
leverage the local set-up. For example, printed matter is very important to our business so we 
are sourcing a good amount of it locally...we will only use local clusters when the cost, 
quality and service meet our expectations’. Although some contracting work is being 
conducted, there is little sharing of services and practically no joint initiatives. BEAT 
Consulting (2011, p. 11) find that ‘[s]uch linkages should be extended to include both intra- 
and inter-sectoral linkages, comprising industry participants from a local indigenous industry 
and locally established foreign direct investors operating in synergy through an effective 
technology transfer mechanism’. The 2010 Innovation Union Scoreboard ranks Malta 
thirtieth out of thirty-four countries in terms of the intensity of innovative SMEs 
collaborating with each other.  
 
Debono (Alpha) points out that ‘[o]ur government needs to listen to all representatives of our 
industry and not just to foreign operators’. Schembri (Aurobindo) believes that the social 
partners, including the political parties, should undergo a reality check about the state of the 
industry in Malta, ‘[i]t is about time we start thinking strategically about the future of 
pharmaceuticals in our country’  
 
5.7.5 Other RCDCs 
 
As already mentioned in this chapter, one of the resources that many overseas investors 
operating in Malta mention is the competence of the local workforce to communicate with 
foreigners, especially its ability to speak English. At times, this sounds clichéd but in reality, 
the local population has a long tradition of working with expatriates and this facilitates 
communication. Schembri (Aurobindo) notes that this is in sharp contrast with his company’s 
experience in other countries, ‘[p]ractically 80% of the problems we face in our overseas 
plants arise out of poor communications’.  Local manufacturers praise the work ethic, 
flexibility  and productivity of the Maltese. Although these capabilities can be  considered as 
a separate RCDC yet in reality they are also a characteristic of  strategic flexibility which is 
not just the final outcome of the system but also a separate competence in its own right which 
is ‘learnt’ through experience.  
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Another reason which various interviewees (foreign ones) refer to is Malta’s attractive tax 
system. Through the operation of the tax refund system, Malta offers one of the lowest 
effective tax rates in the EU. Malta operates a full imputation system that eliminates the 
economic double taxation of company profits. Maltese resident companies are subject to tax 
in Malta at the corporate tax rate of 35%, however, upon the distribution of dividends, the 
shareholders are entitled to a refund of the Malta tax charge (generally, 6/7th of 35% = 30%). 
The combination of the tax incentives, together with the tax refund system, generally results 
in an effective tax of zero to a maximum of 5%. Although such a ‘resource’ appears to be 
important, it is not considered as critical for the pharmaceutical industry in Malta. Tax 
incentives may improve profitability, but even without them, the pharmaceutical industry 
would have still thrived in Malta. 
5.7.6 Strategic Flexibility 
 
The stimulus emerging from EU membership enabled the local economy to embark on new 
opportunities or grow existing ones that generally compensated for those economic activities, 
which membership itself (and/or globalisation) rendered uncompetitive. Pharmaceuticals are 
one such opportunity (others being, for example, financial services and internet gaming) 
which Malta has seized in the past decade. Practically, all the interviewees deem flexibility as 
a fundamental advantage of operating from Malta and many of them believe that flexibility is 
part of the local mind-set. Particularly interesting is the point made by Giromini (Siegfried) 
who praised the adaptability rather than just the flexibility of Maltese workers  to emphasise 
that this is not purely a ‘mechanical’ but a conscious disposition to meet customer needs.  It 
has already been noted that the flexibility and productivity of the local workforce in the 
pharmaceutical industry can be considered as an integral part of  strategic flexibility. This 
arch-competence was built along the years and had helped local industries such as textiles 
and electronics to thrive before. When these industries moved to lower cost countries, some 
of their workers were re-trained and engaged by the pharmaceutical industry. Galea (Malta 
Enterprise) confirms that these workers ‘[w]ere given specific training by ETC so that they 
would be able to work in the pharmaceutical industry’. This flexibility is evidenced also by 
the way that local education institutions, especially the Chemistry Department at the UoM 
and MCAST adapted their curricula to meet the emerging needs of the pharmaceutical 
industry.  
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The capability of  ‘managing complexity’ too is closely to that of strategic flexibility. This 
ability of the local pharmaceutical industry to produce a relative broad mix of products, 
specialising in short runs and fast delivery is a characteristic of ‘near-shore’ locations which 
make good for their higher costs by focusing on niche products and services. Zammit 
(Actavis) explains that ‘[l]ocal production costs are higher than in the other fourteen plants of 
our company across the world which, achieve lower costs due to standardisation; we are 
renowned for our flexibility and adaptability’. This means that the local operation competes 
with the Group’s other manufacturing plants not on costs but on flexibility. Containing costs 
is important but not critical as the local operation is not expected to reap cost advantages 
from long runs and economies of scale. Short runs require frequent change overs and the time 
required in foregone production tends to be very expensive. This is especially so for bigger 
producers, since the downtime required to change from one SKU to another can vary from 
sixteen to twenty-four hours. Zammit (Actavis) concludes that ‘[a]lthough Malta has higher 
“conversion costs” than all the other plants of our company on a worldwide basis, it is 
unbeatable at changing from one product to another’. 
 
Strategic flexibility is closely linked to market sensing and a customer-focus. ‘Customer 
satisfaction represents a key business driver for Actavis thus providing its clients with an 
optimal service level. This is being achieved through the maximization of our operational 
flexibility’ (Actavis, 2012a). Debono (Alpha) stresses the need of ‘[i]mproving our 
disposition to accommodate clients and be flexible’ while Galea Kenely (Starpharma) notes 
that ‘[o]ur company has to stay in touch with clients so as to ‘foresee problems’ and be able 
to offer timely support’. The international market scenario for pharmaceuticals is changing at 
a rapid pace. Biopharmaceuticals are becoming increasingly popular. Continued fiscal 
constraints in Western countries are forcing governments to save money on healthcare so as 
to cope with ever-growing needs. Many governments are asking for smaller batches, 
especially  of more expensive pharmaceuticals, to keep the cost of stocks as low as possible. 
Over the last decade, the EU membership has enabled the local pharmaceutical industry to 
grow and re-position itself on global markets. The industry changed its marketing moving 
away from dependence on aid-financed pharmaceuticals meant for poor countries to the 
development of generics meant for EU and global markets. This re-positioning of the 
pharmaceutical industry led to an impressive improvement in its turnover and value added. 
This shift over recent years ran in parallel to another ‘structural’ shift within the local 
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pharmaceutical industry itself, away from manufacturing to partial manufacturing and re-
packaging operations. This shift negatively impacts gross value added and raises questions on 
the undercurrents within the local pharmaceutical industry and their impact on its longer-term 
competitiveness. 
 
While it may be argued that such shifts reflect the very capability of the local pharmaceutical 
industry to adapt to changing global dynamics, they raise questions as to whether Malta is 
destined to serve as an assembly powerhouse for more technologically advanced countries in 
this sector also? Most interviewees agree that the basic rationale for the pharmaceutical 
industry in Malta is not to be found in R&D but in exploiting opportunities created by patent 
law and in producing ‘niche’ pharmaceuticals. The fact that few medical patents were 
registered in Malta prior to the EU membership (due to its small domestic market) opened an 
opportunity window to work on developing their generic equivalent before the actual expiry 
of the patent, as envisaged under the Bolar exemption. This enables a number of local 
pharmaceutical companies to specialise in what is referred to as ‘patent’ or ‘novelty’ 
launches, whereby generics are air-freighted on the eve of expiry of a patent to permit the 
earliest possible pipeline filling. This brings ‘first-mover’ benefits which arise from the 
capability of an enterprise to capture a significant market position by being first on the 
market. It is to be noted that a patent generally does not expire on the same date in every 
country and this enables Maltese suppliers (or their clients) to move from one market to the 
other to exploit in full this ‘first-mover’ advantage. 
 
‘Patent launches’ often result in a competitive advantage which lasts for about six months. It 
is likely that within this period, competitor products enter the market and any price advantage 
will be significantly reduced, if not completely eliminated. A typical local operator does 
between thirty and forty new launches in a year. Many of these operators talk about becoming 
a ‘one-stop’ shop, offering a customised, complete and flexible service. Apart from all the 
necessary certification and regulatory procedures, local companies are able to prepare and file 
house documents (a mandatory five years) as well as sample retention (required for the 
lifetime of the product). Local operators are building expertise in ‘patent opportunities’ and 
carry extensive research to determine which patents will expire, when and where. This 
specialisation in ‘regulation’ has been facilitated by the fact that English, the language of the 
pharmaceutical industry, is also an official language of Malta. Perceiving the opportunity, 
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and moving flexibly and fast to become ‘first movers’ in a particular market upon the expiry 
of a patent underlines the competitive advantage of the local pharmaceutical industry. The 
pharmaceutical industry in Malta manifests significant strategic flexibility as it continues to 
morph to adapt to global changes, both at the industry and enterprise levels. This strategic 
flexibility does not necessarily lead (in the short term) to superior performance, as evidenced 
by its falling value added. 
 
Table 13 shows the key findings of this research with regards to the arch-RCDCs identified in 
the alternative framework for the superior economic performance of small states. 
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Arch-RCDC National Level Industry Level Enterprise Level 
Market Sensing Impact of EU membership on 
Malta’s public policy & societal 
resources. Access to EU & global 
markets 
Transposition of EU legislation relating 
to pharmaceuticals. Inflow of FDI key 
for market sensing 
Parent (or alliance with foreign partners) 
dependent. Patent specialisation  leads to 
market sensing, Visits to international 
fairs & conferences 
Change 
Management 
Commitment of local political parties 
to EU membership post 2003 
elections 
Industry essentially export-oriented and 
posed little threat to powerful importers 
group. Medicines Authority key driver 
of change with support from other local 
institutions (ME, education etc) 
No real resistance within enterprises to 
change process given the commitment of 
top management. This is true also for 
Actavis the leader of the industry. 
Knowledge 
Capacity 
Minimal R&D activities Long tradition in pharmacy and law. 
FDI main channel for importing know-
how. Build-up of knowledge in public 
sector slower. Lack of a deliberate 
policy reflected in struggle to improve 
supply of HR and upgrading 
infrastructure 
Actavis served as the cradle of the 
industry. Local operators dependent on 
parent company, except for ‘patent 
launchers’ which exploit legal knowledge 
Alliance Capability Malta’s own form of democratic 
corporatism-MCESD & MEUSAC 
Little beyond some joint lobbying. 
Some inter-linkages with local 
suppliers.  
Local operators are stand-alone units  
with close collaboration  with foreign 
partners (mostly parent companies) 
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Other RCDCs? Taxation? Adaptability and productivity of local 
workforce (strategic flexibility?) 
 
Strategic 
Flexibility 
EU membership (and globalisation) 
required deep economic 
restructuring. The country quick to 
adapt and renovate 
Significant growth and upgrading of the 
local pharmaceutical industry. 
Flexibility and fast response underpin 
its competitiveness in ever-changing EU 
and global markets 
Continued transformation of local 
pharmaceutical enterprises to adjust and 
tap opportunities arising from changing 
market conditions 
 
Table 13: Key Findings as per Alternative Theoretical Framework for Small States’ SEP 
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The findings of the research confirm Malta’s credentials as an ‘open system’ and highlighted 
the impact of EU legislation on the development of societal institutions and public policy 
related to the Maltese pharmaceutical industry. The sector performance shows that after that 
the Maltese pharmaceutical industry registered high growth in the immediate period 
following EU accession. This growth has been slowing down especially in terms of output 
and gross value added. At the same time the level of exports has continued to rise reflecting a 
continued restructuring of the industry. The findings of the field research also show that 
Malta has built a competitive advantage in generics. While EU membership was of utmost 
importance in creating the right operating environment for generics, what proved to be 
fundamental for the growth that followed was international patent law. FDI also played a 
critical role in the development of the pharmaceutical industry. Malta’s market sensing in 
this case study was boosted by EU membership at the sector level and by FDI at the 
enterprise level. In terms of change management, at the national level EU membership 
accepted by practically all of society and given the export-orientation of the Maltese 
pharmaceutical industry there was little resistance to its continued growth. Even at an 
enterprise level there was full commitment by top management to make the best out of the 
opportunities that EU membership offered. 
 
At the time of the EU membership, Actavis incorporated much of the local pharmaceutical 
manufacturing knowledge base. This base rapidly expanded through the inflow of significant 
FDI. The relevant EU directives were included in the Medicines Act (2003) which set the 
stage for the industry’s expansion and increased awareness (and knowledge) about the 
industry within the public sector. The lack of a deliberate strategy resulted in some 
institutions, and in particular education, being unprepared for the specific needs of the 
pharmaceutical industry. The propensity of societal organisations, including enterprises, to 
work together (as well as with external agents) to achieve common goals is captured in 
‘alliance capability’. The research shows that the Maltese lack a culture of working together 
but compensate for it by a high propensity to collaborate with foreigners. As a result, there 
are practically no inter-linkages at the industry level, with the umbilical cord for enterprises 
being attached to their parent company. Malta’s own type of ‘democratic corporatism’ is 
evidenced within its MCESD. All interviewees agreed on the importance of flexibility for the 
local pharmaceutical industry. This has enabled enterprises to specialise in short runs and 
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fast delivery. This ability to manage complexity enables local enterprises to avoid competing 
just on costs. This competitive advantage is further enhanced through ‘novelty launches’ as 
well as ‘batch release’ of imported medicines (mostly from Asia) unto EU markets. The 
continued restructuring of the pharmaceutical industry in Malta reflects this consistent 
search for new opportunities, which if success ultimately manifests itself as strategic 
flexibility. 
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6. Discussion and Conclusion 
 
The final chapter revisits the research problem in the light of the main findings of the thesis  
and includes an extensive discussion on how these relate to the superior performance of 
small states. Some conclusive considerations are then made with regard to this experience, 
along with broader implications for policymakers and entrepreneurs in small states. Specific 
answers to the research questions are given and an outline of the contribution of the research 
is made. 
 
The lack of an agreed definition has not helped in understanding the key issues facing small 
states (Neumann & Gstohl, 2006). Easterly and Kraay (2000) note that the theoretical study 
of small states has been plagued by definition problems. Prevailing models of the state, 
sovereignty and economic systems, themselves ‘contribute only in a limited way to our 
understanding of the internal dynamics and external relations of micro-states’ (Warrington, 
1994a, p. 128). This research indicates that small is a polymorphous construct (Thorhallsson 
& Wivel, 2006),  a comparative term (Sanders, 2005) and that irrespective of the criterion 
used, it will always be subjective and arbitrary (Thorhallsson & Wivel, 2006). Bailes (2011, 
p. 2) observes that ‘a state is “small” when it feels and acts small’. Warrington (1997a) sees 
‘micro-states’ as a complex association of a demographic, geographic or economic scale with 
political autonomy.  
 
Matters are further complicated by the fact that ‘the borders between such categories as 
‘micro state’, ‘small state’ and ‘middle power’ are usually blurred and arbitrary’ (Neumann & 
Gstohl, 2004, p. 6). The point at which a boundary is drawn around the category ‘micro-state’ 
is an entirely arbitrary matter determined by an implicit but generally held assumption about 
the ‘ordinary’ size of states (Warrington, 1994b). Issues arising out of ‘smallness’ have many 
times been intertwined and confused with those arising out of geophysical considerations 
(especially location and ‘islandness’), statehood (including sovereignty and jurisdiction) and 
the level of economic development (Neumann & Gstohl, 2006). Hache (1998, p. 49) notes 
that ‘Islandness is often treated as the critical determinant factor rather than small size per se, 
primarily because most small states are also island or archipelagic’. There is general 
consensus that many of the issues encountered by small island states are similar to those of 
smallness in general (Read, 2002). Newitt (1992, p. 16) asserts ‘[n]ot all small states are 
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islands and not all island states are small; but the problem of “smallness” is given an added 
dimension in the case of an island’.  
 
Small states are faced with two forms of economic challenges: the first are inherent and 
largely fixed (arising from peripherality, smallness and islandness), while the second are 
contingent, emanating mainly from governance practices (Prasad, 2008). Armstrong and 
Read (2003, p. 111) argue that the key economic growth challenges facing small states are 
primarily because of their size and not their topography: ‘Islands, land-locked and littoral 
small states therefore need to be regarded taxonomically as separate and distinct sub-sets of 
small states in general, with the island and land-locked sub-sets possessing specific additional 
problems arising from their isolation’. Generally, the size of population is taken as a proxy 
for a range of other economic characteristics, all of which are deemed to bestow particular 
vulnerabilities on small states (Heron, 2008). Both the World Bank and Commonwealth 
Secretariat use the ‘population principle’ to categorise states (Misra, 2004). Small states have 
been defined from 1 million to 20 million and over, with different cut-points in between 
(Tonurist, 2010). In the 1950s and 1960s, a small state was perceived as having from 10 to 15 
million people. By the 1980s, this had fallen to 5 million and by the 1990s, it had dropped to 
1–1.5 million. Crowards (2002) suggests that the threshold levels were modified downwards 
to avoid classifying most states as small. The World Bank (2008a, p. 5) suggests that ‘the size 
of countries can be ranked along a continuous scale’. Members of the WTO, in the context of 
their on-going debate on small economies, associate smallness with a country’s share of 
world trade. UNCTAD (2007) classifies 92 countries as being ‘structurally weak, vulnerable 
and small economies’ and it too uses a country’s share of world trade as one of the proxies 
for small size. UNCTAD notes that by itself, a country’s share of world trade ignores the 
importance and potential of the ‘non-tradable’ segment of its economy and proposes that it 
may be more relevant to consider relative prices that a small state fetches for its exports. 
 
Due to the lack of an adequate definition of a small state, this research had to formulate its 
own parameters of what constitutes ‘smallness’. It proposes the concept of an ‘open system’ 
which essentially brings together two elements: the relative lack of economic power and a 
population which is less than 1.5 million. 
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A second key consideration in the study of small states is whether this is still relevant in a 
globalised world (characterised by a relative decline in the supremacy of the nation-state) and 
a post-industrial economy (which is not so dependent on mass production and mass markets).  
Historically, small states were looked upon favourably. Greek philosophers emphasised the 
benefits of small and homogeneous polities. ‘Aristotle argued that a polity should be no 
larger than a size in which everybody knows personally everybody else’ (Alesina, 2003, p. 
303). The experience of small European ‘illustrates a traditional paradox in international 
relations concerning the strength of the weak’ (Katzenstein, 1985, p. 21). The success of 
some small states in achieving economic growth has stimulated interest in them (Armstrong 
& Read, 2003b, p. 99), and they should be treated as a special case of development paradigms 
(Karunasekera, 1994).  
 
There is no consensus on what is special about small states. Some argue that nothing is 
special in being small, while others claim that size is an important factor. Other analysts 
suggest that what matters most is isolation (The World Bank, 2008a). Read (2002) concludes 
that location rather than smallness or isolation per se should be considered. Alesina and 
Spolaore (2003) perceive the ideal ‘size’ of a state as a trade-off between the benefits of size 
and costs of heterogeneity. The benefits of size relate to economies of scale in the provision 
of public goods and policies, larger domestic markets, interregional insurance and 
redistribution. The costs stem from significant differences in cultural, religious, linguistic or 
economic factors that may lead to different individual choices with regard to public goods 
and policies. A big state can spread the cost of producing public goods across more people, 
thus reducing the cost per capita; however, the larger the nation is, the less homogeneous its 
population becomes, giving rise to more complex interests and conflicts.  
 
As globalisation advances, the benefit of having a large domestic market diminishes, with the 
trade-off between size and homogeneity shifting in favour of the latter. The risks arising from 
small state instability are probably the most important factor militating against their 
development (Wint, 2002). Diversification is viewed as a strategy to reduce risk (Thomas & 
Pang, 2007). The search for diversification in small states affects the mind-set of individuals 
as well as households (Guilmoto & Sandron, 2001). Aubert and Chen (2008, p. 179) propose 
that the small island mentality emphasises ‘economic survival, and along with this survival 
instinct, a pragmatic attitude of doing whatever it takes to stay economically competitive’. 
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‘Occupational multiplicity’, common in small islands, is a natural survival strategy and a 
characteristic of areas where employment opportunities are scarce, precarious and seasonal. 
‘The involvement in diverse activities enables an intensive use of scarce management skills 
and provides a measure of security, or fall back, in the event of failure’ (Baldacchino, 1998, 
p. 274). Streeten (1998) criticises small states for harping on their handicaps and vulnerability 
to get increased aid flows and more advantageous trade concessions. Vulnerability to external 
forces is, according to Warrington (1997a p. 102). ‘both a bleak reality and a useful device 
for gaining leverage with external partners’. 
 
Autonomy is a valuable, adaptable asset that can pay handsome dividends if used astutely; a 
microstate’s ‘governing wits’ may well compensate for the economic, demographic, cultural 
and political disadvantages that are legitimately associated with small scale (Warrington, 
1997b, p. 105). Small states have been assisted by international organisations, notably 
UNCTAD, the Commonwealth Secretariat and the UNDP, in proving that they deserve 
special consideration (Fairbairn, 2007, p. 133). Between 1993 and 2004, the per capita aid 
received by small states (US $210) was almost 17 times that received by all developing 
countries (US $12). Also, whereas official development assistance is almost 15 percent of 
gross national income in small states, it accounts for only one percent for other developing 
countries (Favoro & Peretz, 2008, p. 275). That small states seek to capitalise on their 
perceived weaknesses to further their trade prospects is widely accepted. Yet, they also face a 
number of structural disadvantages. As Jones and Birkbeck (2011, p. 1) point out, ‘[s]mall 
states live with a paradox when it comes to trade negotiations. They depend on international 
trade to a greater extent than any other group of countries, yet they have the weakest voice 
when it comes to influencing the rules that govern trade’.  
 
Small states have little to offer negotiating partners through market access concessions, their 
institutional negotiating capacity is limited as they have few trade negotiators and inadequate 
budgets and they may at times be subjected to coercive threats by more powerful states. Some 
small states have joined, or are considering joining, supra-national regional blocs to address 
some of their ‘size’ limitations. Quoting Michael McVey, a UNWTO consultant, Scheyvens 
and Momsen (2008, p. 495) say that ‘[s]mall island communities tend to have an exaggerated 
sense of independence and self-importance’ and that it is unrealistic of small island states to 
expect to control their own destinies. 
 184 
 
 
The concept of ‘governed interdependence’ (Weiss, 2000) is also of relevance to an open 
system. Proximity is not only geophysical but also ‘relational’ as most social players tend to 
know each other well. ‘Relational’ proximity arises from the greater and faster impact of 
decisions and actions by one social player on the rest of society. This tends to impact the 
distribution of power, which as shall be argued later when discussing impacts on how an open 
system reacts to external change. Developing an ‘alliance capability’ (including a disposition 
to work together and network) is perhaps the biggest cultural challenge facing an open 
system’. Given these proximity considerations, the politico-socio-economic framework of an 
‘open system’ has to be seen holistically, as this makes it bigger than the sum of its 
components. In today’s intensely competitive and globalised world, ‘alliance capability’ is an 
arch-RCDC which reflects the propensity of the units of an open system to work together in 
pursuit of their goals. Strategic alliances enable an open system and its various sub-systems 
to create and share key externalities which are unique ‘societal resources’ and hence, difficult 
for international competitors to imitate. But, as this research’s case study finds, the scope of 
such alliances in an open system are not limited to local players but includes their teaming up 
with others overseas. 
 
‘Alliance capability’ creates an additional dimension to other RCDCs by stimulating trust, 
reducing uncertainty and improving the speed and quality of decision-making. The literature 
on small states typically argues that in the era of ‘globalisation’, it still makes sense to 
analyse the ‘smallness’ of states. Differences between small and large countries are real, even 
though researchers have contradicted each other as to whether ‘small states differ from larger 
states on economic, social and political factors’ (Bräutigam & Woolcock, 2002, p. 187). The 
study of small states is an exercise in diversity. While small states differ from one another, 
they share enough characteristics to make their separate study academically interesting and of 
practical interest. Small states are ‘simply too numerous and-sometimes individually, but 
certainly collectively-too important to ignore’ (Neumann & Gstohl, 2006, p. 3). This research 
finds that understanding ‘smallness’ is important not so much to find ways to ‘offset’ their 
perceived vulnerability, but rather because small states face similar challenges in achieving a 
superior economic performance. 
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Globalisation and post-industrialisation create new opportunities and threats for small states. 
The changing scenarios call for a new mind-set by politicians and policymakers; one which 
emphasises creative thinking and a can-do attitude rather than vulnerability as was the case in 
the industrial era. It is unfortunate that a large part of small state studies has been conditioned 
by the weak, powerless perspective emanating from international relations. Equating 
‘smallness’ with ‘vulnerability’ was natural at a time when mainstream economics projected 
industrialisation, with its dependence on urbanisation, big populations and large-scale 
manufacturing, as the primary path towards economic development. The vulnerability 
approach has been criticised for perpetuating a ‘dependency’ culture which negatively 
impacts the developmental efforts of small states. Discourse on fragility and vulnerability 
suggests that small societies cannot do without assistance from outsiders and this adversely 
affects the self-esteem of small states and stifles their initiative (Scheyvens & Momsen, 
2008). The vulnerability mindset inflicts ‘lasting damage on people’s images of themselves 
and on their ability to act with relative autonomy in their endeavours to survive reasonably 
well within the international system’ (Hau’ofa, 1994, p. 152). Later, the pursuit of resilience 
to offset vulnerability started to be seen as the primary challenge facing small states. The 
resilience school assumes that the origin of vulnerabilities is exogenous and mostly 
determined by international economic conditions, whereas the capacity to adapt is internal 
and dominated by socio-psychological traits (Baldacchino & Bertram, 2009).  
 
Resilience studies stop short of explaining why some countries manage to have better 
governance and policymaking capabilities than others. They adopt a static approach as small 
states rarely have a preferred, steady-state position to which they want to return after 
‘turbulence’. The dynamism of real life obliges a small state to consistently seek to develop 
its economy to offer a better way of life to its citizens. The vulnerability paradigm is 
condemned as being a version of structural determinism. ‘The presumption that constraints of 
small size and geographical separateness render small economies particularly economically 
“vulnerable” is both conceptually and empirically unsatisfactory. Conceptually, there are 
advantages as well as disadvantages to being small and isolated’ (Baldacchino & Bertram, 
2009, p. 146). 
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This research literature review highlights a number of key considerations: 
  
o Practically all approaches confirm the importance of specialisation. The key questions 
which emerge relate to the ‘nature’ that this specialisation should take, how it can be 
achieved by a small state and what type of terms of trade will it generate.  
o The shift from comparative to competitive advantage. This suggests that in today’s 
globalised environment, specialisation does not necessarily result from inherited 
resources but from created ones.  
o The need to distinguish between economic growth and development, with the latter being 
closely associated with the capacity to ‘sustain’ competitive advantage.  
o There is no single definition of a small state or a small economy and new perspectives 
and emerging economic scenarios call for a re-definition of ‘smallness’.  
o The importance of good governance. While the government is still expected to play a 
primary role, an increasingly complex operating environment calls for a higher propensity 
to ‘work together’ with the other social partners.  
o Increasingly dynamic environments call for theoretical explanations that go beyond a 
static and equilibrium-seeking analysis. 
 
Katzenstein (1985, p. 79) notes that ‘[t]he industrial adjustment strategy of the small 
European states stresses specialisation in export markets’. Given the smallness of domestic 
markets, it is logical to expect that ‘industrial’ specialisation be export-oriented. However, 
this tells us little about the ‘nature’ that this specialisation should take. Exports have to face 
international trade rules and the dynamics of international markets. Specialisation in an open 
system is a complex phenomenon. Specialisation leads to increased knowledge and 
innovation and determines the ability of an open system to engage in higher value activities, 
thereby improving productivity. High-tech activities are not synonymous to high-value 
added. Politicians and policymakers are fascinated by hi-tech ventures and tend to ignore the 
potential of conventional ones. What matters is not the economic sectors in which a country 
competes, but how it competes (Porter, 1998). In an open system this inevitably relates to the 
quality of human resources available. Lifelong learning and on-going training programmes 
are essential if an open system is to anticipate/adapt to the change emerging from global 
markets. The demands of the global economy require that strategies incorporate human 
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resource development into larger economic strategies (The Asia Pacific Economic Co-
operation, 2011)  
 
Another popular misconception regarding value added is that it results automatically from 
bigger factories, increased automation and longer production runs. In the post-industrial era, 
value creation results from innovation and strategic marketing, which add extra value for 
customers. ‘Niche’ activities appear to be more appropriate for an open system. Niche 
marketing involves designing and producing goods and services meant for specific, often 
secondary, market segments. These activities are profitable due to the benefits of ‘focus’ (as 
per Porter’s generic strategies) and specialisation. The strategies generally demand a level of 
business sophistication which is not easily available in an open system. The contribution of 
‘specialisation’ in a small economy changes along the economic development path. The lack 
of ‘economies of scale’ has to be off-set through ‘economies of scope’. At the factor-driven 
stage, the primary impact of specialisation is in creating additional value though vertical and 
horizontal diversification.  
 
At the efficiency-driven stage, its main contribution is in building absorption capacity, 
including technical know-how, which enhances operational effectiveness. At the innovation-
driven stage, specialisation generates knowledge (including technological know-how and 
marketing) which enables enterprises to carve unique market positions and reap higher 
returns. Another key consideration that is often overlooked by small state studies relates to 
risk minimisation. In an open system, this is an equally desirable public policy objective as 
high economic growth. The growth and development path of small states faces greater risk 
because of their size (UNCTAD, 1988). According to Wint (2002), the risks arising from 
small state openness is probably the most important factor militating against their 
development.  
 
Given the limited number of economic activities that can be undertaken in an open system, 
concentrating on a ‘narrow’ set of economic activities implies that, should things go wrong in 
a particular sector, this will have an unduly high impact on the rest of the economy. This, for 
example, has been the experience of small states such as Mauritius, whose economy was 
unduly dependent on the clothing sector. When this sector collapsed due to a number of 
factors, including changes in global textile trade rules, the country suffered a severe setback, 
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which affected the standard of living of many people. Guilmoto and Sandron (2001, p. 137) 
state that the ‘[l]ack of proper information and perceived high risk induce small states to 
prioritise diversification rather than specialisation which may prove too onerous in a time of 
crisis’. Diversification implies a trade-off with specialisation. The danger with too much 
diversification is that it may lead to too many low-value economic activities with no linkages 
or synergy. Having such a ‘fragmented’ economy, producing a broad array of goods and 
services, is no blueprint for an open system competing on global markets.  
 
Strategic management is critical for an open system. As Deloitte Consulting (2008) notes, it 
involves finding the right balance between ‘profit’ maximisation and ‘risk’ minimisation. 
Given the importance of these two objectives, the solution for an open system is to try to seek 
‘diversification within specialisation’ (This is not to be confused with flexible specialisation 
which is essentially a production structure involving a number of smaller units.). Such an 
economic strategy entails specialising in a few sectors while ensuring that there is a sufficient 
range of diversified activities within each sector. Equally important is the development of 
inter-linkages between the economic sectors themselves. Given that an open system generally 
has limited possibilities of vertical integration, it needs to promote ‘horizontal’ integration. If 
an open system wishes to develop, for example, its agriculture and tourism sectors, it should 
ensure that the agricultural produce is diversified and feeds the local tourist industry, rather 
than cater to export markets. A further critical deliberation relates to ‘market power’. By 
definition, an open system has insignificant, or no market power, on international markets.  
 
R-A theory perceives market power as arising from the ‘unique resource assortment’ of the 
enterprise/state, which enables it to command an ‘advantageous’ market position either in 
terms of lower costs, higher customer value or both. Business studies conceive market power 
as arising from ‘supply’ and/or ‘demand’ factors. Supply factors generally relate to 
advantages due to ‘natural’ monopolies, resources and competencies, economies of scale, 
technological (process) sophistication and product innovation. Demand advantages arise 
mainly through strategy and the manipulation of market structures. In economics, ‘market 
power’ is normally associated with the performance of enterprises; but countries too are able 
to exert power on international markets as they use trade policies to enhance their own 
welfare (Tasdogan et al., 2005). Armstrong and Read (2002, p. 436) note that having market 
power seems to be ‘the minimum criterion for a large country rather than a means to classify 
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small states as a distinct group’. The point made by Armstrong and Read is more practical 
than theoretical and their reservations can be overcome by conceiving ‘market power’ as a 
dynamic concept along a continuum rather than a static one determined by some threshold 
below, which a country has no ‘market power’ at all. International economics perceives 
‘market power’ as being reflected in the ‘terms of trade’ of a country. The terms of trade are 
the ratio of export prices relative to import prices. It indicates how much a country can obtain 
in imports per unit of its exports. An increase in purchasing power from a rise in the terms of 
trade is obtained by comparing real GDP with real gross domestic income (GDI).  
 
For any given pattern of real output and expenditure, a rise in the terms of trade will directly 
impact the trade balance and current account position. Assuming no changes in quantities, 
higher export prices will generate an increase in export earnings and thus, an equivalent shift 
in the trade balance. Brissimis and Kosma (2005) remark that the impact of the exchange rate 
(which at a national level is a type of ‘price of prices’) on a firm’s market power remains 
largely unexplored. When the exchange rate changes, a firm may choose to pass the cost 
shock fully onto its selling price (complete pass-through) or absorb the cost shock and keep 
its selling price unchanged (no pass-through), or some combination of the two.  
 
Katzenstein (1985) finds that large industrial states tend to export the costs of such changes, 
while small European states tend to absorb them. By definition, an open system lacks a 
significant degree of market power. It is, of course, possible for a small state to achieve a 
high degree of market power. (Luxembourg, with its specialisation in financial services, is a 
clear example. Vatican City, despite its physical and demographic smallness, is one of the 
most influential and well-off states in the world). There is no appropriate measure which 
captures the market power of different countries in a meaningful way. (The terms of trade 
indicates how a country is doing over a period of time and does not directly compare the 
performance of different countries). Ideally, such a measure should also differentiate between 
‘temporary’ and ‘sustainable’ market power.  
 
There are hypothetically three sources of national market power on the global market and 
these arise from, 
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1. Portfolio investment held overseas in a particular industry. This type of market power 
though important tends to be limited and of little value from a decision-making 
viewpoint. 
2. The level of exports and degree to which a state (and its enterprises) can influence prices 
(an enterprise through its ‘ex-factory’ prices and the state through the exchange rate).  
3. Knowledge and capital transfers. This is the most ‘sophisticated’ and sustainable form of 
market power, and is usually in the form of FDI, franchising, licensing and management 
contracts.  
 
The global market is generally characterised by oligopolistic structures that generate various 
forms of ‘market power’ (Sweezy, 1999). Although there have been attempts by some 
developing economies to achieve market power through branding (such as Jaffa oranges and 
Chiquita bananas) or ‘cartelisation’ of primary products (OPEC in the 1970s), their success 
has been limited and short-lived. An open system at the factor-driven stage is generally 
unable to influence the price of its exports. Small states dependent on the export of primary 
products are very sensitive to fluctuations in their earnings and their fortunes vary with 
demand in the world markets. Historically, the prices of primary exports are on a downward 
trend relative to those of manufactured exports.  
 
At the efficiency-driven stage, an open system is still a ‘price-taker’. At this stage, it will 
retain a greater share of the value being created, through higher wages and possibly increased 
taxation. Efficiency-driven economies tend to push their exports through operational 
effectiveness and lower costs. It is only at the innovation-driven stage that significant 
business sophistication enables enterprises to influence, if not determine, the prices they fetch 
for their goods and services. (When this happens, one of the defining characteristics of an 
open system is lost and that economy although ‘small’ would have achieved a high level of 
market power). High dependence on the international business of an open system makes the 
strategic management of its interface with the rest of the world critical. Openness can be as 
much a blessing or a curse. Rodrick (1999) points out that 
 
• Openness by itself is not a reliable mechanism to generate sustained economic growth 
Openness is likely to exert pressures that widen income and wealth disparities within 
countries 
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• Openness leaves countries vulnerable to external shocks that can trigger domestic 
conflicts and political upheavals.  
 
Economic integration has been indicated as a possible path for a small state to offset the 
limitations of its size. But economic integration is no easy solution and it too needs to be 
properly managed to benefit a small state. Small states which opt for economic integration 
need to ensure that membership benefits their competitiveness and economic development. 
The pragmatism and focus which such a strategic choice demands is not easily forthcoming 
from political leaders of small states who usually prefer grander schemes. The primary 
research finds that the impact of the EU membership on Malta is similar to that of a big 
pebble thrown in a small pond—there were multiple ripple effects which at times re-enforced, 
and at others, worked against one another. Economic integration comes at a price as it 
reduces the flexibility of an open system and has to learn to live with directives not tailor-
made to its requirements. Given the increased uncertainty created by political, economic, 
social, technological and environmental changes, ‘policymakers in the 21st century need to 
adopt a proactive mind-set rather than a reactive cognitive one’ (Chareonwangsak & 
Kitthananan, 2009, p. 3).  
 
Globalisation brings new opportunities as well as changed risks, and ‘a more integrated 
global economy may enable smaller, more ‘nimble’ states to adapt quickly to changing 
conditions and more readily to identify and pursue strategic development policies’ 
(Bräutigam & Woolcock , 2002, p. 185). Small states are more flexible and adjust quickly to 
change (Bräutigam & Woolcock, 2002). Katzenstein (1985) finds that small European states 
adjust to economic change through a carefully calibrated balance of economic flexibility and 
political stability, combining international liberalisation with domestic compensation. How 
fast an open system anticipates, or adjusts to, exogenous change depends on its ‘propensity to 
change’, of which leadership and the power structure are two major determinants. Finkelstein 
(1992) notes that power management is a key factor that impacts and shapes strategic 
flexibility. Change externally triggered is likely to have a significant impact on the politico-
social fabric of a small state. Stakeholders tend to have a different perception of change, and 
they interpret and react to it in diverse ways. Stakeholders who believe that their power 
and/or vested interests are threatened by change will do their utmost to resist it. This leads 
many political economists to emphasise the importance of involving all stakeholders in 
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managing the change process. Governments find it increasingly hard to find the political 
power to transform economies on their own and need the support of the social partners. 
 
The politics of a large-scale system tend to be more complex as they add elements and 
problems not characteristic of simpler systems (Kanter, 1997). This appears to be one 
possible explanation as to why an open system is better able to manage the change process. 
Fonseca (2002, p. 8) observes that in a dynamic environment, states are constantly learning 
and creating knowledge as they respond to ‘gestures made by other states and other 
participants in complex responsive processes’. Given that an open system constantly faces 
exogenous change, it tends to improve its capability to deal with change through a process of 
‘learning by doing’. Katzenstein (1985, p. 44) finds that ‘political leaders in the open 
economies of the small states are ... accustomed to accept as normal rates of economic change 
and dislocation that elites in large countries regard as intolerably high’. He adds that for the 
small (European) states, economic change is a fact of life, and that their economic openness 
and domestic politics do not permit them the luxury of long-term plans for sector 
transformation. ‘Their strategy is flexible, reactive and incremental as they continually 
improvise in living with change’ (Katzenstein, 1985, p. 24). On the negative side, a relatively 
small change on international markets can trigger strong enough forces that impact 
significantly on an open system. March (1991) points out that if organisations are to be 
successful, they need to maintain a proper balance between exploration and exploitation. 
Moving too slow or fast entails a risk which a small state cannot afford. 
 
Shimizu and Hitt (2004, p. 45) remark that ‘[a]bandonment of an initiative too quickly 
because of initial problems may result in the loss of a large future potential benefit, while 
overly strong commitment to a money-losing project can only exacerbate problems’. The 
importance of an open system determining the strategic logic of its economic activities has 
already been noted and its relevance is further emphasised by the need to find this ‘right’ 
balance. At any point in time, too much flexibility could jeopardise the identity, RCDCs 
building programme and longer-term competitive advantage of an open system. Figure 27 
builds on Rogers’ innovation adoption curve to graphically show how an open system differs 
from a large state in accepting and adapting to change.
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Figure 27: Acceptance of change by large and small states 
 
Finding the right balance between exploitation and exploration conditions the ability of an 
open system to achieve strategic flexibility. Strategic flexibility is both an arch-RCDC which 
permeates throughout the open system as well as a feature of its output; it is a dynamic 
capability in its own right as well as an outcome of other dynamic capabilities (Combe & 
Greenley, 2004). Staying flexible in strategic terms is not equivalent to jumping from one 
strategy to another, but implies a continuous transformation and incorporation of new ideas 
that maintains operational effectiveness while encouraging innovation. Achieving 
competitive advantage is a ‘war of movement’ not a ‘war of position’ (Ohmae, 1982). 
Movement requires that entrepreneurs identify new opportunities to consistently re-define 
competitive advantage. (This is consistent with R-A theory which perceives competitive 
dynamics to be dynamic and disequilibrium provoking). 
 
The case study finds that the strategic thrust of the pharmaceutical industry in Malta is more 
‘emergent’ than ‘deliberate’. Many of the international enterprises setting up operations in the 
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country find their own path on how to take advantage of existing opportunities. The Maltese 
pharmaceutical industry operates at the efficiency stage, and its profitability is heavily reliant 
on operational effectiveness rather than innovation. Efficiency in an open system assumes a 
different dimension than that projected by conventional competitiveness reports. In a small 
states, efficiency arises out of adaptability, speed, agility and responsiveness that make it 
possible to identify niches such as ‘managing complexity’ rather than exploiting economies 
of scale through mass production. Relatively higher unit labour costs in Malta (compared to 
most East European and Asian countries) are offset through a specialisation in short runs and 
fast delivery. The little market power available to local pharmaceutical enterprises arises 
from the ‘temporary’ opportunity window arising out of international patent laws. Only one 
firm, ICP, undertakes research in Malta, which can be considered as being innovative rather 
than a part of a quality assurance programme. 
 
A report by the United Nations (2006, p. 31) asserts that ‘access to appropriate technologies 
remains crucial for the sustainable development of small island developing States’. The 
knowledge capacity of an open system provides the framework within which local know-how 
and technology develops to support economic activities and includes the capability to absorb, 
adapt and develop imported knowledge. Criscuolo and Narula (2008, p. 56) hold that national 
absorptive capacity and the accumulation of knowledge stock are simultaneously determined. 
This implies that different phases of technological development require different strategies, 
‘During the catching-up phase, knowledge accumulation occurs predominately through the 
absorption of trade and/or inward FDI-related R & D spill-overs’. Imported goods embody 
technological know-how, ‘countries can acquire foreign knowledge through trade and 
increase their growth rate through trade liberalization’ (Schiff & Wang, 2008, p. 1). Openness 
renders a small state receptive to new products, trends and values thereby facilitating the 
familiarisation, absorption and possibly adaptation of technology. Familiarisation with 
foreign technology through international trade, however, does not automatically mean that 
that technology can easily be exploited for production purposes. Economic integration too 
may facilitate access to technology, but ultimately what matters is the ability of an open 
system to absorb that technology and make it part of its own pool of knowledge. For this to 
happen, an open system needs to have the right institutions and supporting public policies in 
place. 
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This research concludes that the knowledge capacity of an open system is an arch-RCDC as it 
impacts other RCDCs and conditions the ability to exploit opportunities emerging from the 
international market. This has been the case of the pharmaceutical industry in Malta, even 
though knowledge is driven by a legal competence in patents rather than conventional R&D. 
This study also highlights the excellent market-sensing capabilities of the Maltese. Although 
they generally lacked the resources and competencies associated with the pharmaceutical 
industry, they were quick to sense the opportunity arising out of EU membership. The 
Maltese have a history and reputation in trading and these market sensing capabilities were 
nurtured over the ages. Traders cultivate a unique sense of ‘opportunity’: under the rule of the 
Knights of St. John, the Maltese thrived on piracy. The opportunity of operating in a ‘patent 
free’ EU environment permits the pharmaceutical industry in Malta to overcome all other 
operational disadvantages. The EU membership facilitates access not only to the vast single 
European market but also to other key markets around the world. Membership also provides a 
certificate of legality and respectability for pharmaceutical enterprises operating from Malta. 
FDI originating from many parts of the world (Switzerland, India, Italy, Spain, Iceland, the 
United States and Palestine) provides technology, manpower and other resources, which are 
not readily available locally. FDI helped ‘circumvent’ local limitations and enabled 
enterprises to find a niche on the global market. 
 
Actavis, the industry’s first and largest pharmaceutical venture, lobbied for Malta to obtain 
conditions favouring generics in the country’s pre-accession negotiations with the EU. ICP, 
the other pharmaceutical operator at the time, favoured an operating environment that would 
have facilitated the setting up of other originator companies, but it lacked the power of 
Actavis. Once Actavis’ desires were met, ME worked hard to induce other foreign enterprises 
to branch their generics operations to Malta. Ventures set up locally by FDI combined 
enterprise-specific ‘market sensing’ capabilities with technological and management know-
how. Both the EU and FDI served as change agents, which helped ‘short-circuit’ the 
development process of the pharmaceutical industry in Malta. Above all, they facilitated the 
sourcing of specialised personnel, which was not readily available in the country. The field 
research also shows that innovation in a small state is not necessarily driven by business 
sophistication grounded in technology. In the case study, innovation arises from a unique 
market sensing capability; one which favours ‘exploration’ rather than ‘exploitation’. Market 
sensing is evidently closely associated with entrepreneurship in an open system. The local 
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pharmaceutical industry managed to flourish in a relatively short period through rapid 
changes in public policy as well as in the societal resources (including institutions). It is the 
merit of Maltese politicians, policymakers and social partners that the necessary changes 
were implemented so fast and in such an effective way. This was facilitated by the fact that 
the pharmaceutical industry in Malta is practically fully export-oriented, that is, there was 
little resistance to these changes from local vested interests and power circles. 
 
In particular, Malta was obliged to adopt the EU’s ‘acquis communitaire’ which stipulated 
the right legislative framework and called for the setting up of a Medicines Authority 
responsible for the upkeep of standards. The implications of this for an open system are that 
to tap a market opportunity, the re-configuration of existing ‘resources’ or the creation of new 
ones has to also include improvements in the supporting institutional infrastructure. Market 
sensing while essential in identifying emerging opportunities on international markets 
requires the mobilisation of the other arch-RCDCs if it is to be effective. Local 
pharmaceutical operators manage to build competitive advantage by focusing on operations 
relating to ‘managing complexity’, ‘novelty launches’ and ‘batch releasing’ activities. This 
focus enables operators not to compete just on lower costs and cheaper prices. ‘Novelty 
launches’, in particular, give operators a degree of bargaining power as there are few 
alternative locations within the EU which offer this possibility. This ‘market power’ is, 
however, a fleeting one as it generally disappears within a relatively short time (six months is 
the minimum time necessary for other suppliers to start selling a similar generic). Shortly 
after a ‘novelty launch’ is complete, that there arises the need to embark on the next one. If an 
enterprise is successful in achieving this, then its market power can be ‘rolled-on’. 
Unfortunately, for local operators, there will come a time (estimated to be within the next 
eight years) when there will be no more medicinal patents which are not registered in Malta. 
 
The trajectory followed by the pharmaceutical industry in Malta does not exploit externalities 
arising from operational linkages and networking in a significant way. Of the arch-RCDCs, 
‘alliance capability’ appears to be the ‘weakest link’ of the proposed framework. While this is 
evidently the case at the enterprise level (within Malta itself), it can be argued that the 
country has made excellent use of its ‘alliance capability’ by forging a strategic partnership 
with the EU. The umbilical cord of local enterprises is not among themselves (as part of a 
network or cluster) but with enterprises abroad (mostly their parent company). As explained 
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without these alliances, the industry would not have prospered in a relatively short time. The 
growth of the pharmaceutical sector was an integral part of the restructuring of the Maltese 
economy. Its growth compensated for the relative decline of the manufacturing sector. The 
EU membership helped revitalise the small pharmaceutical sector that existed pre-accession 
and enabled it to achieve a higher than average output and value-added per employee. 
 
One foreign pharmaceutical operator remarks that ‘Malta is the best kept secret in the EU’.  
 
This does not mean that the pharmaceutical industry in the country has no weaknesses or 
faces no challenges. Reduced bureaucracy, a better qualified Patent Office, consolidation of 
supporting services, an enhanced physical infrastructure and the continued convergence of 
education and training courses to meet its needs are some of the significant challenges facing 
the local industry. The construction of the Life Sciences Centre is likely to be a white 
elephant as Malta lacks the necessary knowledge base. FDI may once again come to the 
rescue; but it will not be easy to transfer the high level of knowledge and expertise necessary 
to support such a Centre. 
 
There is also growing awareness within the local industry that other EU member states such 
as Cyprus, Bulgaria and Rumania are carefully studying Malta’s experience in this field to 
carve a similar niche for themselves. Existing operators believe that enterprises from these 
countries are likely to become significant competitors in the very near future. Perhaps the 
biggest challenge facing the local pharmaceutical industry lies within its own basic rationale: 
the ability to work on patented medicines which have not been registered in Malta. This 
advantage will not last forever, and local policymakers need to decide upon the strategic logic 
of the industry. Will it be considered as just another passing opportunity, letting it ‘sunset’, or 
does it have the potential to be leveraged? An open system tends to be uneasy with 
specialisation and ‘leverage’ strategies which require ‘deep’ commitments and ‘sunken 
investments’. It is this that led Katzenstein (1985, p. 44) to conclude that given that economic 
change is a fact of life for small European states, ‘their economic openness and domestic 
politics do not permit them the luxury of long-term plans for sector transformation’. An open 
system has to be creative, building on its strengths rather than seeking to address its 
weaknesses. Many such open systems, like Malta, have a competence in trading rather than in 
manufacturing. A trader lives for the day, seizing the opportunity as it arises. Tomorrow is 
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another day and hopefully, it will bring a new opportunity. A trader’s mindset is driven by 
manoeuvrability rather than sustainability. Knowledge in an open system’ tends to be market, 
rather than technology, driven. 
 
This explains the high propensity of Maltese entrepreneurs to build strategic partnerships 
with foreigners while finding it hard to co-operate among themselves. This is not so much 
about mistrust but a realisation that they can only offer each other more of what they already 
possess. The big question which follows from these reflections is whether it makes sense to 
talk about a ‘leverage’ strategic logic in small states. Should Maltese policymakers let the 
pharmaceutical industry try to chart its way forward in an emergent fashion or should they 
deliberately seek to give it strategic direction? The superior performance of Luxembourg in 
financial services seems to suggest that it is possible to combine an opportunistic logic with a 
leverage one. This is best seen as a ‘snake in the tunnel’ strategy, with the tunnel determining 
the longer-term direction but allowing the snake (local operators) to manoeuvre within the set 
limits to tap into opportunities as they arise.  
 
This research journey goes through a number of paths and gathers many useful insights, 
which do not necessarily lead to a unique final destination. A lot more work needs to be done 
to determine the validity of these insights and the hypotheses suggested. Additional research 
is required in terms of on further case studies of successful industries in small states. In 
particular, there appears to be scope for comparative studies that analyse the experiences of a 
successful industry in a number of small states. Bullishly, Farrugia (2013) claims that it is in 
the genes of the Maltese people to overcome hurdles. Katzenstein (1985) concludes that small 
states are like frogs escaping from snakes. But the real challenge for a small state should go 
beyond survival: a frog may never become a snake but it may dream of becoming a prince. 
 
In conclusion the research questions are being re-visited in the light of the knowledge gained 
through this thesis: 
 
a. How do small states’ economies differ from those of larger states?  
 
This research finds that in a post-industrial world small size ‘per se’ does not appear to be the 
most distinctive criteria for giving due attention to the realities of small states. Irrespective of 
size, economies still have to specialise if they are to benefit from international business. Of 
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course, most small states remain characterised by a high degree of openness and limited 
economies of scale. In an age of globalisation openness is not necessarily a limitation. 
Indeed, if a small state manages properly its interface with the world and regional economies, 
openness can become a strength. Economies of scale can, and should, be replaced by 
economies of scope. What emerges as being of fundamental importance for small states is 
that they place such a high priority on risk minimisation compared to larger states. In small 
states specialisation becomes conditioned by the fear of over-dependence on a narrow set of 
economic activities.  
 
b. Why are these differences important for competitiveness and superior economic 
performance?  
 
According to this research these differences are important for competitiveness because risk 
minimisation ultimately impacts on the way that a small state seeks specialisation. 
Specialisation is the key to achieving market power and not remaining dependent on 
competing on low costs. A good number of small states have shown that this is achievable. 
The danger is that small states which over-emphasise risk minimisation end up with a 
diversified but highly fragmented economy which hinders them from achieving a superior 
economic performance.  
 
c. How can insights from existing theories contribute towards developing an alternative 
approach? 
 
The literature review carried out as part of this research generated a number of important 
insights as to the factors (such as good governance, social capital, strategic flexibility) 
leading to improved economic performance. Of particular relevance is R-A theory, a general 
theory of competition, which provides a theoretical framework for understanding the superior 
performance of firms as well as national economies.  For R-A theory, such a superior 
performance is the result by the search for comparative advantage  and the propensity to 
engage in proactive and reactive innovation. This theory also assigns a special role to the 
development of societal resources and structures as well as public policy.  The alternative 
theoretical framework proposed in this research draws a lot on the logic and insights of R-A 
theory. It, however, goes a step further by identifying a set of  higher-order competencies 
which give meaning to all the other competencies and resources and which have to be ever-
present.  
 
 
d. How does EU membership impact on the development of the pharmaceutical industry in 
Malta? 
 
The case study finds that EU membership transformed the pharmaceutical industry in Malta. 
EU directives had to be transposed into local legislation and this not only led to extensive 
changes in public policy but also in the setting up of new institutions and the restructuring of 
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existing ones. What proved of utmost importance for the development of the pharmaceutical 
industry in Malta was not operating standards or market access but the EU’s patent law, 
including the Bolar exemption. EU membership also helped improve the reputation of the 
local pharmaceutical industry as foreign buyers appreciated that before exporting products 
stringent quality standards had to be met by Maltese pharmaceutical enterprises. 
 
 
e. Does the experience of the pharmaceutical industry in Malta confirm or otherwise the 
relevance of the major components of the proposed theoretical model? 
Generally speaking the relevance of the arch-RCDCs was confirmed even though the 
importance of the ‘alliance capability’ did not come out strong enough. Much more research 
is necessary to ascertain the role that these arch-RCDCs play in determining the competitive 
advantage of an industry. 
This thesis makes a contribution to theory in a number of ways: 
 
International business has conventionally been concerned with global corporations and 
advance economies. Only relatively recently did branch out to include a study about the role 
of small and medium enterprises in international business. This research opens yet another 
branch relating to the role of small states in international business and how to strategically 
manage their interface with the global market to reap adequate returns. The researcher’s own 
experience shows that the diamond of national competitiveness model proposed by Porter 
(1998) has been extensively applied by both analysts and policymakers in small states to 
understand the competitiveness of their economies or particular industries. Yet this model has 
limited applicability to the realities of small states and can lead to misguided policy 
prescriptions and decisions. The alternative approach proposed in this study emphasises the 
importance of understanding the resources and competencies of the small state and to seek 
how best to exploit them on the global market. 
 
This research throws extensive light on the concept of superior economic performance. The 
comprehensive literature review on the subject confirms that although there is a general 
understanding of what it entails there is no one single measure by which the performance of a 
small state can be properly gauged. This research highlights the issues involved and suggests 
what such a measure could entail.  
 
 
 201 
 
Application of R-A theory in a different context, that of a small state.  
 
The importance of strategic management for the superior economic performance of small 
states and the importance of their developing the ‘right’ resources and competencies in line 
with the strategic logic of their respective industries. (Strategic logic goes beyond 
conventional economic parameters such as the number of jobs created, exports generated and 
value-added). 
 
This thesis presents small states as an organisation, an ‘open system’. It sets a precedent by 
drawing on insights and explanations arising from organisational theory to the study of small 
states. This opens new possibilities for ‘organisational’ theory to explore given that most 
states are smaller than the average global corporation. 
 
From a practical point of view this research follows an innovative approach to the 
competitiveness and superior economic performance of small states which hives specific 
consideration to their realities. It highlights the importance of carrying out research on 
specific industries as at times general perceptions may be misleading. The popular perception 
(propagated mostly by politicians) of the pharmaceutical industry in Malta is that it is a 
highly successful one driven by  R & D, when in reality it is driven by international patent 
law with R & D expenditure by the industry in 2010 falling to less than three percent of 
output. 
 
It should help policymakers and the business community in small states to think differently 
and start focusing on competencies and resources rather than conventional economic assets. 
They too have to be innovative and entrepreneurial in perceiving competencies and resources 
in a different way. Jurisdiction, peripherality, flexibility, natural beauty are the type of 
competencies and resources that they should be exploiting so as to improve their 
competitiveness. The focus on transforming and building new competencies and resources 
has important implications also for education and manpower strategies.  Particular industries 
in small states may come and go; what remains are the competencies and resources that 
would have been gained. This research sets the ground for future research on small states 
within international business as well as other business disciplines. It would be highly 
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interesting to study for example the performance of the pharmaceutical industry in another 
small state or even to study the impact of Malta’s EU membership on another local industry. 
 
This research has been a most rewarding journey which in many ways serves as a point of 
departure rather than arrival. If it leads to further research on small states, it would have 
achieved one of its primary objectives.  
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Annex 1:  Illustrative list of interview questions 
 
The Maltese Pharmaceutical Industry 
Semi-Structured Interviews with Management 
 
 
Interviewee:                                                                                 Designation: 
 
Date of Interview: 
 
 
 
 
Questions 
 
 
1. What is the impact of Malta’s EU membership on the local pharmaceutical industry? 
 
2. What is the impact of membership on the operating environment? 
 
3. What is the impact of membership on your firm?  
 
4. What are the primary challenges facing the industry? Have they changed since 2004? 
 
5. Do you agree that the local industry is still competing mostly on costs? 
 
6. What needs to be done to enable your enterprise to increase its value added?  
 
7. What degree of control does your enterprise have over the prices it charges? 
 
8. Do you feel that local enterprises have a say in the evolution of EU directives and policies? 
 
9. Do pharmaceutical enterprises in Malta collaborate and network? 
 
10. What would you say are the major assets/competencies of your enterprise? 
 
11.How do you see the future of the pharmaceutical industry in Malta? 
 
 
